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Background: Depression is usually managed in primary care and antidepressants are often the first-line
treatment, but only half of those treated respond to a single antidepressant.
Objectives: To investigate whether or not combining mirtazapine with serotonin–noradrenaline reuptake
inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants results in better patient
outcomes and more efficient NHS care than SNRI or SSRI therapy alone in treatment-resistant
depression (TRD).
Design: The MIR trial was a two-parallel-group, multicentre, pragmatic, placebo-controlled randomised
trial with allocation at the level of the individual.
Setting: Participants were recruited from primary care in Bristol, Exeter, Hull/York and Manchester/Keele.
Participants: Eligible participants were aged ≥ 18 years; were taking a SSRI or a SNRI antidepressant for at
least 6 weeks at an adequate dose; scored ≥ 14 points on the Beck Depression Inventory-II (BDI-II); were
adherent to medication; and met the International Statistical Classification of Diseases and Related Health
Problems, Tenth Revision, criteria for depression.
Interventions: Participants were randomised using a computer-generated code to either oral mirtazapine
or a matched placebo, starting at a dose of 15 mg daily for 2 weeks and increasing to 30 mg daily for up
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to 12 months, in addition to their usual antidepressant. Participants, their general practitioners (GPs) and
the research team were blind to the allocation.
Main outcome measures: The primary outcome was depression symptoms at 12 weeks post randomisation
compared with baseline, measured as a continuous variable using the BDI-II. Secondary outcomes (at 12, 24
and 52 weeks) included response, remission of depression, change in anxiety symptoms, adverse events (AEs),
quality of life, adherence to medication, health and social care use and cost-effectiveness. Outcomes were
analysed on an intention-to-treat basis. A qualitative study explored patients’ views and experiences of
managing depression and GPs’ views on prescribing a second antidepressant.
Results: There were 480 patients randomised to the trial (mirtazapine and usual care, n = 241; placebo
and usual care, n = 239), of whom 431 patients (89.8%) were followed up at 12 weeks. BDI-II scores at
12 weeks were lower in the mirtazapine group than the placebo group after adjustment for baseline
BDI-II score and minimisation and stratification variables [difference –1.83 points, 95% confidence interval
(CI) –3.92 to 0.27 points; p = 0.087]. This was smaller than the minimum clinically important difference and
the CI included the null. The difference became smaller at subsequent time points (24 weeks: –0.85 points,
95% CI –3.12 to 1.43 points; 12 months: 0.17 points, 95% CI –2.13 to 2.46 points). More participants in
the mirtazapine group withdrew from the trial medication, citing mild AEs (46 vs. 9 participants).
Conclusions: This study did not find convincing evidence of a clinically important benefit for mirtazapine
in addition to a SSRI or a SNRI antidepressant over placebo in primary care patients with TRD. There was
no evidence that the addition of mirtazapine was a cost-effective use of NHS resources. GPs and patients
were concerned about adding an additional antidepressant.
Limitations: Voluntary unblinding for participants after the primary outcome at 12 weeks made
interpretation of longer-term outcomes more difficult.
Future work: Treatment-resistant depression remains an area of important, unmet need, with limited
evidence of effective treatments. Promising interventions include augmentation with atypical antipsychotics
and treatment using transcranial magnetic stimulation.
Trial registration: Current Controlled Trials ISRCTN06653773; EudraCT number 2012-000090-23.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 22, No. 63. See the NIHR Journals Library website
for further project information.
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Glossary
Baseline recruitment A meeting with the research associate in which the research associate provided a
full explanation of trial participation, took consent and completed the trial baseline case report form.
Code-break A record held by the University Hospitals Bristol NHS Foundation Trust of the allocation of
active drug and placebo (and medicine identification number) by patient identification number.
Index consultation The routine consultation between the patient and the primary care clinician
responsible for the patient’s routine care, in which the patient’s general practitioner identified that the
patient was suffering from depression and had had at least 6 weeks of treatment with a selective
serotonin reuptake inhibitor or a serotonin–noradrenaline reuptake inhibitor antidepressant. The clinician
introduced the trial, took written consent for the patient to be contacted by the study team and carried
out a detailed check of eligibility, including checking for potential drug interactions on the general practice
information system.
Medicine identification number The unique number assigned to the investigational medicinal product
at manufacture (by the investigational medicinal product manufacturer, using the randomisation data
provided by the Bristol Randomised Trials Collaboration) and assigned to the patient identification number
according to the randomisation schedule provided to the University Hospitals Bristol NHS Foundation Trust
by the Bristol Randomised Trials Collaboration.
Medicine pack The packaging containing the investigational medicinal product uniquely identified by the
medicine identification number.
Patient identification number The unique number assigned to a recruited patient by the research
associate following receipt of the completed reply slip.
Patient information sheet The information sheet given to patients by the general practitioner during the
consultation or posted to potential participants by the general practice. All patients were provided with
the full patient information sheet. A summary patient information sheet was also sent to participants with
their baseline appointment letter.
Randomisation data A list of random numbers generated by the Bristol Randomised Trials Collaboration
in line with the requirements of the trial sponsor and the medicine supplier [Sharp Clinical Services (UK)
Ltd, Crickhowell, UK] and provided to Sharp Clinical Services (UK) Ltd (in a manner that maintained the
complete blinding of the trial team) for their use in numbering the medicine packs that were provided to
the four trial centres. The bottle numbers formed the identifiers on the open code-break document sent
with each delivery of medication packs.
Randomisation schedule Instructions provided by the Bristol Randomised Trials Collaboration to the four
trial centres regarding active compared with placebo medicine allocation.
Responsible clinician The general practitioner who took responsibility for the clinical management of
a patient, for the initial confirmation of the patient’s eligibility to take part in the trial (final confirmation
was the responsibility of the principal investigator) and for checking for possible drug interactions on the
general practice information system.
Site Sites were defined as the four recruiting centres in the MIR trial (for the purposes of research and
development, Research Ethics Committee applications, etc.).
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xxi
Source data For the MIR trial, the source data were considered to be the data recorded on the case
report form by the research associate and by the patient. When data had been entered directly online,
without the use of paper forms, these were taken as the source data.
Trial Participation Card Trial participants were requested to carry this with them while participating in
the trial. It recorded the medicine and patient identification numbers to be used for emergency unblinding.
Trial prescription This was the prescription for the trial medication, issued after confirmation that a
patient was eligible and randomised, and was signed by the site’s clinical leader or nominated deputy.
It was then sent directly to the trial pharmacy.
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Plain English summary
Antidepressants are very often prescribed for people with depression, but many patients who takeantidepressants in an adequate dose for an adequate length of time remain depressed. We have called
this treatment-resistant depression (TRD). One possible way of helping patients with TRD is to combine two
antidepressants, adding a second when the first does not help. Some small studies have suggested that it
might be beneficial to add the antidepressant mirtazapine to patients’ usual antidepressant, as it works in
a slightly different way from the widely used antidepressants such as fluoxetine, and that the combination
is well tolerated by patients.
We tested this idea in a large study including 480 participants. All of the participants who entered the
study were depressed and had been taking an antidepressant for at least 6 weeks. They were randomly
assigned to take either mirtazapine or an inactive placebo in addition to their usual antidepressant. The
medications were identical in appearance, and the participants and the study team did not know which
group the participants had been assigned to.
After 12 weeks of treatment, we reassessed participants’ depression to see whether or not the combination
of their usual antidepressant with mirtazapine was more effective than the combination with placebo. We
did not find convincing evidence of a clinically important benefit for mirtazapine in addition to another
antidepressant over placebo in this treatment-resistant group of depressed patients in general practice. Mild
adverse events were more common in the mirtazapine group and more participants in this group stopped
the treatment before the end of the study.
Based on this study, we cannot recommend this combination of antidepressants with confidence as a
routine treatment for patients who have not responded to a single antidepressant.
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Scientific summary
Background
Depression is among the top five contributors to the global burden of disease and by 2030 is predicted to
be the leading cause of disability in high-income countries. People with depression are usually managed
in primary care and antidepressants are usually the first-line treatment. The number of prescriptions for
antidepressants has risen dramatically in recent years, increasing by 6.8% (3.9 million items) between
2014 and 2015 (a total of 61 million items).
However, many patients do not respond to antidepressants. The STAR*D (Sequenced Treatment Alternatives
to Relieve Depression) study found that half of those treated did not experience a reduction of ≥ 50% in
depressive symptoms following 12–14 weeks of treatment with a single antidepressant. The reasons for
non-response include non-adherence to medication. However, a substantial proportion of those who take their
antidepressants in an adequate dose and for an adequate period do not experience a clinically meaningful
improvement in their depressive symptoms. This can be termed treatment-resistant depression (TRD).
Definitions of TRD in research are varied. The National Institute for Health and Care Excellence advises
general practitioners (GPs) to reconsider treatment if there has been no response after 4–6 weeks of
antidepressant medication. Therefore, a definition of TRD that is relevant to UK primary care includes
patients who still meet the International Statistical Classification of Diseases and Related Health Problems,
Tenth Revision (ICD-10), criteria for depression after taking a selective serotonin reuptake inhibitor (SSRI) or
a serotonin–noradrenaline reuptake inhibitor (SNRI) antidepressant at an adequate dose for a minimum of
6 weeks. However, there is currently limited evidence to guide GPs in the management of these patients.
Several pharmacological strategies have been proposed to treat those with TRD, including increasing the
dose of antidepressant, switching antidepressants, combining two antidepressants and augmenting the
antidepressant with another psychotropic drug. There is a pharmacological rationale for adding a second
antidepressant with a different and complementary mode of action to SSRIs or SNRIs. Mirtazapine, an
alpha2-adrenoreceptor antagonist, has the potential for a synergistic action with SSRIs and SNRIs and
could enhance the clinical response compared with monotherapy. There have been three small trials of
this combination of antidepressant, with encouraging results. However, these trials did not compare the
combination in a treatment-resistant population.
Objectives
Our aim was to determine the clinical effectiveness and cost-effectiveness of adding mirtazapine to a
SSRI or a SNRI prescription in reducing depressive symptoms and improving quality of life (QoL) at 12 and
24 weeks and 12 months, compared with adding placebo. A qualitative study explored the views and
experiences of patients of taking either two antidepressant medications or an antidepressant and a
placebo, their reasons for adhering to or stopping the medication and the views of GPs on prescribing
combined antidepressant therapy.
Methods
The MIR trial was a two-parallel-group, multicentre, pragmatic, placebo-controlled randomised trial, with
allocation at the level of the individual. Patients were recruited from general practices in four centres:
(1) Bristol, (2) Exeter, (3) Hull/York and (4) Manchester/Keele.
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Eligible patients (1) were aged ≥ 18 years; (2) were currently taking antidepressants, had done so for at
least 6 weeks and had adhered to their medication; (3) had a Beck Depression Inventory-II (BDI-II) score
of ≥ 14 points; and (4) fulfilled ICD-10 criteria for depression. We excluded patients with bipolar disorder,
psychosis or major alcohol/substance abuse; those who were unable to complete the questionnaires; and
women who were pregnant, breastfeeding or planning a pregnancy.
A three-stage recruitment process was used to identify potential participants. General practices searched
their computerised records to identify patients who had received repeated prescriptions for an antidepressant
during the previous 4 months and who were being prescribed an antidepressant at an adequate dose. GPs
screened this list of patients and excluded patients based on study criteria. A letter of invitation and brief
information about the study was sent to the potentially eligible participants, seeking permission for the
research team to contact them.
The GPs could also invite patients to take part in the study during a consultation. GPs provided patients
with information about the study and obtained permission to pass their contact details to the research
team. Those who agreed were sent a postal questionnaire. This included questions about their depressive
symptoms (BDI-II) and use of antidepressants.
Those who met the definition of TRD (based on severity of depressive symptoms and adherence to
antidepressants for at least 6 weeks) were contacted by a researcher by telephone to ascertain
their eligibility.
Baseline assessments to establish eligibility were conducted in the patients’ own homes, at their GP surgeries
or at nearby NHS/university premises. Only those patients who fulfilled ICD-10 criteria (category F32) for
their current depressive episode (assessed using the Clinical Interview Schedule – Revised), had a BDI-II score
of ≥ 14 points and were continuing to take the prescribed antidepressant at an adequate dose were eligible
to participate in the trial.
Those who were eligible and gave written informed consent were randomised, using a computer-generated
code. Participants were randomly assigned to one of two treatments: (1) one × 15-mg mirtazapine capsule
daily for 2 weeks followed by two × 15-mg mirtazapine capsules for up to 50 weeks or (2) identical
placebo capsules.
Randomisation was carried out using a computerised system and was stratified by centre and minimised
on baseline BDI-II score (mild < 26 points; moderate 26–34 points; severe ≥ 35 points), sex (male/female)
and receipt of psychological services (yes/no).
The labelling of medication packs was approved by the Medicines and Healthcare products Regulatory
Agency. Each medication pack had an identification number, randomly generated to ensure that
mirtazapine and placebo medicine packs were indistinguishable to maintain allocation concealment.
The random number was generated by the Bristol Randomised Trials Collaboration and provided to
the manufacturer.
Participants and GPs were advised to use with caution other serotonergic drugs, such as tramadol or the
triptan group of drugs, and those taking monoamine oxidase inhibitors were excluded.
Participants were free to withdraw from the medication at any time. Participants, clinicians, outcome
assessors and the research team were blinded to allocation. After collection of the primary outcome
measure at 12 weeks, participants were offered the opportunity to be unblinded or to remain blind to
allocation. Those who elected to be unblinded would no longer receive the trial medication but outcome
measures would be collected. All participants continued with their GP care and their usual antidepressants.
Clinicians were not restricted in referring their patients to psychological services.
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Participants were followed up at 2, 6, 12, 24 and 52 weeks. To maximise response rates, follow-up
assessments at 6, 12, 24 and 52 weeks were conducted at a face-to-face appointment with a researcher.
If this was not possible, questionnaires were posted or completed over the telephone. Only the 2-week
follow-up data were collected solely by telephone.
The primary outcome was change in BDI-II score at 12 weeks post randomisation, measured as a continuous
variable. With 200 participants in each group, we would have 91% power to detect a difference of 0.33
standard deviations (SDs) at the 5% level. This is equivalent to 3–4 points on the BDI-II, a clinically important
difference. Allowing for 15% loss to follow-up at 12 weeks, we needed to recruit 472 patients.
Secondary outcomes were ‘response’, defined as a ≥ 50% reduction in BDI-II score compared with baseline;
‘remission’, defined as a BDI-II score of < 10 points; change in anxiety symptoms, measured using the
Generalised Anxiety Disorder-7 questionnaire; adherence to antidepressants; QoL, measured using the
EuroQoL-5 Dimensions, five-level version; social and physical functioning, measured using the Short Form
questionnaire-12 items; and adverse events (AEs), measured using the Antidepressant Side-Effect Checklist
(ASEC). All of these secondary outcomes were measured at 12, 24 (excluding ASEC) and 52 weeks.
The primary comparative analyses of clinical effectiveness were conducted according to the principle of
intention to treat (ITT), without imputation of missing data.
Cost-effectiveness was measured using self-report resource use questionnaires at 12 and 24 weeks and
at 12 months, in addition to primary care practice data on consultations, services and prescriptions over
the 12-month trial period. The perspective for the primary analysis is that of the NHS and personal social
services. Personal costs and productivity costs for patients who missed work are included in a secondary
analysis from the societal perspective.
We conducted semistructured interviews with people who were invited to participate in the trial but who
declined, trial participants and GPs. We explored reasons for declining to participate, reasons for adhering
to or stopping medication and views and experiences of GPs about managing people with depression,
with a focus on prescribing.
A purposeful sampling strategy was used to ensure that interviews were held with individuals in both
groups of the trial in all four centres. Interviews were conducted either by telephone (patients who
declined participation in the trial and GPs) or face to face. Analysis was conducted within each data set
and then comparison was carried out across the data sets. NVivo 10 (QSR International, Warrington, UK)
was used to store data and aid with analysis.
Results
A total of 480 patients were randomised (mirtazapine and usual care, n = 241; placebo and usual care,
n = 239), of whom 431 (89.8%) were followed up at 12 weeks, 403 (84.0%) at 24 weeks and 390
(81.3%) at 12 months.
The two groups were similar in baseline characteristics, but there was some evidence that patients in the
mirtazapine group had more severe depression. Patients randomised to mirtazapine were more likely to
have a prior history of depression and a higher proportion had had suicidal thoughts.
At 12 weeks, the mean BDI-II score was 18.0 points (SD 12.3 points) in those randomised to the mirtazapine
group compared with 19.7 points (SD 12.4 points) in those randomised to the placebo group. There was
a small difference in favour of the intervention after adjustment for baseline BDI-II score, centre, baseline
BDI-II score terciles, sex and whether or not the patient was receiving psychological therapy at baseline.
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The confidence interval (CI) included the null, consistent with the possibility that there was no difference
between the two treatment groups (difference –1.83 points, 95% CI –3.92 to 0.27 points; p = 0.087).
Further adjustment for characteristics showing an imbalance at baseline did not change this result
meaningfully. At 24 weeks and 12 months, the adjusted differences in BDI-II scores between the two
groups became smaller (24 weeks: difference –0.85 points, 95% CI –3.12 to 1.43 points; 12 months:
difference 0.17 points, 95% CI –2.13 to 2.46 points).
Similar trends of small differences between the treatment groups in favour of the mirtazapine group were
observed for other secondary outcomes at 12 weeks, including response to treatment [odds ratio (OR) 1.39,
95% CI 0.94 to 2.07], remission of depression symptoms (OR 1.29, 95% CI 0.82 to 2.02), anxiety symptoms
(difference in GAD-7 scores –0.98 points, 95% CI –1.93 to –0.03 points), quality of life (difference in EQ-5D-5L
scores 0.01 points, 95% CI –0.02 to 0.05 points), difference in SF-12 aggregate physical functioning score
–1.09 points, 95% CI –2.75 to 0.57 points) and difference in SF-12 aggregate mental functioning score
3.91 points, 95% CI 1.63 to 6.20 points). This was also true for the complier-average causal effect (CACE)
analysis (difference in mean BDI-II scores –2.39 points, 95% CI –5.18 to 0.40 points) and a per-protocol analysis
(difference in mean BDI-II scores –2.18 points, 95% CI –4.60 to 0.24 points).
There was no important between-group difference in AEs, measured using the ASEC. Most reported AEs
were minor and no serious AEs were directly attributable to the intervention. In the intervention group,
167 participants reported AEs, 46 of whom reported AEs associated with stopping the trial medication,
whereas 91 participants in the placebo group reported AEs, only nine of whom stopped the trial medication.
No clinically important differences in quality-adjusted life-years (QALYs) or costs were observed between the
two groups at 12 or 52 weeks. At the primary outcome end point of 12 weeks, participants in the active
treatment arm reported QALYs of 0.163 and participants in the control arm reported QALYs of 0.162, a
difference of 0.002 QALYs (95% CI –0.002 to 0.005 QALYs). The active treatment arm at 12 weeks had
higher costs (£65) than the control arm (£63). The difference in costs was small (£2, 95% CI –£27 to £31).
At 52 weeks, participants in the treatment arm had an incremental gain of 0.009 QALYS (95% CI –0.016
to 0.035 QALYs) and an incremental cost of £69 (95% CI –£74 to £206) compared with the placebo arm.
In the qualitative study, participants described the ‘hard work’ of managing depression. Those in the study
often described a ‘crisis point’ motivating their desire for change, whereas those who declined participation
were concerned that additional treatment might disrupt their hard-won equilibrium. GPs were concerned
that the use of two antidepressants would result in more AEs for those on long-term treatment.
Conclusions
l This study did not find convincing evidence of a clinically important benefit for mirtazapine in addition
to a SSRI or SNRI antidepressant over placebo in a treatment-resistant group of depressed patients in
primary care.
l The corrected mean difference in BDI-II score between the groups after 12 weeks was 1.83 points
(95% CI –3.92 to 0.27 points) in favour of the intervention, which was less than the prespecified
clinically significant difference of 3–4 points. Although the lower limit of the 95% CI (–3.92 points)
means that it is not possible to exclude a clinically meaningful effect, the CI included the null,
indicating that there may be no difference in outcomes between the groups.
l The evidence for clinical effectiveness is similarly weak for the secondary outcomes of response and
remission at 12 weeks. Outcomes at later time points showed smaller between-group differences.
l Complier-average causal effect and per-protocol analyses, which are designed to estimate treatment effects
in those who comply, showed slightly larger differences than the ITT analyses, but CIs included the null.
l Prespecified subgroup analyses based on severity and degree of treatment resistance did not show any
evidence of effect modification.
l No clinically important differences in QALYs or costs were observed between the two groups at 12 or
52 weeks.
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Implications for health care
l The evidence presented in this study does not support the addition of mirtazapine to SSRI or SNRI
antidepressants for TRD in routine primary care.
l Minor AEs associated with stopping the trial medication were more likely in the mirtazapine group.
l General practitioners have concerns about the burden of AEs for those who are taking two
antidepressants long term. Patients who declined to join the MIR trial were concerned about disturbing
an ‘equilibrium’ that they had reached with a single antidepressant.
Implications for future research
l There is a need for further research into combination and augmentation treatments for people with
TRD that can be prescribed or delivered in primary care.
l It is important that future studies in this area define TRD in a way that is appropriate to primary care,
where there is the greatest potential for access to care.
Trial registration
This trial is registered as ISRCTN06653773 and EudraCT number 2012-000090-23.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Depression is ranked among the top five contributors to the global burden of disease and by 2030 is
predicted to be the leading cause of disability in high-income countries.1 In the UK, people with depression
are usually managed in primary care and antidepressants are often the first-line treatment. The number of
prescriptions for antidepressants has risen dramatically in recent years, increasing by 6.8% (3.9 million
items) between 2014 and 2015. Indeed, antidepressants have shown a greater increase in the volume of
prescribing in recent years than drugs for any other therapeutic area, with over 61 million prescriptions
being issued in England in 2015, at a cost of £2685M.2
However, the largest study of sequenced treatment for depression, the STAR*D (Sequenced Treatment
Alternatives to Relieve Depression) study,3 found that half of those treated did not experience a reduction
of ≥ 50% in depressive symptoms following 12–14 weeks of treatment with a single antidepressant.
The reasons for non-response include non-adherence to medication, which may be a result of intolerance.
However, a substantial proportion of those who take their antidepressants in an adequate dose and for
an adequate period do not experience a clinically meaningful improvement in their depressive symptoms.
This can be termed treatment-resistant depression (TRD).
When first-line antidepressant treatments do not work, general practitioners (GPs) can be unsure of what
to offer next. The National Institute for Health and Care Excellence (NICE) now advises GPs to reconsider
the treatment options if there has been no response after 4–6 weeks of treatment with antidepressant
medication.4 However, there is currently limited evidence to guide management.
Existing evidence on the pharmacological management of
treatment-resistant depression
The current NICE guideline4 describes the following pharmacological strategies for sequencing treatments
after inadequate response to the initial treatment: switching antidepressants, augmenting medication by
adding a drug that is not an antidepressant and combining antidepressants. The guideline4 comments
that the evidence for the benefit of switching, either within or between classes, is weak.
Connolly and Thase5 comment that switching antidepressants after an inadequate response is not
‘unequivocally supported by the data, although switching from a SSRI [selective serotonin reuptake
inhibitor] to venlafaxine or mirtazapine may offer greater benefits’. Similarly, there is very little evidence
on combining two antidepressants.
The evidence for the effectiveness of augmentation with a non-antidepressant is likewise of variable
quality. There is some evidence for augmentation with lithium or a thyroid hormone, but mainly in
combination with tricyclic antidepressants, which are not prescribed as often today. The use of the atypical
antipsychotics to augment the newer antidepressants is better supported by research,6,7 with quetiapine
(Seroquel; AstraZeneca plc, Cambridge, UK) and aripiprazole (Abilify®; Otsuka Pharmaceutical Co. Ltd,
Tokyo, Japan) the most promising.8 However, this combination has not, to date, been adopted with any
enthusiasm in UK primary care. This may be because of a lack of experience in prescribing them for this
indication as they are usually initiated in secondary care. There are also concerns about their adverse
events (AEs), including sedation, metabolic syndrome and central obesity and extrapyramidal effects.9
Indeed, the current NICE guidance recommends that antidepressants should not be combined or
augmented without the advice of a consultant psychiatrist.4
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It is possible that GPs would consider adding a second antidepressant, rather than an atypical antipsychotic
or lithium, as part of the management of TRD. They are more familiar with these drugs and their starting
routines; in addition, there is less concern about their AEs and less need for monitoring. In general, stepwise
combination of drug treatments is a standard part of the management of chronic diseases such as asthma
and hypertension in primary care and has led to improved clinical outcomes. GPs are comfortable with this
model of care and would probably readily adopt this strategy if it were found to be effective. We think that
there may be an opportunity to substantially improve the treatment of people with depression in primary
care by using antidepressants in combination. However, one of the reasons that this strategy has not been
adopted is the lack of convincing evidence for its effectiveness, especially in the primary care setting.
There is a pharmacological rationale for adding a second antidepressant to selective serotonin reuptake
inhibitors (SSRIs) or serotonin–noradrenaline reuptake inhibitors (SNRIs) with a different and complementary
mode of action. Mirtazapine, an alpha2-adrenoreceptor antagonist, increases central noradrenergic
and serotonergic neurotransmission by inhibiting negative feedback from synaptic noradrenaline (NA)
acting on presynaptic alpha2 autoreceptors on noradrenergic neurones and alpha2 heteroreceptors on
5-hydroxytryptaminergic (5-HT) neurones. Its mechanism of action is, therefore, different from that of both
SSRIs and SNRIs, which inhibit synaptic neurotransmitter reuptake after release. Thus, treatment with
mirtazapine in combination with either a SSRI or a SNRI may produce a sustained increase in both 5-HT and
NA synaptic availability in terminal fields. A further property of mirtazapine not shared by SSRIs and SNRIs is
its affinity for the 5-HT2C receptor, where it acts as an inverse agonist. This mechanism has been linked to
specific therapeutic effects. Overall, there is the potential for a synergistic action that could enhance the
clinical response compared with the response of those patients receiving only monotherapy. Mirtazapine is
now off patent and relatively inexpensive.
Because of its different mechanism of action, there is an argument that switching to mirtazapine alone
after SSRI treatment failure might be an effective strategy, rather than subjecting patients to the potential
AE burden of a second medication. The STAR*D study compared mirtazapine with nortriptyline in a group
of patients who had not responded to two consecutive antidepressant monotherapy regimes.10 The rates
of remission were low for both drugs, suggesting that switching to mirtazapine monotherapy is not the
most useful strategy.
In spite of the potential benefit of combining mirtazapine with a SSRI, there is relatively little trial evidence
to support this strategy. Carpenter et al.11 compared the addition of mirtazapine to a SSRI with placebo in a
group of 26 patients who had not responded to at least 4 weeks of monotherapy. Although the sample size
was very small, the results in terms of effectiveness and tolerability are encouraging,11 but more definitive
evidence is required before widespread adoption of this strategy. In patients who have not failed previous
treatment, Blier et al.12,13 reported that mirtazapine in combination with a SSRI gave a greater improvement
than monotherapy12 and that it was well tolerated with either a SSRI or a SNRI (venlafaxine),13 with both
combinations providing significantly higher remission rates than a SSRI alone. In contrast, a larger study
found no benefit from combining antidepressants, including mirtazapine and venlafaxine, over SSRI
monotherapy with escitalopram (Cipralex®; Lundbeck, Copenhagen, Denmark), although combined
treatment had a higher side-effect burden.14
Mirtazapine treatment is, however, associated with more weight gain than SSRIs15 and, therefore, as well
as assessing the efficacy of its combination with SSRIs, it is important to determine its AE burden,
especially when used long term.
Defining treatment-resistant depression
Many definitions of TRD have been proposed. These definitions cover a broad spectrum, ranging from
failure to respond to at least 4 weeks of antidepressant medication given at an adequate dose16 to more
stringent criteria based on non-response to multiple courses of treatment.5 A number of staging systems
have been proposed, including, most recently, the three-stage model suggested by Conway et al.17
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However, as the authors acknowledge, although the various models may provide guidance in defining
TRD, they lack empirical support.
In this study we used a more inclusive definition of TRD, that is, patients who still met the International
Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10),18 criteria for
depression after taking a SSRI or a SNRI antidepressant at an adequate dose [based on the British National
Formulary (BNF)19 and advice from psychopharmacology experts] for a minimum of 6 weeks. This definition
corresponds to stage I TRD as described by Thase and Rush.20 It is directly relevant to UK primary care, given
the large numbers of non-responders in primary care and the current uncertainty about what course of
action to recommend for this group of patients.
Although this 6-week criterion seems a relatively short period to define treatment resistance, many of
the patients who satisfy this criterion of ‘non-response’ are suffering from moderate to severe chronic
depression. The baseline measures for a recent study of the effectiveness of cognitive–behavioural therapy
(CBT) for TRD in primary care, CoBalT (Cognitive behavioural therapy as an adjunct to pharmacotherapy
for primary care patients with treatment resistant depression: a randomised controlled trial),21 found
that 59% of those recruited had been depressed for > 2 years, 70% had been prescribed their current
antidepressant for > 12 months and 28% satisfied the ICD-10 criteria18 for severe depression. These data
on chronicity and severity illustrate the extent of the unmet need in this population.22
It is, therefore, important to undertake a study to investigate the effectiveness of the addition of
mirtazapine to SSRIs or to SNRIs in primary care. In the UK, most depression is diagnosed and treated in
primary care; this is where most antidepressants are prescribed and where most treatment resistance is
encountered. The rise in antidepressant prescribing has continued at a steady rate in the UK despite the
introduction of the government initiative Improving Access to Psychological Services (IAPT). Failure to
adequately respond to treatment is a substantial problem and there is a need to develop the evidence base
for the rational prescribing of antidepressants in primary care. An effective intervention has the potential
to have a substantial impact on the health and economic burden associated with this patient group.
Aims and objectives
This trial investigated whether or not combining mirtazapine with SNRI or SSRI antidepressants results in
better patient outcomes and more efficient NHS care than SNRI or SSRI therapy alone in TRD. All patients
who entered the trial were recruited from primary care and had TRD, defined as meeting ICD-1018 criteria
for depression after at least 6 weeks of treatment with either a SSRI or a SNRI antidepressant at an
adequate dose.
Our specific aims were to:
l determine the effectiveness of the addition of the antidepressant mirtazapine to a SSRI or a SNRI in
reducing depressive symptoms and improving quality of life (QoL) at 12 and 24 weeks and 12 months
(compared with the addition of a placebo)
l determine the cost-effectiveness of this intervention over 12 months
l qualitatively explore patients’ views and experiences of taking either two antidepressant medications or
an antidepressant and a placebo and identify patients’ reasons for completing or not completing the
study, including reasons for withdrawal from the study medication
l qualitatively explore GPs’ views on prescribing combined antidepressant therapy in this patient group.
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Chapter 2 Methods
Study design
The MIR trial was a two-parallel-group, multicentre, pragmatic, placebo-controlled randomised trial with
allocation at the level of the individual. Patients were recruited from general practices in England in the areas
surrounding our four recruiting centres: (1) Bristol, (2) Exeter, (3) Hull/York and (4) Manchester/Keele. The
primary outcome was measured at 12 weeks. The double-blinded randomised allocation was maintained for
a period of 12 months, although participants could be unblinded at their request or at the request of their
GP after measurement of the primary outcome at 12 weeks; outcomes were also measured at 24 weeks and
12 months.
An economic evaluation was conducted alongside the randomised controlled trial (RCT) to evaluate
the cost-effectiveness of the intervention at 12 months (see Chapter 4). A nested qualitative study was
conducted to explore patients’ and GPs’ views of the use of an additional antidepressant (see Chapter 5).
The trial protocol has been published.23
Ethics approval and research governance
Ethics approval for the study was given by South East Wales Research Ethics Committee (REC) Panel C
(reference: 12/WA/0353). Bristol Clinical Commissioning Group (CCG) and other relevant CCGs provided
research governance assurance. Clinical trial authorisation was provided by the Medicines and Healthcare
products Regulatory Agency (MHRA). The trial sponsor was the University of Bristol. The trial was registered
as EudraCT number 2012-000090-23 (January 2012) and ISRCTN06653773 (September 2012). A summary
of the changes made to the original protocol is given in Table 1.
Participants
The trial sought to recruit participants from primary care who had depression that had not responded to at
least 6 weeks of treatment with SSRI or SNRI antidepressants, prescribed at an adequate dose. We planned
to recruit 470 participants over 18 months from 96 practices in four centres.
Inclusion criteria (all must apply)
Eligible patients were those who met all of the following criteria.
l Aged ≥ 18 years and in primary care.
l Treated for depression for at least 6 weeks with any one of the following SSRI or SNRI antidepressants
at recommended BNF doses – fluoxetine, sertraline, citalopram, escitalopram, fluvoxamine, paroxetine,
duloxetine or venlafaxine (see Appendix 1, Table 25 for the adequate dose table).
l Adhered to their medication. Adherence to medication is difficult to measure. To operationalise our
definition of treatment resistance, we used the Morisky four-item self-report measure of compliance,24
as adapted for CoBalT.25 The Morisky measure has previously been validated against electronic
monitoring bottles, with a score of zero (range 0–4) indicating at least 80% compliance.18,26 Given the
relatively long half-life of antidepressant medication, individuals who have forgotten to take one or two
tablets were not excluded.
l Scored ≥ 14 points on the Beck Depression Inventory-II (BDI-II).27
l An ICD-10 diagnosis of depression [assessed using the Clinical Interview Schedule – Revised (CIS-R)].28
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Exclusion criteria (presence of any warrants exclusion)
General practitioners were asked to exclude patients who fulfilled any of the following exclusion criteria at
the time of the record search:
l patients currently taking combined or augmented antidepressant treatment
l patients having their medication managed by a psychiatrist
l patients with dementia (formal diagnosis), bipolar disorder, psychosis or alcohol or substance
abuse/dependence
l women who were pregnant, planning a pregnancy or breastfeeding
l patients who were unable to complete the study questionnaires
l patients who had had a previous adverse reaction to mirtazapine
l patients currently being treated with a monoamine oxidase inhibitor (MAOI), including moclobemide,
or with other medical contraindications to mirtazapine.
TABLE 1 Summary of changes to the original MIR trial protocol
Description Submitted Approved
Original submission (v8.3) 8 November 2012 N/A
Amendment 1 (protocol v8.4) 23 January 2013 25 January 2013
Revised submission
Not setting an upper age limit
Clarification of DMEC to review data
Defining an adequate dose of a SSRI/SNRI
Unblinding option at 12 weeks
Dementia included in exclusion criteria
Clarification of GP changes to drug regime because of failure to respond
Amendment 2 (protocol v8.5) 3 April 2013 N/A
Changes requested by REC
Addition of PCT sites
Clarification of minimisation criteria and of issue of medicine to
unblinded participants
GP information sheet revised
PIS
Amendment 3 (protocol v8.6) 16 April 2013 23 April 2013
Response to REC-suggested changes
Change wording from ‘tablet’ to ‘capsule’
Amendment 4 (protocol v8.7) 4 October 2013 4 October 2013
Dates for project milestones revised
Appendix 3: UHB’s AE SOP replaced with MIR trial-specific AE SOP
Amendment 5 (protocol v8.8) 3 July 2015 11 September 2015
Section 13.3 Expected Adverse Events and Reactions updated to reflect a
revised SMPC
Immediate implementation because of urgent safety measures
DMEC, Data Monitoring and Ethics Committee; N/A, not applicable; PCT, primary care trust; PIS, patient information sheet;
SMPC, Summary of Medicinal Product Characteristics; SOP, standard operating procedure; UHB, University Hospital Bristol
NHS Foundation Trust.
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Recruitment of participants
We used two methods of recruitment: record search and in-consultation recruitment.
Method 1: search of general practice computerised records to identify patients being
treated for depression
The search of general practice computerised records identified all patients in the appropriate age range who
had been prescribed SSRI or SNRI antidepressants for ≥ 6 weeks and who were currently being prescribed
an antidepressant medication at an adequate dose for depression, as recommended in the BNF.19
The GPs then screened this list of patients and excluded those patients who fulfilled any of the exclusion
criteria listed above. A letter of invitation and a brief information leaflet about the study were sent by the
general practice to the remaining potential participants. This letter sought permission for the research team
to contact potential participants and to send a questionnaire asking about their depressive symptoms and
adherence to antidepressant medication. Potential participants replied directly to the study team indicating
whether or not they agreed to be contacted. One reminder was sent to those who did not respond to the
initial letter of invitation.
On the reply slip, those who did not wish to participate were asked to indicate their age, sex and reason
for non-participation. In addition, non-participants were asked to indicate their willingness to take part in a
brief telephone interview to discuss their reasons for non-participation.
Anonymised data on the age and sex of those patients who were mailed an invitation to participate but
who did not respond (or who refused to participate when invited during the consultation) were collected
to assess the generalisability of the study findings.
Method 2: in-consultation recruitment
The GPs could also invite patients to take part in the study during a consultation. In such cases, they
provided patients with an information leaflet about the study and obtained permission to pass their contact
details to the research team. The research team then mailed a questionnaire to potential participants asking
them about their depressive symptoms and adherence to antidepressant medication.
Postal screening: assessment of depressive symptoms and adherence to antidepressants
All those who agreed to be contacted by the research team (in response to either the postal invitation or a
direct invitation from their GP during a consultation) were sent a postal questionnaire. This questionnaire
collected data on the following:
l severity of depressive symptoms, using the BDI-II
l duration of antidepressant treatment, dose of medication and adherence to medication, using the
Morisky measure of compliance
l sociodemographic variables (age, sex, marital status, ethnicity, educational qualifications, employment
status, home ownership and financial difficulties).
One reminder was sent to those individuals who did not return a completed postal questionnaire within
2 weeks.
The GPs were then asked to review all of the patients who appeared to be eligible on the postal screening
and to sign a form to confirm that these patients were suitable to be prescribed mirtazapine. Once GP
approval was received, patients were contacted by a researcher by telephone and invited to attend a
face-to-face appointment with a researcher to discuss participation in the trial and to assess their eligibility.
The date, time and location of the baseline appointment were confirmed by letter. A detailed patient
information sheet (PIS) and a detailed leaflet about mirtazapine were also enclosed; patients were asked to
read both prior to attending the baseline appointment.
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Patients who completed the screening process but were not eligible to participate received a letter
informing them of this and thanking them for taking part. The letter explained that their GP had also been
informed and would continue to care for them as usual. The GP received a letter which explained that the
patient was ineligible as he or she had not met one or more of the eligibility criteria, but that the GP could
refer the patient back to the trial if these factors changed. If the patient had given permission in the postal
questionnaire, the GP also received a report that gave more detail about the inclusion criteria that were
not satisfied, as well as the individual’s score on the BDI-II.
Baseline assessment
The baseline assessment was conducted in the patient’s home or at the GP’s surgery or on university premises.
The researcher explained the study in detail and obtained written informed consent for the baseline assessment.
If the potential participant agreed to the assessment, they completed the following questionnaires:
l BDI-II
l Morisky questionnaire (adherence to medication)
l Patient Health Questionnaire-9 items (PHQ-9),29 a brief measure of depression
l CIS-R, an in-depth psychiatric questionnaire that gives an ICD-10 diagnosis.
Patients were also asked for details of their prescribed medication, prior use of antidepressants and
whether or not they were currently in receipt of psychological therapy. In addition, sociodemographic
details were recorded (age, sex, ethnicity, marital status), together with information on a number of
socioeconomic markers (employment status, housing situation).
Potential participants who scored ≥ 14 points on the BDI-II and who had an ICD-10 primary diagnosis
of depression using the CIS-R, were told that they were potentially eligible to enter the trial [pending
confirmation by the principal investigator (PI)] and were asked to provide further written consent for trial
participation and indicate whether or not they were willing to be contacted about future research projects.
These potentially eligible participants were also asked to complete some further questionnaires including the:
l General Anxiety Disorder-7 (GAD-7) questionnaire30
l EuroQoL-5 Dimensions, five-level version (EQ-5D-5L),31 a brief measure of health-related QoL
l Short Form questionnaire-12 items (SF-12), a brief measure of mental and physical functioning32
l Antidepressant Side-Effect Checklist (ASEC), a measure of antidepressant side effects.33
They were asked further questions about their history of depression, whether or not they had ever been
referred to a psychiatrist and the strength of their preference for active treatment over placebo (as this
could potentially affect medication adherence and outcomes). Additional information was collected on life
events, financial stress, social support and use of alcohol.34
Once the baseline assessment was complete, the local research clinician (PI) reviewed the baseline
information and confirmed whether or not the patient was eligible for the MIR trial.
Informed consent
Prior to the start of the baseline assessment, patients were asked to provide written informed consent for
the storage and processing of the data collected at the time of the assessment. This covered the data
collected from both those who were found to be ineligible to participate in the trial as well as those who
were eligible, thus, enabling the trial to be reported in line with the Consolidated Standards of Reporting
Trials (CONSORT) guidelines.35 Those patients who were identified as eligible to participate in the trial
were asked to provide additional written informed consent for this purpose. The original signed and dated
consent forms were held securely as part of the trial site file, with copies given to both the participants and
their GPs for their records.
METHODS
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Randomisation, concealment of allocation and blinding
Following the baseline assessment, eligible and consenting participants were randomised using the automated
randomisation service provided by the Bristol Randomised Trials Collaboration (BRTC). Randomisation was
carried out by means of a computer-generated code to ensure concealment of allocation.
Randomisation was stratified by centre (n= 4) to ensure balance in terms of local differences. Minimisation was
used to ensure balance in important prognostic indicators, that is, baseline BDI-II score (using approximate
tertiles derived from CoBalT baseline scores: < 26 points; 26–34 points; ≥ 35 points), sex and whether or not
the patient was currently receiving a psychological therapy (yes/no). We used minimisation with a probability
weighing of 0.8 to reduce predictability.36
Once this had been completed, the University Hospitals Bristol NHS Foundation Trust (UHB) pharmacy,
which was the central trial pharmacy, was notified. A participant pack containing an initial 8-week supply
of medication was sent by registered post from the UHB pharmacy either to participants’ GP surgery or,
in exceptional circumstances, to their home.
Treatment group allocation
Participants were randomly assigned to one of two treatments: (1) one × 15-mg encapsulated mirtazapine
tablet daily for 2 weeks followed by two × 15-mg encapsulated mirtazapine tablets for up to 50 weeks or
(2) identical placebo tablets. Participants were free to withdraw from the medication at any time. Participants,
clinicians, outcome assessors and the research team were blinded to allocation. All participants continued
with their GP care and usual antidepressants as agreed by their GP. Clinicians were not restricted in their use
of psychological services.
Unblinding was available through the trial pharmacy at all times in case of a medical emergency
(‘emergency unblinding’). After the 12-week primary outcome had been completed, the code could also
be broken at the request of a participant or his or her GP (‘elective unblinding’). Those who had not
requested emergency or elective unblinding were unblinded at the end of the follow-up period or on
withdrawal from the study. The trial team did not provide further supplies of the trial medication once
participants had been unblinded.
Follow-up
Follow-up data collection took place at five time points: 2, 6, 12 and 24 weeks and 12 months post
randomisation. Measurement of the primary outcome took place at the 12-week follow-up. The 12-month
follow-up was designed to enable the investigation of any longer-term effects on study outcomes.
At 2 weeks post baseline, researchers contacted participants briefly by telephone to check that they had
received and started their trial medication. At 6, 12 and 24 weeks and at 12 months, participants were
asked to complete self-report outcome questionnaires. The follow-up schedule is summarised in the flow
chart presented in Figure 1. Follow-up questionnaires could be completed face to face with the researcher,
by telephone or by post. If a postal questionnaire was not returned, a reminder was sent.
Throughout the follow-up process participants were asked about possible AEs and were advised to consult
their GP about these if appropriate. Participants were sent a £5 gift voucher with the 12- and 24-week
and the 12-month questionnaires, to thank them for their participation.
At the end of the 12-month follow-up period (or on withdrawal from the study), participants were advised
to return to their GP to discuss their continued care.
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Withdrawal of trial participants
Participants could withdraw from the trial at any time, for any reason, without their medical care being
affected. When possible, data already collected would continue to be used in the trial; participants who
withdrew from the trial were asked if they were still willing to provide follow-up data. If a patient
withdrew, the reason for, and type of, withdrawal was documented on the case report form (CRF).
Principal investigators had the right to withdraw participants from the trial medication in the event of intercurrent
illness, AEs, serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs) or protocol
violations or for administrative reasons or other reasons; this was documented on the CRF.
Although there is no evidence that the medication is teratogenic, if a participant discovered that she was
pregnant during the trial, she was instructed to stop her trial medication immediately, although she was still
able to continue to participate in completion of the trial outcome measures if she wished. A longer monitoring
period was put in place to establish the safe delivery of a healthy infant, at which point follow-up would stop.
Data collection and management
To standardise processes across the four centres and maximise data quality, researchers were trained to use
detailed standard operating procedures (SOPs) for each stage of data collection. A number of cross-checks
were routinely performed as a means of ensuring that any data inconsistencies arising from either the
baseline assessment or a follow-up were identified and resolved. Trial data were entered into an OpenClinica
version 3.1.4 (Waltham, MA, USA) database at each centre. A range of data validation checks were carried
2-week telephone call
Check receipt of medication
6-week questionnaire
BDI-II, adherence, AEs
12-week questionnaire
BDI-II (primary outcome), PHQ-9, GAD-7, EQ-5D-5L, SF-12, Morisky and other
adherence questions, ASEC, AEs, health economics questionnaire
24-week questionnaire
BDI-II, PHQ-9, GAD-7, EQ-5D-5L, SF-12, Morisky and other adherence questions,
AEs, health economics questionnaire
12-month questionnaire
BDI-II, PHQ-9, GAD-7, EQ-5D-5L, SF-12, Morisky and other adherence questions,
ASEC, AEs, health economics questionnaire, study feedback
questionnaire
Mirtazapine Placebo
Randomised
FIGURE 1 Follow-up schedule.
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out in both Microsoft Access® 2013 (Microsoft Corporation, Redmond, WA, USA) and Stata® 14 (StataCorp
LP, College Station, TX, USA) to minimise erroneous or missing data.
The trial sponsor took primary responsibility for ensuring that the design of the study met appropriate
standards and that arrangements were in place to ensure appropriate conduct and reporting. The trial was
run in accordance with Good Clinical Practice (GCP)37 and current regulatory guidance.
We employed standard strategies to ensure the quality of the data; for example, a random sample of 10%
of CRFs was checked by the trial research team against entries within the database. Consistency checks on
key variables were also conducted to identify unlikely or inconsistent responses. These were checked by
the research team against hard-copy questionnaires and the database was updated accordingly.
Outcome measures
Primary outcome
The primary outcome was change in the BDI-II score at 12 weeks post randomisation, measured as a
continuous variable.
The BDI-II is a 21-item self-report instrument used to measure the severity of depressive symptoms
occurring over the previous 2 weeks; it has been widely used in depression trials and extensively validated.27
The 21 items are rated on a four-point severity scale (0–3) and are summed to give a total score (range
0–63 points). A higher score on the BDI-II denotes more severe depression.
Secondary outcomes
The BDI-II was also completed at 24 weeks and at 12 months to assess the longer-term effect of the
intervention. Other outcome measures included at the 12- and 24-week and the 12-month follow-up
assessments are listed below:
1. treatment response, measured as an improvement of ≥ 50% in BDI-II score at 12 weeks compared
with baseline
2. the rate of remission of symptoms, defined as a BDI-II score of < 10 points at 12 weeks
3. depression, as measured using the PHQ-9
4. change in anxiety symptoms (measured using the GAD-7) at 12 weeks
5. all of the above outcomes at 24 weeks and 12 months
6. antidepressant use and adherence (using the Morisky questionnaire and additional questions)
7. QoL (measured using the EQ-5D-5L)
8. social and physical functioning (measured using the SF-12) at 12 and 24 weeks and 12 months
9. AEs, including any new symptoms or worsening of existing symptoms, consultations for a documented
deterioration in illness and SAEs (self-reported or from a review of primary care notes) and side effects
(measured using the ASEC) at 12 weeks and 12 months
10. cost-effectiveness from the perspectives of the NHS, patients and society (using self-report
questionnaires at 12 and 24 weeks and at 12 months and using primary care practice data on
consultations, services and prescriptions over the 12-month trial period).
See Appendix 1, Table 26 for a full schedule of the questionnaires used.
Handling missing items
For the BDI-II, PHQ-9 and GAD-7, the research team dealt with any missing data at an individual item level
by adopting the following rule: if ≥ 10% of the items were incomplete, the data collected on that measure
for that participant were disregarded. However, if < 10% of the items on a particular measure were
missing, missing item(s) were imputed using the mean of the remaining items (rounded to an integer).
Therefore, when an individual had completed 19 or 20 items for the primary outcome measure (BDI-II),
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the remaining one or two items were imputed. For all other measures (PHQ-9 and GAD-7), the 10% rule
meant that only a single item would be imputed. Data were complete for the majority of the sample. The
scoring manuals for the SF-12 and EQ-5D-5L, which require the application of complex scoring algorithms,
indicated that, if any item was missing, the scale score should not be calculated.
A number of sensitivity analyses were conducted to assess the impact of missing primary outcome data on
the main findings.
Trial medication
The active trial drug was mirtazapine: one × 15-mg oral capsule per day for 2 weeks, followed by 2 × 15-mg
oral capsules per day for up to 12 months. The mirtazapine was encapsulated and the placebo was an identical
capsule filled with an inert excipient. The placebo capsule exactly matched the encapsulated mirtazapine in
dimensions and appearance, so that allocation concealment and blinding of the trial were maintained.
Packaging, labelling and dispensing
The labelling of medication packs was MHRA approved and conformed to Annexe 13 of good manufacturing
practice standards and Article 13.3 of Directive 2001/20/EC.38 Each medication pack had a medicine
identification number, randomly generated to ensure that mirtazapine and placebo medicine packs were
indistinguishable and, thus, maintain allocation concealment. The random numbers were generated by the
BRTC and provided to the manufacturer, who used them to form the identifiers.
Sharp Clinical Services (UK) Ltd (Crickhowell, UK) provided qualified person services and distribution and
project management. It shipped labelled and numbered packages to the central trial pharmacy (UHB
Clinical Trials Pharmacy), where the trial medication was stored under controlled conditions. Storage was
secure and there were delegation logs for access, for which the trial pharmacy took responsibility. The trial
pharmacy dispensed individual participant packs and oversaw the packaging and posting of those packs.
Participant packs contained no more than an 8-week supply of the trial medication and were posted by
recorded delivery. All deliveries were logged to ensure drug accountability. The trial medication was
shipped and stored in conditions in line with the manufacturer’s stability data.
Concomitant medication
Pharmacodynamic interactions
Mirtazapine should not be administered concomitantly with MAOIs or within 2 weeks after discontinuation
of MAOI therapy. Likewise, about 2 weeks should pass before patients treated with mirtazapine are
treated with MAOIs. Participants in this study were not treated with MAOIs and GPs were advised to wait
at least 2 weeks after stopping the trial medication before starting a MAOI.
Co-administration with other serotonergic active substances [L-tryptophan, triptans, tramadol, linezolid
(Zyvox®; Pfizer, New York, NY, USA), lithium and St John’s wort (Hypericum perforatum) preparations] may
lead to serotonin-associated effects; therefore, participants were advised to use these medications with
caution. Mirtazapine may increase the sedating properties of benzodiazepines and other sedatives (notably
most antipsychotic drugs, antihistamine H1 antagonists and opioids). Caution should be exercised when
these medicinal products are prescribed together with mirtazapine.
Mirtazapine may increase the central nervous system depressant effect of alcohol. Participants were,
therefore, advised to be cautious in their intake of alcohol while taking mirtazapine.
Other concomitant care (including switching, discontinuing or changing the dose of SSRI/SNRI medication
and receipt of psychological therapies) was not prohibited.
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Trial-stopping rules
The trial could be prematurely discontinued by the sponsor, chief investigator, regulatory authority or
funder on the basis of new safety information or for other reasons given by the Data Monitoring and
Ethics Committee (DMEC) or Trial Steering Committee (TSC).
The trial could be prematurely discontinued because of a lack of recruitment or on advice from the TSC.
If the trial was to be prematurely discontinued, active participants would have to be informed and no
further participant data would have been collected.
Justification of sample size
Original sample size calculation
The primary outcome was BDI-II score, reported as a continuous variable. It is difficult to estimate a clinically
important difference in BDI-II score, although the NICE guideline panel for the first depression guideline39
suggests that this corresponds to about 3 points [standard deviation (SD) 0.35 points] on the Hamilton
Depression Rating Scale (HDRS)40 for non-treatment-resistant patients and 2 points for those who are
treatment resistant. The equivalent difference to 3 HDRS points for the BDI-II total score would be 3–4 points
(SD 10–12 points in CoBalT), which is also a clinically important difference from the patient perspective.41
With 200 participants in each group, we would have 91% power to detect a difference of 0.33 SDs at the
5% level. Allowing for a 15% loss to follow-up at 12 weeks, we wanted to recruit 472 patients.
For our secondary outcome, response rate, defined as a 50% reduction in symptoms using the BDI-II score,
200 patients in each group would yield 90% power to detect a difference of between 30% and 46%
in response, or an odds ratio (OR) of 2, at a two-sided 5% significance level. We therefore aimed to recruit
120 patients from 24 general practices at each of the four recruiting centres.
Blinding
Participants, GPs and investigators were blinded to treatment. The effectiveness of blinding was assessed
by a brief questionnaire asking participants to which arm they believed they had been allocated at the
12-week follow-up.
Statistical analysis
Baseline data analyses
Baseline sociodemographic and clinical characteristics were described by treatment group to ascertain
any marked imbalances and inform any additional adjustment of the primary and secondary analyses as
appropriate. Continuous variables were summarised using the mean and SD [or median and interquartile
range (IQR) if the distribution was skewed] and categorical data were summarised as frequencies and
proportions. All antidepressant medication use at baseline was reported by class, name, dose and duration
of treatment.
Stratification, minimisation and sociodemographic variables and measures of depression and treatment
preference, assessed at baseline, were explored for associations with ‘missingness’ of the primary outcome
measure at 12 and 24 weeks and 12 months. Comparisons were made using chi-squared tests for
categorical variables and t-tests and Mann–Whitney U-tests for continuous variables.
Primary analysis
Analysis and reporting were in line with CONSORT guidelines,35 with the primary analyses being conducted
on an intention-to-treat (ITT) basis. The primary analysis was the BDI-II score at 12 weeks post randomisation,
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measured as a continuous variable. Linear regression modelling was used to compare the randomised
groups, adjusting for stratification and minimisation baseline variables and baseline BDI-II score.
Analyses of secondary outcomes were conducted by adjusting for the baseline measure of the outcome
variable and stratification and minimisation variables. Linear regression was used for continuous outcomes
and logistic regression models were used for binary outcomes.
Secondary analyses
Secondary analyses of the primary and all secondary outcomes included additional adjustment for variables
demonstrating a marked imbalance at baseline (ascertained using descriptive statistics).
In all analyses, we have presented regression coefficients (or ORs for binary outcomes), with 95% CIs and
p-values.
Subgroup analyses
We conducted a number of prespecified analyses to investigate any differential effects in subgroups defined
by a number of factors. These were carried out by introducing appropriate interaction terms in the regression
models. We carried out these analyses by baseline depression severity (BDI-II) and a multilevel measure of
degree of treatment resistance based on duration of symptoms and prior treatment with antidepressants.
Sensitivity analyses
In all tables, missing data are indicated in the footnotes. For our analysis of the primary outcome, we
investigated the influence of missing data using sensitivity analyses that made different assumptions: ‘best’-
and ‘worst’-case scenarios and multiple imputation by chained equation (MICE) to impute missing data.42,43
When using MICE, 25 data sets were generated and 10 switching procedures undertaken. The imputation
model included all variables predictive of missingness, together with all of the variables used in the primary
analysis. Results from the ITT analyses of complete cases are presented alongside these analyses.
Per-protocol analyses were conducted at 12 weeks and at 12 months for the primary outcome. As these
are likely to be biased, we also adopted a complier-average causal effect (CACE)44 approach.
A further sensitivity analysis using CACE methods was conducted at 24 weeks and 12 months. If we
define ‘compliers’ as those who had continued taking their trial medication up until 12 weeks, we could
then estimate the effect of completing a 12-week course of mirtazapine on depression outcomes at the
later follow-up points (24 weeks and 12 months).
Safety reporting and disclosure
Definitions
Adverse event
Adverse events were defined as any untoward medical occurrence in a clinical trial participant. An AE did
not necessarily have to have a causal relationship with the trial treatment. An AE could, therefore, be any
unfavourable and unintended sign (including an abnormal finding), symptom or disease temporally
associated with the use of a medicinal (investigational) product, whether or not related to the medicinal
(investigational) product [International Conference on Harmonisation (ICH) definition].45 This included any
occurrence that was new in onset or aggravated in severity or frequency from the baseline condition, or
abnormal results of diagnostic procedures, including laboratory test abnormalities. All AEs were recorded
on the CRF for the duration of participants’ direct involvement in the trial (12 months).
METHODS
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Serious adverse event
A SAE was defined by the ICH45 as any untoward medical occurrence that, at any dose of the trial medication,
meets any of the following conditions:
l Resulted in the death of the participant.
l Was life-threatening. The term ‘life-threatening’ referred to an event in which the participant was at
risk of death at the time of the event; it did not refer to an event that hypothetically might have caused
death if it were more severe.
l Required inpatient hospitalisation or prolongation of existing hospitalisation. For any events that were
not immediately life-threatening or did not result in death or hospitalisation, but that could jeopardise
the participant or required intervention to prevent one of these outcomes, the chief investigator would
exercise his/her scientific and medical judgement to decide whether or not such an event required
expedited reporting to UHB (who acted on behalf of the sponsor in these instances).
l Resulted in persistent or significant disability/incapacity. This means any event that seriously disrupted
the ability of the participant to lead a normal life; in other words, one that led to a persistent or
permanent significant change, deterioration, injury or perturbation of the participant’s body functions
or structure, physical activity and/or QoL.
l Was a congenital anomaly/birth defect. This related to exposure to the trial drug before conception
(in men or women) or during pregnancy that resulted in an adverse outcome in the child.
l Other medical events. This related to medical events that could jeopardise the subject or required an
intervention to prevent a characteristic or consequence of a SAE. Such events were referred to as
‘important medical events’ and were also considered as ‘serious’ in accordance with the definition of
a SAE.
Adverse event associated with the use of the drug
An AE was considered to be associated with the use of the drug if the attribution was possible, probable
or very likely, as in the following definitions:
l Not related – an AE that was not related to the use of the drug.
l Doubtful – an AE for which an alternative explanation was more likely, for example concomitant drug(s),
concomitant disease(s) or the relationship in time suggesting that a causal relationship was unlikely.
l Possible – an AE that might be because of the use of the drug and for which an alternative explanation,
for example concomitant drug(s) or concomitant disease(s), was inconclusive. The relationship in time
was reasonable and, therefore, the causal relationship could not be excluded.
l Probable – an AE that might be the result of the use of the drug. The relationship in time was suggestive
(e.g. confirmed by withdrawal from trial medication). An alternative explanation was less likely, for
example concomitant drug(s) or concomitant disease(s).
l Very likely – an AE that was listed as a possible adverse reaction and could not be reasonably explained
by an alternative explanation, for example concomitant drug(s) or concomitant disease(s). The
relationship in time was very suggestive (e.g. it was confirmed by withdrawal from trial medication
and reintroduction).
Procedure for reporting
All AE reporting was in accordance with the MIR trial SOP for AE reporting (see Appendix 1).
All adverse events
All AEs were reported by the chief investigator from the time that a signed and dated informed consent
form was obtained until completion of the last trial-related procedure (collection of follow-up data
12 months after randomisation). Those occurrences meeting the definition of SAEs were reported using
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the SAE form (see Appendix 1), including SAEs spontaneously reported to the investigator within 30 days
after the participant had completed the trial (including post-trial follow-up). UHB, on behalf of the sponsor,
would evaluate any safety information that was spontaneously reported by a chief investigator beyond the
time frame specified in the protocol. All AEs, regardless of seriousness, severity or presumed relationship
to the trial drug, were recorded in the source document and the CRF, together with any measures taken.
All PIs recorded in the CRF their opinion concerning the relationship of the AE to the trial therapy.
UHB, on behalf of the sponsor, assumed responsibility for appropriate reporting of AEs to the regulatory
authorities.
Serious adverse events
All SAEs were reported to UHB (who monitored SAEs on behalf of the sponsor) and the relevant PI by a
delegated member of the research team within 24 hours of their knowledge of the event. The chief
investigator and trial manager were also informed. All SAEs that were not resolved by the end of the
trial (i.e. by the end of the primary care notes review follow-up period), or that were not resolved on
discontinuation of the participant’s participation in the trial, were followed until (1) the event resolved/
stabilised/returned to baseline, (2) the event could be attributed to other factors unrelated to the trial or
(3) it became unlikely that additional information could be obtained.
The death of a participant was considered a SAE, as was any event requiring hospitalisation (or prolongation
of hospitalisation) that occurred during the course of a participant’s participation. Exceptions to this were
hospitalisations for:
l social reasons, in the absence of an AE
l in-clinic protocol measures
l surgery or procedure planned before entry into the trial (this was documented on the CRF).
Suspected unexpected serious adverse reaction
All relevant information about a SUSAR that occurred during the course of the trial was reported to the
MHRA and the relevant ethics committee by UHB, on behalf of the sponsor, as soon as possible (fatal or
life-threatening SUSARs were reported within 7 days; those that were not fatal or life-threatening were
reported within 15 days).
The expectedness of an AE was determined by whether or not it was listed in the Summary of Medicinal
Product Characteristics (SMPC), the BNF and/or the study protocol.
Expected AEs and adverse reactions are presented in Appendix 1, Box 2.
Quality assurance
Good Clinical Practice37 is an international ethical and scientific quality standard for designing, conducting,
recording and reporting studies that involve the participation of human subjects. Compliance with this
standard provides public assurance that the rights, safety and well-being of trial subjects are protected,
consistent with the principles that originated in the Declaration of Helsinki,46 and that the clinical trial data
are credible. This research trial ran in accordance with GCP.
Direct access to source data/documents
The PIs and trial site teams allowed monitors (from UHB, on behalf of the sponsor), persons responsible for
the audit, representatives of the REC and representatives of the regulatory authorities to have direct access
to source data/documents. This was reflected in the PIS. Trial monitoring was undertaken on behalf of the
sponsor by UHB using their monitoring SOP.
METHODS
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Trial monitoring
Before the trial
The PIs and trial sites allowed the monitors to visit the sites and facilities where the trial took place to
ensure compliance with the protocol requirements. The University of Bristol’s Green Light procedure was
implemented in each of the other collaborating centres in order to document preparedness to conduct
recruitment locally. A monitoring plan was agreed prior to commencement of the trial.
During the trial
The PIs allowed the monitors and/or the sponsor to:
l inspect the sites, the facilities and the material used for the trial
l meet all members of their team involved in the trial
l consult all of the documents relevant to the trial
l check that the CRFs had been filled out correctly
l directly access source documents to compare data therein with the data in the CRFs
l verify that the trial was carried out in compliance with the protocol and local regulatory requirements
l carry out trial monitoring at regular intervals, depending on the recruitment rate and arranged between
the chief investigator and monitor.
All information dealt with during these visits was treated as strictly confidential.
Quality assurance during the trial
We employed standard strategies to ensure the quality of the data; for example, a random sample of 20%
of the CRFs was checked by the trial research team against entries in the database. Recruiting sites were
asked to perform a self-audit on all entries and provide a report to the Bristol trial centre (who would
report to the trial sponsor). A 10% sample audit was conducted by the UHB monitoring team.
The content of the database was validated at two stages, as follows:
1. At the data-entry stage, validation rules were set to run on submission of data in order to direct
researchers to fields that required completion, should any essential fields be missed, and to flag up
anomalous or incomplete entries so that researchers could correct data prior to final submission of the
electronic CRF.
2. Management information regarding data quality and completeness at centre, site and patient level was
generated from data within the trial database and used by the trial manager to inform the implementation
and monitoring of the trial.
Standard operating procedures were developed to address each aspect of quality control and the quality
assurance procedures.
Data handling
The database and randomisation system were designed to protect patient information and maintain
anonymity. Data were stored securely in line with the Data Protection Act 1998.47 The chief investigator
was the custodian of the data. Access to the final data set was restricted to the MIR trial team in the first
instance. The team were open to requests by other investigators to access anonymised data.
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Other methodological issues
Extension to the trial in 2015
We were obliged to request additional funding for the trial to meet the recruitment target set out in the
trial protocol. At the end of September 2014, we had recruited and randomised 200 participants. The
recruitment period as set out in the original application was to have ended on 28 February 2015. The final
target was 470 participants and it was not likely that we would achieve this within the designated time
frame. Recruitment rates during the study had been good and to target. However, there were delays in
set-up and in obtaining the necessary permissions from regulatory bodies and finalising contracts with the
supplier of the trial medication. An extension of 7 months was awarded and we recruited 480 participants
in the revised timescale.
Elective unblinding after the primary outcome at 12 weeks
In the initial study design we proposed that participants would remain blind to allocation for 52 weeks.
However, we were advised by the REC that this was not ethically acceptable and that we should offer
elective unblinding after the 12-week primary outcome. Therefore, after the 12-week follow-up and data
collection (the primary outcome), participants who wished to continue in the study had the following
two options:
1. to continue with the trial medication, blind to allocation, with the understanding that they could be
unblinded at any time if they wished
2. to be unblinded to their allocation, which would mean that they would no longer receive the trial
medication but would remain in the study.
The randomised blinded design was, therefore, preserved intact up until the primary outcome at 12 weeks.
However, after that point, participants could discover whether they had been taking placebo or the active
treatment. Those who were unblinded then had the option to discontinue their treatment or to consult
their GP and request treatment with mirtazapine. Therefore, in addition to the two blinded groups who
continued to receive the trial medication, there were now four unblinded groups, as follows, all of whom
were included in the remaining follow-ups:
1. those who had been taking placebo up to 12 weeks and who decided to request mirtazapine from
their GP
2. those who had been taking placebo up to 12 weeks and who did not request mirtazapine
3. those who had been taking mirtazapine up to 12 weeks and who decided to continue with the drug,
now supplied by their GP
4. those who had been taking mirtazapine up to 12 weeks and who decided not to continue with this drug.
METHODS
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Chapter 3 Results
Practice details
Across four centres, 106 general practices agreed to collaborate in the MIR trial; record searches were
conducted and mailings sent out. A summary of the practice characteristics of the participating general
practices is presented in Table 2. The median number of patients invited to participate in the study per
general practice was similar in all four centres.
Flow of participants into the trial
A screening process was designed first to identify those patients being treated for depression and then to
assess their depressive symptoms and adherence to antidepressant medication to identify the target population
who were potentially eligible to participate in the MIR trial. Potential participants were then invited to a
baseline assessment with a researcher to establish their eligibility. The flow of participants through these three
stages is outlined in Figure 2. The screening process commenced in August 2013 and the final patient was
randomised to the trial on 6 October 2015. All follow-up data were collected between August 2015 and
31 October 2016.
Search of general practice computerised records to identify patients being treated
for depression
There were 26,898 patients aged ≥ 18 years who were currently being prescribed antidepressants for
≥ 6 weeks at an adequate dose identified through searches of the general practice computerised records.
A further 166 individuals were referred to the study directly by their GP. GPs excluded 7932 individuals
who were ineligible. Fifty patients were invited as a result of an administrative error and responded,
of whom 15 opted in to participate in the trial.
TABLE 2 Practice details by centre
Practice details
Centre
TotalBristol Exeter Manchester/Keele Hull/York
Number of practices 33 22 31 20 106
Practice size (number of
patients), median (IQR)
10,100
(8442–14,019)
9890
(4802–13,695)
6021
(3926–9292)
11,862
(6056–14,800)
9200
(5869–13,353)
Number of full-time GPs
per practice, mean (SD)
6 (2.2) 6 (3.9) 5 (3.1) 6 (2.5) 6 (3.0)
Number of patients per practice
Invited, median (IQR) 158 (77–215) 150 (86–261) 118 (73–248) 261 (143–405) 153 (80–262)
Completed screening
questionnaire, median
(IQR)
22 (8–28) 23 (14–31) 12 (6–34) 29 (16–42) 21 (9–32)
Randomised, median
(IQR)
5 (2–9) 4 (3–8) 2 (1–3) 6 (4–9) 4 (2–7)
Percentage of patients
completing screening
questionnaire who were
randomised
26 24 13 20 21
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Baseline interviews
(n = 751)
Invited to participate
(n = 18,966)
Direct GP referrals
(n = 166)
Opted out
[n = 4702 (25%)]
Randomised
(n = 480)
Excluded by GPs
(n = 7932)
Sent postal screen
[n = 2299
(2135 opt-ins and 164 referrals)]
• No response, n = 296
• Not eligible, n = 827
• Declined, n = 60
Eligible at postal screen
(n = 1116) • Eligible but declined, n = 105
• Excluded (pre-baseline call), n = 71
• GP exclusion, n = 52
• GP approval not provided before recruitment
   closure, n = 42
• Pre-baseline call not complete before
   recruitment closure, n = 35
• Baseline scheduled but not completed before
   recruitment closure, n = 60
Opted in
[n = 2180 (11%)]
Identified by record search
(n = 26,898)
No response
[n = 12,134 (64%)]
Eligible
(n = 481)
Reason ineligible:
• No ICD-10 depression and/or BDI-II score  < 14,
   n = 268
• Alcohol dependence, n = 1
• Recent dose change, n = 1
Eligible but declined
(n = 1)
Opted in too late
(n = 45)
Responded despite exclusiona
(n = 50)
Referred too late
(n = 2)
Opted out
(n = 35)
Opted in
(n = 15)
Not eligible
(n = 270)
FIGURE 2 Flow of participants: recruitment pathway. a, Invited by practice despite GP exclusion. Of these, 15 patients
opted in (of whom 3 were randomised). Note: Some patients may be ineligible for more than one reason.
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In total, 19,016 patients were mailed a letter of invitation to participate in the study, asking for their
permission for the research team to contact them (although 50 of these were invited in error having been
excluded by their GPs). GPs invited 166 patients to take part during consultation. Of these, 2180 patients
(11%) responded to the letter of invitation and opted in, 4702 (25%) responded and opted out and
12,134 (64%) did not respond to the invitation (see Figure 2).
When available, information on age and sex were recorded from GP records and are summarised in
Appendix 2, Tables 28 and 29.
Assessment of depressive symptoms and adherence to antidepressant medication
A screening questionnaire was mailed to 2299 potential participants, of whom 296 individuals did not
complete the assessment screen and 60 declined. Of those who returned their questionnaire, 827 were
not eligible; mostly this was because their BDI-II score was below the threshold of 14 points, they were not
adhering to their antidepressant medication or they did not meet the criteria for an adequate dose/duration
of treatment. Other reasons for ineligibility at this stage were pregnancy, breastfeeding, treatment with
mirtazapine or amitriptyline and being part of another Clinical Trial of an Investigational Medicinal Product
(CTIMP). In total, 1116 patients were eligible at the postal screen stage. However, 105 decided not to
participate, 71 were excluded at the pre-baseline check and 52 were excluded by their GP as not suitable.
A total of 137 were excluded because their checks were not completed before the closure of recruitment.
When available, information on age and sex were recorded from GP records and are summarised in
Appendix 2, Table 30.
Baseline assessment of eligibility to participate in the randomised controlled trial
A total of 751 potential participants attended a face-to-face baseline appointment with a researcher
to establish their eligibility to participate in the MIR trial and obtain written informed consent. In total,
270 individuals were ineligible to participate. The majority (n = 268) were ineligible because they did not
meet the ICD-10 criteria for depression or failed to meet the BDI-II threshold. In total, 480 individuals were
eligible to participate, gave written informed consent and were randomised.
The available information on age, sex and socioeconomic status for those who did and did not attend a
baseline assessment is summarised in Table 3.
Summary of recruitment by centre
There were 480 participants recruited to the study from the four study centres. Bristol recruited the most
participants (n = 177), Exeter recruited 122 participants, Hull/York recruited 99 participants and Manchester/
Keele recruited 82 participants. A summary of recruitment by centre is presented in Appendix 2, Table 31.
A summary of the overall predicted and actual recruitment is provided in Figure 3. Owing to delays in
start-up, a 7-month extension was needed to meet the final target.
Follow-up of participants in the trial
Of the 480 participants randomised, 241 were allocated to receive usual care and mirtazapine and the
remaining 239 were allocated to receive usual care and placebo. The CONSORT flow diagram for the MIR
trial is presented in Figure 4. The number of participants who withdrew from the study – as well as a
breakdown of the reasons for withdrawal – is presented alongside the number who were lost to follow-up
at each follow-up time point.
There were six withdrawals among the participants allocated to receive usual care and mirtazapine and
12 withdrawals among those allocated to receive usual care and placebo (including one participant who
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TABLE 3 Comparison of age, sex and socioeconomic status of potential participants who did and did not attend a
baseline assessment
Sociodemographic characteristics
Attendance
Did not attend (N= 365) Attended (N= 751)
Age (years)
Number with available data 365 751
Mean (SD) 50.22 (14.6) 51.20 (13.4)
Sex
Number with available data 365 751
Female, n (%) 260 (71.2) 513 (68.3)
Employment status
Number with available data 363 746
In paid employment, n (%) 198 (54.6) 390 (52.3)
Not in employment, n (%) 165 (45.5) 356 (47.7)
Educational attainment
Number with available data 363 750
A level, Higher or above, n (%) 146 (40.2) 360 (48.0)
GCSE, Standard Grade or above, n (%) 129 (35.5) 247 (32.9)
No formal qualifications, n (%) 88 (24.2) 143 (19.1)
Housing
Number with available data 364 750
Home owner, n (%) 208 (57.1) 432 (57.6)
Tenant or living with relative/friend, n (%) 150 (41.2) 314 (41.9)
Hostel/care home, homeless or other, n (%) 6 (1.7) 4 (0.5)
A level, Advanced level; GCSE, General Certificate of Secondary Education.
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FIGURE 3 Predicted and actual recruitment.
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Allocated to usual care and mirtazapine
(n = 241)
Not followed up
(n = 11)
• Withdrew from study, n = 2
• Not willing to take part, n = 2
• Lost to follow up, n = 9
Not followed up
(n = 21)
• Withdrew from study, n = 3
• Not willing to take part, n = 2
• Other, n = 1
• Lost to follow up, n = 18
Patients contacted at 6 weeks
(n = 230)
• Returned questionnaire, n = 219
• Completed BDI-II, n = 217
Patients contacted at 12 weeks
(n = 220)
Not followed up
(n = 32)
Patients contacted at 24 weeks
(n = 209)
• Returned questionnaire, n = 196
• Completed BDI-II, n = 196
Not followed up
(n = 50)
• Withdrew from study, n = 6
• Not willing to take part, n = 2
• Health, n = 1
• Other, n = 3
• Lost to follow up, n = 44
Patients contacted at 52 weeks
(n = 191)
• Returned questionnaire, n = 191
• Completed BDI-II, n = 190
Randomised
(n = 480)
• Returned questionnaire, n = 214
• Received treatment as planned, n = 156
• Completed BDI-II, n = 214
Allocated to usual care and placebo
(n = 239)
• Withdrew from study, n = 4
• Not willing to take part, n = 2
• Other, n = 3
• Lost to follow up, n = 28
Not followed up
(n = 12)
• Withdrew from study, n = 3
• Not willing to take part, n = 3
• Lost to follow up, n = 9
Not followed up
(n = 15)
• Withdrew from study, n = 5
• Not willing to take part, n = 5
• Lost to follow up, n = 10
Patients contacted at 6 weeks
(n = 227)
• Returned questionnaire, n = 221
• Completed BDI-II, n = 221
Patients reached at 12 weeks
(n = 224)
Not followed up
(n = 23)
Patients contacted at 24 weeks
(n = 216)
• Returned questionnaire, n = 207
• Completed BDI-II, n = 206
Not followed up
(n = 40)
• Withdrew from study, n = 12
• Not willing to take part, n = 8
• Health, n = 2
• Other, n = 2
• Lost to follow up, n = 28
Patients contacted at 52 weeks
(n = 199)
• Returned questionnaire, n = 199
• Completed BDI-II, n = 198a
• Returned questionnaire, n = 217
• Received treatment as planned, n = 180
• Completed BDI-II, n = 217
• Withdrew from study, n = 8
• Not willing to take part, n = 7
• Other, n = 1
• Lost to follow up, n = 15
FIGURE 4 Flow of participants from randomisation onwards. a, One participant allocated to usual care and placebo
withdrew after 12 months of follow-up.
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withdrew after 12 months of follow-up). Withdrawals tended to occur later in follow-up and the most
common reason for withdrawal in both groups was a lack of willingness to take part. The timings and
reasons for withdrawals are described in Figure 4 and in Appendix 2, Tables 32 and 33.
There were 19 protocol deviations affecting 20 participants (10 among those allocated to usual care and
mirtazapine and 10 among those allocated to usual care and placebo). These included one instance when
a participant was given the medication of another participant (both participants were allocated to the
placebo arm) and one instance when one participant allocated to the placebo arm received another
participant’s mirtazapine prescription and vice versa. The most common protocol deviation was participants
having difficulty receiving the medication (10 participants). In one case, this led to an emergency
unblinding and, in another, the GP prescribed mirtazapine. All protocol deviations are summarised in
Appendix 2, Tables 34 and 35.
Baseline characteristics of randomised participants
Table 4 provides a summary of the descriptive statistics used to assess the baseline comparability of
the randomised groups. Data were collected at baseline on sociodemographic characteristics, caring
responsibilities, treatment preference, severity of depression and measures of depression. A number of
baseline imbalances were observed, suggesting that participants in the mirtazapine group had more severe
depression. Participants randomised to this group were more likely to have had a prior history of depression
and their last course of antidepressants was more recent. A higher proportion of participants in the
mirtazapine group than the placebo group had suicidal thoughts at baseline.
All patients were taking a SSRI or SNRI at baseline; the most commonly prescribed treatments were
citalopram (41.7%) and fluoxetine (24.6%) at doses of 20–60 mg (see Appendix 2, Table 36). There was
little difference between the two groups in this respect: 40.7% of participants allocated to usual care and
mirtazapine and 42.7% of participants allocated to usual care and placebo received citalopram at baseline,
and 23.2% and 24.6%, respectively, were taking fluoxetine. In the mirtazapine group, 10.4% were taking
a SNRI and in the placebo group 9.6% were taking a SNRI.
Losses to follow-up
Follow-up rates were slightly higher in the group allocated to usual treatment and placebo and the
difference increased after 12 weeks (see Figure 4). At 12 weeks, 88.8% of participants allocated to usual
care and mirtazapine and 90.8% of participants allocated to usual care and placebo were contacted for
follow-up. By 24 weeks, 81.3% of participants allocated to usual care and mirtazapine were contacted
compared with 86.6% of participants allocated to usual care and placebo. At 52 weeks, these proportions
were 79.3% and 83.3%, respectively.
Missing data
The pattern of missing data was explored by identifying variables recorded at baseline that were associated
with ‘missingness’ of the primary outcome at 12 weeks’ follow-up. Table 5 presents the frequency and
proportion of missing data by baseline characteristic.
At each time point, when participants were successfully contacted, few did not complete sufficient
components of the BDI-II questionnaire to calculate a score (see Figure 4).
The pattern of missing data was further explored by identifying variables recorded at baseline that were
associated with ‘missingness’ of the BDI-II score at 24 weeks and 12 months, as presented in Appendix 2,
Tables 37 and 38.
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TABLE 4 Baseline characteristics of randomised participants
Variable
Allocated groups
Mirtazapine+ usual care
(N= 241), n (%)
Placebo+ usual care
(N= 239), n (%)
Stratification variable
Centre
Bristol 89 (36.9) 88 (36.8)
Exeter 61 (25.3) 61 (25.5)
Manchester/Keele 41 (17.0) 41 (17.2)
Hull/York 50 (20.7) 49 (20.5)
Minimisation variables
Female 168 (69.7) 164 (68.6)
Baseline BDI-II score, points
14–25 77 (32.0) 79 (33.1)
26–34 78 (32.4) 78 (32.6)
≥ 35 86 (35.7) 82 (34.3)
Currently receiving psychological services 33 (13.7) 29 (12.1)
Sociodemographic variables
Age (years), mean (SD) 50.4 (13.8) 49.9 (12.5)
Ethnic group
White 233 (96.7) 235 (98.3)
Mixed 6 (2.5) 2 (0.8)
Asian/British Asian 1 (0.4) 1 (0.4)
Other 1 (0.4) 1 (0.4)
Marital status
Married/cohabiting 142 (58.9) 135 (56.5)
Single 47 (19.5) 53 (22.2)
Separated 9 (3.7) 9 (3.8)
Divorced 32 (13.3) 27 (11.3)
Widowed 11 (4.6) 15 (6.3)
Employment status
Employed 109 (45.2) 135 (56.5)
Unemployed 132 (54.8) 104 (43.5)
Educational attainment
Degree or equivalent 44 (18.3) 51 (21.3)
HNC, HND, SVQ (Level 4 or 5) or RSA Higher Diploma 17 (7.1) 28 (11.7)
A level, Higher or equivalent [GNVQ/NVQ Advanced,
GSVQ/SVQ (Level 3) or RSA Advanced Diploma]
54 (22.4) 36 (15.1)
GSCE, Standard Grade, O level or equivalent 72 (29.9) 78 (32.6)
No formal qualification 54 (22.4) 46 (19.2)
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TABLE 4 Baseline characteristics of randomised participants (continued )
Variable
Allocated groups
Mirtazapine+ usual care
(N= 241), n (%)
Placebo+ usual care
(N= 239), n (%)
Housing
Home owner 129 (53.5) 134 (56.1)
Tenant 96 (39.8) 88 (36.8)
Living with relative or friend 16 (6.6) 16 (6.7)
Other 0 (0.0) 1 (0.4)
Financial well-being
Comfortable/OK 111 (46.1) 113 (47.3)
Just about getting by or worse 130 (53.9) 126 (52.7)
Alcohol consumption (units), median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–4.0)
Number of life events in the past 6 months, mean (SD) 1.0 (1.0) 1.1 (1.0)
Social support score, mean (SD) 12.2 (4.1) 12.8 (4.0)
Caring responsibilities
Providing care for someone who is disabled 30 (12.4) 37 (15.5)
How many children aged < 5 years live with you?
None 213 (88.4) 219 (91.6)
1 or 2 27 (11.2) 18 (7.5)
≥ 3 1 (0.4) 2 (0.8)
Treatment preference
Do you have a preference for either group?
Prefer to receive mirtazapine 143 (59.3) 146 (61.1)
Prefer to receive placebo 2 (0.8) 0 (0.0)
Do not mind either way 96 (39.8) 93 (38.9)
If you were to be allocated to the other group, how disappointed would you be?a
Very 16 (11.0) 25 (17.1)
Moderately 54 (37.2) 39 (26.7)
A little bit 45 (31.0) 44 (30.1)
Not really 30 (20.7) 38 (26.0)
Measures of depression
Suffered from depression in the past 206 (85.5) 190 (79.5)
Previous referral to a psychiatrist for depressionb 71 (34.5) 60 (31.6)
Number of prior episodes of depressionc
None 3 (1.5) 5 (2.6)
1 14 (6.8) 8 (4.2)
2–4 82 (39.8) 79 (41.6)
≥ 5 107 (51.9) 98 (51.6)
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TABLE 4 Baseline characteristics of randomised participants (continued )
Variable
Allocated groups
Mirtazapine+ usual care
(N= 241), n (%)
Placebo+ usual care
(N= 239), n (%)
Duration of current course of antidepressants
< 6 months 26 (10.8) 20 (8.4)
≥ 6 months 215 (89.2) 219 (91.6)
ICD-10 primary diagnosis
Mild 38 (15.8) 44 (18.4)
Moderate 138 (57.3) 144 (60.3)
Severe 65 (27.0) 51 (21.3)
Secondary psychiatric diagnosis according to the CIS-R
No diagnosis identified 2 (0.8) 5 (2.1)
Mixed anxiety and depressive disorder (mild) 26 (10.8) 31 (13.0)
Generalised anxiety disorder (mild) 2 (0.8) 3 (1.3)
Mixed anxiety and depressive disorder 62 (25.7) 52 (21.8)
Specific (isolated) phobia 13 (5.4) 12 (5.0)
Social phobia 7 (2.9) 15 (6.3)
Agoraphobia 12 (5.0) 9 (3.8)
Generalised anxiety disorder 87 (36.1) 97 (40.6)
Panic disorder 30 (12.4) 15 (6.3)
BDI-II score (points), mean (SD) 31.5 (10.2) 30.6 (9.6)
GAD-7 score (points), mean (SD)d 11.3 (4.8) 10.7 (4.8)
PHQ-9 score (points), mean (SD) 16.7 (5.5) 16.0 (5.5)
EQ-5D-5L score (points), mean (SD)e 0.7 (0.3) 0.7 (0.2)
SF-12 aggregate physical functioning score (points), mean (SD) 45.7 (13.8) 46.4 (13.1)
SF-12 aggregate mental functioning score (points), mean (SD) 27.9 (9.6) 29.2 (9.7)
CIS-R score, mean (SD) 28.3 (8.2) 27.0 (8.3)
Suicidal ideation (CIS-R thoughts/plans)
No suicidal thoughts 81 (33.6) 119 (49.8)
Patient feels life is not worth living 59 (24.5) 44 (18.4)
Suicidal thoughts 101 (41.9) 76 (31.8)
A level, Advanced level; GCSE, General Certificate of Secondary Education; GNVQ, General National Vocational Qualification;
GSVQ, General Scottish Vocational Qualification; HNC, Higher National Certificate; HND, Higher National Diploma;
NVQ, National Vocational Qualification; RSA, Royal Society of Arts; SVQ, Scottish Vocational Qualification.
a Number of missing observations: n = 96 mirtazapine, n= 93 placebo.
b Number of missing observations: n = 35 mirtazapine, n= 49 placebo.
c Number of missing observations: n = 35 mirtazapine, n= 49 placebo.
d Number of missing observations: n = 3 mirtazapine, n= 0 placebo.
e Number of missing observations: n = 1 mirtazapine, n= 1 placebo.
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TABLE 5 Summary of baseline variables related to missing BDI-II score data at 12 weeks
Variable
Data, n (%)
Present (N= 431) Missing (N= 49) p-value
Stratification variable
Centre
Bristol 164 (38.1) 13 (26.5) 0.231
Exeter 110 (25.5) 12 (24.5)
Manchester/Keele 73 (16.9) 9 (18.4)
Hull/York 84 (19.5) 15 (30.6)
Minimisation variables
Female 291 (67.5) 41 (83.7) 0.02
Baseline BDI-II score (points)
14–25 147 (34.1) 9 (18.4) 0.083
26–34 137 (31.8) 19 (38.8)
≥ 35 147 (34.1) 21 (42.9)
Currently receiving psychological services 54 (12.5) 8 (16.3) 0.453
Sociodemographic variables
Age (years), mean (SD) 50.7 (13.0) 45.4 (13.8) 0.008
Ethnic group
White 419 (97.2) 49 (100.0) 0.706
Mixed 8 (1.9) 0 (0.0)
Asian/British Asian 2 (0.5) 0 (0.0)
Other 2 (0.5) 0 (0.0)
Marital status
Married/cohabiting 252 (58.5) 25 (51.0) 0.333
Single 89 (20.6) 11 (22.4)
Separated 16 (3.7) 2 (4.1)
Divorced 49 (11.4) 10 (20.4)
Widowed 25 (5.8) 1 (2.0)
Employment status
Employed 217 (50.3) 27 (55.1) 0.528
Unemployed 214 (49.7) 22 (44.9)
Educational attainment
Degree or equivalent 87 (20.2) 8 (16.3) 0.429
HNC, HND, SVQ (Level 4 or 5) or RSA Higher Diploma 38 (8.8) 7 (14.3)
A level, Higher or equivalent [GNVQ/NVQ Advanced,
GSVQ/SVQ (Level 3) or RSA Advanced Diploma]
79 (18.3) 11 (22.4)
GSCE, Standard Grade, O level or equivalent 139 (32.3) 11 (22.4)
No formal qualification 88 (20.4) 12 (24.5)
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TABLE 5 Summary of baseline variables related to missing BDI-II score data at 12 weeks (continued )
Variable
Data, n (%)
Present (N= 431) Missing (N= 49) p-value
Housing
Home owner 242 (56.1) 21 (42.9) 0.160
Tenant 158 (36.7) 26 (53.1)
Living with relative or friend 30 (7.0) 2 (4.1)
Other 1 (0.2) 0 (0.0)
Financial well-being
Comfortable/OK 208 (48.3) 16 (32.7) 0.038
Just about getting by or worse 223 (51.7) 33 (67.3)
Alcohol consumption, median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 0.934
Number of life events in the past 6 months, mean (SD) 1.0 (1.0) 1.3 (1.3) 0.125
Social support score, mean (SD) 12.5 (4.1) 12.7 (4.4) 0.596
Providing care for someone who is disabled 60 (13.9) 7 (14.3) 0.944
How many children aged < 5 years live with you?
None 388 (90.0) 44 (89.8) 0.826
1 or 2 40 (9.3) 5 (10.2)
≥ 3 3 (0.7) 0 (0.0)
Treatment preference
Do you have a preference for either group?
Prefer to receive mirtazapine 255 (59.2) 34 (69.4) 0.358
Prefer to receive placebo 2 (0.5) 0 (0.0)
Do not mind either way 174 (40.4) 15 (30.6)
If you were to be allocated to the other group, how disappointed would you be?
Very 36 (14.0) 5 (14.7) 0.743
Moderately 82 (31.9) 11 (32.4)
A little bit 81 (31.5) 8 (23.5)
Not really 58 (22.6) 10 (29.4)
Measures of depression
Suffered from depression in the past 351 (81.4) 45 (91.8) 0.069
Family history of depression 227 (64.7) 36 (80.0) 0.04
Previous referral to a psychiatrist for depression 112 (31.9) 19 (42.2) 0.166
Number of prior episodes of depression
None 8 (2.3) 0 (0.0) 0.278
1 20 (5.7) 2 (4.4)
2–4 147 (41.9) 14 (31.1)
≥ 5 176 (50.1) 29 (64.4)
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TABLE 5 Summary of baseline variables related to missing BDI-II score data at 12 weeks (continued )
Variable
Data, n (%)
Present (N= 431) Missing (N= 49) p-value
Duration of current course of antidepressants,
< 6 months 39 (9.0) 7 (14.3) 0.238
≥ 6 months 392 (91.0) 42 (85.7)
ICD-10 primary diagnosis
Mild 76 (17.6) 6 (12.2) 0.552
Moderate 253 (58.7) 29 (59.2)
Severe 102 (23.7) 14 (28.6)
Secondary psychiatric diagnosis according to the CIS-R
No diagnosis identified 7 (1.6) 0 (0.0) 0.569
Mixed anxiety and depressive disorder (mild) 52 (12.1) 5 (10.2)
Generalised anxiety disorder (mild) 5 (1.2) 0 (0.0)
Mixed anxiety and depressive disorder 100 (23.2) 14 (28.6)
Specific (isolated) phobia 20 (4.6) 5 (10.2)
Social phobia 19 (4.4) 3 (6.1)
Agoraphobia 18 (4.2) 3 (6.1)
Generalised anxiety disorder 170 (39.4) 14 (28.6)
Panic disorder 40 (9.3) 5 (10.2)
BDI-II score (points), mean (SD) 30.8 (9.9) 33.8 (9.7) 0.040
GAD-7 score (points), mean (SD) 10.9 (4.8) 12.0 (4.7) 0.109
PHQ-9 score (points), mean (SD) 16.2 (5.5) 17.4 (5.4) 0.160
EQ-5D-5L score (points), mean (SD) 0.7 (0.2) 0.6 (0.3) 0.064
SF-12 aggregate physical functioning score (points), mean (SD) 45.8 (13.5) 48.4 (13.1) 0.203
SF-12 aggregate mental functioning score (points), mean (SD) 29.0 (9.5) 25.1 (10.2) 0.009
CIS-R score, mean (SD) 27.5 (8.3) 29.0 (8.0) 0.221
Suicidal ideation (CIS-R thoughts/plans)
No suicidal thoughts 180 (41.8) 20 (40.8) 0.983
Patient feels life is not worth living 92 (21.3) 11 (22.4)
Suicidal thoughts 159 (36.9) 18 (36.7)
A level, Advanced level; GCSE, General Certificate of Secondary Education; GNVQ, General National Vocational Qualification;
GSVQ, General Scottish Vocational Qualification; HNC, Higher National Certificate; HND, Higher National Diploma;
NVQ, National Vocational Qualification; RSA, Royal Society of Arts; SVQ, Scottish Vocational Qualification.
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Primary outcome
Depressive symptoms at 12 weeks measured using the continuous Beck Depression
Inventory-II score
The mean BDI-II score at 12 weeks was 18.0 points (SD 12.3 points) in participants randomised to the usual
care and mirtazapine group compared with 19.7 points (SD 12.4 points) in those randomised to usual care and
placebo (Table 6). Higher scores indicate more severe depression, with a maximum possible score of 63 points.
In the primary ITT analysis, participants in the intervention group had a slightly lower BDI-II score than
those in the placebo group (see Table 6). The difference – corrected for baseline BDI-II score, centre,
baseline BDI-II score terciles, sex and whether or not the patient was receiving psychological therapy at
baseline – was less than the minimum clinically relevant difference that we sought to detect (0.33 SDs,
which in this case was 4.1 points on the BDI-II) and the confidence interval (CI) overlapped zero, which
includes the possibility that there is no difference between the two treatment groups. Further adjustment
for variables that suggested some imbalance between the treatment groups at baseline (history of
depression, duration of current course of antidepressants and suicidal ideation) did not meaningfully
change the effect estimate (difference –2.12 points, 95% CI –4.25 to 0.02 points; p = 0.052).
Subgroup analysis
We planned two a priori subgroup analyses to investigate any differential effects according to baseline
depression severity (BDI-II score) and a five-level measure of degree of treatment resistance based on the
duration of symptoms and prior treatment with antidepressants.
In the case of baseline depression severity, we found no evidence that this had any effect on the difference
between the mirtazapine group and the placebo group (p-value for interaction with treatment group= 0.101).
The observed patterns of duration of symptoms and prior treatment with antidepressants at baseline suggested
that a four-level measure of degree of treatment resistance would be more appropriate than the planned
five-level measure. The four-level measure was categorised as follows: (1) no prescribed antidepressants in
the past, (2) prescribed antidepressants in the past and depressed for < 1 year, (3) prescribed antidepressants
in the past and depressed for 1–2 years and (4) prescribed antidepressants in the past and depressed for
> 2 years. There was no evidence that this measure of treatment resistance had any effect on the difference
between the treatment groups (p-value for interaction with treatment group= 0.299).
Sensitivity analyses to examine the impact of missing data
Table 7 presents the results of the ITT analysis for the 431 ‘complete cases’ with BDI-II score outcome
data at 12 weeks and the results from ITT analyses in which the missing data had been estimated using
three methods. In the first method, it was assumed that those with missing BDI-II score outcome data had the
‘worst’ possible score (63 points), in the second method it was assumed that those with missing BDI-II score
outcome data had the ‘best’ possible score (0 points) and in the third method the missing data were imputed
using the method of MICE. The ‘worst’-case scenario approach and the MICE approach yielded smaller
differences than the complete-case analysis. The ‘best’-case scenario approach yielded a slightly larger estimate.
TABLE 6 Primary outcome: mean and difference in mean BDI-II scores at 12 weeks
Randomisation group n Mean (SD), points Difference in meansa 95% CI p-value
Usual care+mirtazapine 214 18.0 (12.3) –1.83 –3.92 to 0.27 0.087
Usual care+ placebo 217 19.7 (12.4)
Total 431 18.8 (12.4)
CI, confidence interval.
a ITT analysis adjusted for baseline BDI-II score and the stratification and other minimisation variables.
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Sensitivity analysis to examine the timing of questionnaire completion
There was evidence of a very small difference in the mean number of days between randomisation and
completion of the 12-week questionnaire: 90.25 days (SD 14.15 days) in the group allocated to usual care
and mirtazapine and 89.00 days (SD 10.3 days) in the group allocated to usual care and placebo. Further
adjusting for this variable in a model of BDI-II scores at 12 weeks (also adjusting for the baseline BDI-II
score and minimisation and stratification variables) did little to change the adjusted difference between the
two treatment groups (difference –1.88 points, 95% CI –3.98 to 0.21 points).
Secondary outcomes
Beck Depression Inventory-II as a continuous score at 24 weeks’ and 12 months’ follow-up
Table 8 summarises the means and differences in mean BDI-II sores at 24 weeks’ and 12 months’
follow-up. In both groups the mean BDI-II scores declined over time. At 24 weeks’ follow-up, those in
the intervention group had a BDI-II score that was 0.85 points lower than those in the placebo group
after adjustment for baseline BDI-II score and stratification and minimisation variables, with a 95% CI of
–3.12 to 1.43 points. At 12 months’ follow-up, the difference between the two groups was 0.17 points
(95% CI –2.13 to 2.46 points). In both cases the CIs overlapped zero, suggesting no evidence of a
difference between the groups. Additional adjustment for the variables that were imbalanced at baseline
increased the size of the differences somewhat but the 95% CIs continued to overlap zero (24 weeks:
difference –1.26 points, 95% CI –3.57 to 1.05 points, p = 0.285; 12 months: difference –0.29 points,
95% CI –2.61 to 2.03 points, p = 0.807).
TABLE 8 Means and differences in mean BDI-II scores at 24 weeks and 12 months
Randomisation groups
24 weeks’ follow-up (N= 402) 12 months’ follow-up (N= 388)
n Mean (SD), points n Mean (SD), points
Usual care +mirtazapine 196 17.3 (12.9) 190 16.8 (12.7)
Usual care + placebo 206 18.2 (12.6) 198 16.7 (12.2)
Regression analyses
Follow-up time point n Difference in meansa 95% CI p-value
24 weeks 402 –0.85 –3.12 to 1.43 0.465
12 months 388 0.17 –2.13 to 2.46 0.886
a ITT analysis adjusted for baseline BDI-II score and the stratification and other minimisation variables.
TABLE 7 Comparison of the results of ITT analysis of complete cases and the results of ITT analysis when missing data
were imputed using ‘best’- and ‘worst’-case scenarios and MICE for the primary outcome of BDI-II score at 12 weeks
Analysis n Difference in meansa 95% CI p-value
Complete case 431 –1.83 –3.92 to 0.27 0.087
‘Best’-case scenario 480 –2.22 –4.41 to –0.03 0.047
‘Worst’-case scenario 480 –1.11 –4.11 to 1.89 0.469
MICE 480 –1.78 –3.90 to 0.34 0.100
a Adjusted for baseline BDI-II score, stratification and other minimisation variables and additional variables showing an
imbalance between treatment groups at baseline.
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Our prespecified statistical analysis plan included a repeated-measures analysis incorporating outcomes at
12 and 24 weeks and 12 months post randomisation to examine whether any treatment effects were
sustained, diminished or emerged later. This analysis was not conducted, given that differences between
the treatment groups at these time points showed no evidence of an important difference.
‘Response’ to treatment at 12 and 24 weeks’ and 12 months’ follow-up
Table 9 summarises the percentages and ORs of ‘response’ to treatment (defined as a reduction in
depressive symptoms on the BDI-II of ≥ 50% relative to baseline) at 12 and 24 weeks’ and 12 months’
follow-up. At each of the time points, the intervention group had an increased odds of response compared
with the usual care group [OR 1.39, 95% CI 0.94 to 2.07; number needed to treat (NNT) = 12]. However,
the CIs at each time point overlapped 1. Additional adjustment for the variables that were imbalanced at
baseline did not make any meaningful difference to the observed difference at 12 weeks’, 24 weeks’ or
12 months’ follow-up (12 weeks: OR 1.45, 95% CI 0.97 to 2.16, p = 0.074; 24 weeks: OR 1.04, 95% CI
0.69 to 1.57, p = 0.842; 12 months: OR 1.05, 95% CI 0.69 to 1.58, p = 0.834).
‘Remission’ of depression symptoms at 12 and 24 weeks’ and 12 months’ follow-up
Table 10 summarises the percentages and ORs of ‘remission’ (defined as having a BDI-II score of < 10) at
12 and 24 weeks’ and 12 months’ follow-up. Those in the intervention group had an increased odds of
‘remission’ at 12 weeks compared with those in the placebo group and the CI overlapped 1 (OR 1.29, 95% CI
0.82 to 2.02; NNT= 18). Similar results were seen at 24 weeks and by 12 months the OR approached 1.
The ORs tended to be slightly increased after adjustment for those variables that were imbalanced between
treatment groups at baseline, but the CIs continued to overlap 1 (12 weeks: OR 1.39, 95% CI 0.88 to 2.21,
p = 0.157; 24 weeks: OR 1.31, 95% CI 0.83 to 2.09, p = 0.249; 12 months: OR 1.02, 95% CI 0.65 to 1.60,
p = 0.940).
Anxiety symptoms at 12 and 24 weeks’ and 12 months’ follow-up
Anxiety symptoms were assessed at baseline and 12 and 24 weeks’ and 12 months’ follow-up using the
GAD-7 questionnaire and were analysed as a continuous score. Higher scores indicate more severe
symptoms of anxiety, with a maximum possible score of 21. Table 11 summarises the mean and differences
in mean GAD-7 scores at 12 and 24 weeks’ and 12 months’ follow-up. At 12 weeks, after correction for
baseline GAD-7 score and minimisation and stratification variables, those in the intervention group had a
mean GAD-7 score that was 0.98 points lower (less anxious) than those in the placebo group, with a
95% CI ranging from a 1.93-point decrease to a 0.03-point decrease. Differences between the two
treatment groups were smaller at subsequent time points and CIs overlapped zero. Additional adjustment
for the variables that were imbalanced at baseline did not alter the results greatly (12 weeks: difference
–1.00 points, 95% CI –1.97 to –0.02 points, p = 0.045; 24 weeks: difference –0.71 points, 95% CI –1.73
to 0.31 points, p = 0.172; 12 months: difference –0.22 points, 95% CI –1.31 to 0.86 points, p = 0.685).
Adherence to antidepressants at 12 weeks’ follow-up
Adherence to the study medication at 12 weeks’ follow-up was assessed using information on participant-
reported breaks in treatment and the Morisky questionnaire. Table 12 summarises the percentages and
ORs of adherence to the study medication at 12 weeks. Although adherence was > 70% in both groups,
those in the intervention group had a 0.55-fold odds of adherence to the study medication at 12 weeks
compared with those in the placebo group. Adjustment for variables that were imbalanced at baseline did
not alter this result (OR 0.56, 95% CI 0.34 to 0.92; p = 0.021).
Although adherence at 24 weeks and 12 months formed part of our planned secondary outcome analyses,
as patients were offered the chance of unblinding at 12 weeks while continuing to be followed up, the
results of these analyses became impossible to interpret and, therefore, are not presented here.
Quality of life at 12 and 24 weeks’ and 12 months’ follow-up
Quality of life was measured using the EQ-5D-5L questionnaire as well as the SF-12 questionnaire, from
which aggregate scores for social and physical functioning were calculated.
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TABLE 10 Percentages and ORs of ‘remission’ of symptoms’ (BDI-II score < 10 points) at 12 and 24 weeks and 12 months, additionally adjusted for variables that showed an
imbalance between treatment groups at baseline
Randomisation group
Length of follow-up
12 weeks (N= 431) 24 weeks (N= 402) 12 months (N= 388)
Total in
group, N
Number (%)
reporting
BDI-II score of
< 10 points
Regression
analysis:
OR,a 95% CI;
p-value
Total in
group, N
Number (%)
reporting
BDI-II score of
< 10 points
Regression
analysis:
OR,a 95% CI;
p-value
Total in
group, N
Number (%)
reporting
BDI-II score of
< 10 points
Regression
analysis:
OR,a 95% CI;
p-value
Usual care +mirtazapine 214 63 (29.4) 1.29, 0.82 to
2.02; 0.266
196 65 (33.2) 1.28, 0.81 to
2.01; 0.287
190 63 (33.2) 0.96, 0.62 to
1.50; 0.873
Usual care + placebo 217 53 (24.4) 206 59 (28.6) 198 67 (33.8)
a ITT analysis adjusted for baseline BDI-II score and the stratification and other minimisation variables.
TABLE 9 Percentages and ORs of ‘response’ to treatment (improvement of ≥ 50% in BDI-II score vs. baseline) at 12 and 24 weeks and 12 months, additionally adjusted for
variables that showed an imbalance between treatment groups at baseline
Randomisation group
Length of follow-up
12 weeks (N= 431) 24 weeks (N= 402) 12 months (N= 388)
Total in
group, N
Number (%)
reporting
improvement of
≥ 50% in BDI-II
score vs. baseline
Regression
analysis:
OR,a 95% CI;
p-value
Total in
group, N
Number (%)
reporting
improvement of
≥ 50% in BDI-II
score vs. baseline
Regression
analysis:
OR,a 95% CI;
p-value
Total in
group, N
Number (%)
reporting
improvement of
≥ 50% in BDI-II
score vs. baseline
Regression
analysis:
OR,a 95% CI;
p-value
Usual care +mirtazapine 214 94 (43.9) 1.39, 0.94 to
2.07; 0.099
196 96 (49.0) 1.01, 0.67 to
1.50; 0.977
190 97 (51.1) 0.99, 0.66 to
1.49; 0.978
Usual care + placebo 217 78 (35.9) 206 100 (48.5) 198 101 (51.0)
a ITT analysis adjusted for baseline BDI-II score and the stratification and other minimisation variables.
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EuroQol-5 Dimensions, five-level version
Table 13 summarises the mean and differences in mean EQ-5D-5L scores at 12 and 24 weeks’ and 12 months’
follow-up. At 12 weeks, after correction for baseline EQ-5D-5L score and minimisation and stratification
variables, participants in the intervention group had a mean score that was 0.01 points higher (better QoL)
than that in the placebo group, with a 95% CI ranging from a 0.02-point decrease to a 0.05-point
increase. Differences between the two treatment groups remained very small at subsequent time points
and CIs overlapped zero. Additional adjustment for the variables that were imbalanced at baseline did not
alter the results greatly (12 weeks: difference 0.01 points, 95% CI –0.02 to 0.05 points, p = 0.389;
24 weeks: difference 0.01 points, 95% CI –0.02 to 0.05 points, p = 0.425; 12 months: difference 0.004
points, 95% CI –0.03 to 0.04 points, p = 0.831).
Short Form questionnaire-12 items aggregate physical functioning score
Table 14 summarises the mean and differences in mean SF-12 aggregate physical functioning scores
at 12 and 24 weeks’ and 12 months’ follow-up. At 12 weeks, after correction for baseline score and
minimisation and stratification variables, participants in the intervention group had a mean score that was
1.09 points lower (worse physical functioning) than that in the placebo group, with a 95% CI ranging
from a 2.75-point decrease to a 0.57-point increase. Differences between the two treatment groups
remained very small and approached zero at subsequent time points and CIs overlapped zero. Additional
adjustment for the variables that were imbalanced at baseline did not alter the results greatly (12 weeks:
difference –0.99 points, 95% CI –2.69 to 0.70 points, p = 0.250; 24 weeks: difference –1.67 points,
95% CI –3.39 to 0.06 points, p = 0.058; 12 months: difference –0.27 points, 95% CI –2.02 to 1.48
points, p = 0.760).
TABLE 11 Mean and differences in mean GAD-7 scores at 12 weeks’, 24 weeks’ and 12 months’ follow-up
Randomisation group
Length of follow-up
12 weeks (N= 431) 24 weeks (N= 401) 12 months (N= 387)
n
Mean (SD),
points n
Mean (SD),
points n
Mean (SD),
points
Usual care+mirtazapine 214 7.15 (5.63) 195 6.83 (5.89) 189 6.81 (6.23)
Usual care+ placebo 217 7.89 (5.78) 206 7.17 (5.86) 198 6.80 (5.73)
Regression analyses
n 428 398 384
Difference in means,a
95% CI (points); p-value
–0.98, –1.93 to –0.03; 0.044 –0.56, –1.56 to 0.44; 0.274 –0.17, –1.23 to 0.90; 0.755
a ITT analysis adjusted for baseline GAD-7 score and the stratification and other minimisation variables.
TABLE 12 Percentages and ORs of adherence at 12 weeks
Randomisation group
Total number
of participants
in group
Number of
participants
reported as
being adherent
% of participants
reported as being
adherent ORa 95% CI p-value
Usual care+mirtazapine 210 156 74.3 0.55 0.34 to 0.89 0.015
Usual care+ placebo 214 180 84.1
Total 424 336 79.3
a ITT analysis adjusted for stratification and other minimisation variables.
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Short Form questionnaire-12 items aggregate mental functioning score
Table 15 summarises the mean and differences in mean SF-12 aggregate mental functioning scores
at 12 and 24 weeks’ and 12 months’ follow-up. At 12 weeks, after correction for baseline score and
minimisation and stratification variables, participants in the intervention group had a mean score that was
3.91 points higher (better mental functioning) than that in the placebo group, with a 95% CI ranging from
a 1.63-point increase to a 6.20-point increase. Differences between the two treatment groups became
smaller at subsequent time points and CIs overlapped zero. Additional adjustment for the variables that
were imbalanced at baseline made the differences slightly larger (12 weeks: difference 4.08 points, 95% CI
1.74 to 6.41 points, p = 0.001; 24 weeks: difference 2.81 points, 95% CI 0.29 to 5.34 points, p = 0.029;
12 months: difference 1.92 points, 95% CI –0.72 to 4.56 points, p = 0.154).
Adverse events related to the trial medication at 12 weeks’ and 12 months’ follow-up
The Antidepressant Side-Effect Checklist measure
The ASEC measure of antidepressant side effects was used to assess whether or not the participant-reported
AEs related to their trial medication. The questionnaire provides a list of 21 symptoms and patients are
asked to report on a scale the severity of these symptoms. The ASEC score relates to the sum of the severity
scores across all items and is treated as a continuous measure. The maximum score is 63 points, indicating
severe side-effects.
TABLE 13 Mean and differences in mean EQ-5D-5L scores at 12 and 24 weeks’ and 12 months’ follow-up
Randomisation group
Length of follow-up
12 weeks (N= 429) 24 weeks (N= 403) 12 months (N= 388)
n
Mean (SD),
points n
Mean (SD),
points n
Mean (SD),
points
Usual care +mirtazapine 213 0.72 (0.27) 196 0.72 (0.25) 189 0.72 (0.28)
Usual care + placebo 216 0.73 (0.25) 207 0.74 (0.25) 199 0.75 (0.25)
Regression analyses
n 427 403 388
Difference in means,a
95% CI (points); p-value
0.01, –0.02 to 0.05; 0.400 0.01, –0.02 to 0.05; 0.464 0.001, –0.04 to 0.04; 0.950
a ITT analysis adjusted for baseline EQ-5D-5L score and stratification and other minimisation variables.
TABLE 14 Mean and differences in mean SF-12 aggregate physical functioning scores at 12 and 24 weeks’ and
12 months’ follow-up
Randomisation group
Length of follow-up
12 weeks (N= 418) 24 weeks (N= 403) 12 months (N= 373)
n
Mean (SD),
points n
Mean (SD),
points n
Mean (SD),
points
Usual care +mirtazapine 208 44.09 (12.87) 191 42.88 (13.02) 182 43.34 (13.42)
Usual care + placebo 210 45.85 (12.54) 201 45.37 (12.75) 191 44.32 (12.49)
Regression analyses
n 410 384 366
Difference in means,a
95% CI (points); p-value
–1.09, –2.75 to 0.57; 0.196 –1.54, –3.23 to 0.15; 0.075 –0.47, –2.19 to 1.24; 0.587
a TT analysis adjusted for baseline SF-12 aggregate physical functioning score and the stratification and other
minimisation variables.
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Table 16 summarises the mean and differences in mean ASEC sores at 12 weeks’ and 12 months’ follow-up.
Participants in the intervention group had a mean ASEC score at 12 weeks that was 0.35 points higher than
that in the placebo group, after adjustment for baseline ASEC score as well as stratification and minimisation
variables. At 12 months, the mean ASEC score in the intervention group was 0.43 points lower than that in
the placebo group. For both groups, the 95% CIs overlapped zero. Additional adjustment for the variables
that were imbalanced at baseline did not make a meaningful difference to the observed results (12 weeks:
difference 0.26 points, 95% CI –1.15 to 1.68 points, p = 0.718; 12 months: difference –0.63 points, 95% CI
–2.42 to 1.16 points, p = 0.489).
Adverse events and serious adverse events by 12 weeks post randomisation
By 12 weeks post randomisation, 167 patients allocated to the mirtazapine and usual care arm reported
168 AEs. The most common AEs were drowsiness (n = 41 events, reported by 41 participants) and weight
increase (n = 24 events, reported by 24 participants). Fifty-three of the AEs were associated with stopping
the trial medication (n = 46 participants); most of these AEs were drowsiness (n = 19). Most of the AEs
were classified as mild (n = 136); only three were considered severe. Nearly half (n = 77) were considered
to be either ‘probably’ or ‘definitely’ related to the trial medication and only 44 were unexpected.
This contrasts with the group allocated to placebo and usual care, in which only 91 AEs from 91 participants
were reported. In this group, 11 AEs were associated with stopping the trial medication (n = 9 participants).
Only five participants reported drowsiness and eight reported an increase in appetite or weight. The most
TABLE 15 Mean and differences in mean SF-12 aggregate mental scores at 12 and 24 weeks’ and 12 months’
follow-up
Randomisation group
Length of follow-up
12 weeks (N= 418) 24 weeks (N= 392) 12 months (N= 373)
n
Mean (SD),
points n
Mean (SD),
points n
Mean (SD),
points
Usual care+mirtazapine 208 39.94 (12.27) 191 39.89 (13.92) 182 40.54 (13.80)
Usual care+ placebo 210 36.33 (12.53) 201 37.91 (12.43) 191 39.25 (13.09)
Regression analyses
n 410 384 366
Difference in means,a
95% CI (points); p-value
3.91, 1.63 to 6.20; 0.001 2.32, –0.17 to 4.80; 0.068 1.42, –1.20 to 4.04; 0.287
a ITT analysis adjusted for baseline EQ-5D-5L score and stratification and other minimisation variables.
TABLE 16 Mean and differences in mean ASEC scores at 12 weeks’ and 12 months’ follow-up
Randomisation group
Length of follow-up
12 weeks (N= 390) 12 months (N= 255)
n
Mean (SD),
points n
Mean (SD),
points
Usual care+mirtazapine 184 10.13 (7.02) 119 9.50 (7.65)
Usual care+ placebo 206 9.77 (7.93) 136 9.59 (8.26)
Regression analyses
n 385 252
Difference in means,a 95% CI (points); p-value 0.35, –1.04 to 1.73; 0.624 –0.43, –2.19 to 1.33; 0.630
a ITT analysis adjusted for baseline ASEC score, stratification and other minimisation variables.
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common AEs were classified as ‘unpleasant dreams’ (n = 9) and musculoskeletal (n = 17). Nearly all were
mild (n = 74) and none was severe.
Very few of the AEs reported by 12 weeks post randomisation were serious. In the group allocated to
mirtazapine and usual care, eight participants reported eight SAEs. These were classified as follows: central
nervous system/transient ischaemic attack (TIA) (n = 1), cardiovascular (n = 1), dental (n = 1), gynaecological
(n = 1), pancreatitis (n = 1), psychiatric (n = 2) and respiratory (n = 1). The two psychiatric events and the
pancreatitis event resulted in the participants stopping treatment.
In the group allocated to placebo and usual treatment, only three SAEs were reported by three participants
[infection (n = 1) and musculoskeletal trauma (n = 2)]. In two cases, the participant stopped the trial
medication. In none of the cases was the SAE thought to be related to the trial medication.
Adverse events and SAEs in the first 12 weeks and AEs between 12 and 52 weeks are described in more
detail in Appendix 2, Tables 39–42.
Depression symptoms assessed using the Patient Health Questionnaire-9 items at
12 weeks’ follow-up
The primary outcome and many of the secondary outcomes were derived from the BDI-II questionnaire
and, to explore the consistency of these results, responses to the PHQ-9 at 12 weeks’ follow-up were
reviewed in a post hoc analysis. The PHQ-9 scores nine symptoms of depression yielding a maximum score
of 27 points; higher scores indicate more severe symptoms of depression.
Table 17 summarises the mean and difference in mean PHQ-9 sores at 12 weeks. Participants in the
intervention group had a mean PHQ-9 score at 12 weeks that was 1.05 points lower than that in the
placebo group after adjustment for baseline PHQ-9 score and stratification and minimisation variables,
with a 95% CI of –2.14 to 0.04 points. The direction of association was the same as that observed for
the BDI-II score outcomes. Additional adjustment for the variables that were imbalanced at baseline made
the difference slightly larger (difference –1.24 points, 95% CI –2.34 to –0.13 points; p = 0.029).
Treatment efficacy
To understand treatment efficacy, we conducted a CACE analysis of the primary outcome at 12 weeks.
The results from this analysis are presented alongside the primary ITT analysis and a per-protocol analysis in
Table 18. The CACE and per-protocol analyses showed slightly larger effects than the ITT analysis, but the
CIs were wider.
‘As-treated’ analysis
After measurement of the primary outcome at 12 weeks’ follow-up, participants were given the option
of continuing in the study blinded, being unblinded and continuing with the study follow-up or being
TABLE 17 Mean and difference in mean PHQ-9 scores at 12 weeks’ follow-up
Randomisation group n Mean (SD) Difference in meansa 95% CI p-value
Usual care +mirtazapine 212 9.74 (6.35) –1.05 –2.14 to 0.04 0.058
Usual care + placebo 217 10.63 (6.21)
Total 429 10.19 (6.29)
a ITT analysis adjusted for baseline PHQ-9 score and stratification and other minimisation variables.
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unblinded and leaving the study. Those unblinded and continuing with the study follow-up no longer
received the trial medication, but were free to obtain a prescription for mirtazapine from their GP.
Because of this, each of the randomly allocated groups in the ITT analysis at 24 weeks and 52 weeks post
randomisation included participants taking and not taking mirtazapine. We therefore conducted an
‘as-treated’ analysis to identify treatment differences between those taking mirtazapine and those not
taking mirtazapine at 24 weeks.
This as-treated analysis compared the BDI-II scores at 24 weeks of participants receiving and adhering to
mirtazapine (regardless of allocation at randomisation) with those of participants not receiving (or not
adhering to) mirtazapine; all participants were adherent to their usual antidepressant treatment. These
restrictions resulted in only 324 participants being considered (compared with 403 in the ITT analysis
who completed a questionnaire at 24 weeks), of whom 199 (61.4%) were not receiving mirtazapine and
125 (38.6%) were receiving mirtazapine. The 12-week BDI-II scores for these groups suggest that, in those
meeting our eligibility criteria, those still adherent to mirtazapine at 24 weeks had lower BDI-II scores
at 12 weeks (mean 16.4 points, SD 11.6 points) than those not taking mirtazapine at 24 weeks (mean
18.6 points, SD 12.4 points).
To further understand who was taking mirtazapine at 24 weeks, we explored which groups the participants
had been originally randomised to. Of the 125 participants receiving mirtazapine at 24 weeks, 117 had
been randomly allocated to the mirtazapine arm of the study and eight opted to get mirtazapine from
their GP. Those taking mirtazapine at 24 weeks were, therefore, composed largely of those randomised to
mirtazapine and their mean 12-week BDI-II score was 15.7 points (SD 11.2 points). However, a small group
of eight participants had been randomised to placebo and these participants’ BDI-II score at 12 weeks was
much higher [mean 26.3 points (SD 14.5 points)]. Of the 199 participants not receiving mirtazapine at
24 weeks, 63 had been randomly allocated to the mirtazapine arm and had since stopped taking it in an
adherent manner. Those never taking mirtazapine had a slightly lower BDI-II score at 12 weeks [mean
17.7 points (SD 12.0 points)] than those who were randomised to mirtazapine but who stopped [mean
20.5 points (SD 13.1 points)].
The mean 24-week BDI-II score was 14.5 points (SD 11.5 points) in the group taking mirtazapine and
18.4 points (SD 12.8 points) in the group not taking mirtazapine. After adjusting for baseline differences,
those taking mirtazapine had a mean BDI-II score that was 3.9 points lower than that in those not
receiving mirtazapine (95% CI –6.45 to –1.37 points).
Analysis of blinded patients at 24 weeks’ and 12 months’ follow-up
To understand outcomes in those participants who chose to remain blinded after the primary outcome,
we conducted analyses of BDI-II scores at 24 weeks’ and 12 months’ follow-up in the subset of participants
who chose to remain blinded at those time points, regardless of adherence to the study medication.
TABLE 18 Comparison of results from ITT, per-protocol and CACE analyses for the primary outcome of BDI-II score
at 12 weeks
Analysis Number of patients in model Difference in meansa (points) 95% CI (points) p-value
ITT 431 –1.83 –3.92 to 0.27 0.087
Per-protocol 327 –2.18 –4.60 to 0.24 0.077
CACE 427 –2.39 –5.18 to 0.40 0.093
a Adjusted for baseline BDI-II score and stratification and other minimisation variables.
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A 24-week questionnaire was returned by 403 participants, of whom 294 remained blinded to their
treatment allocation (152 were allocated to receive mirtazapine and usual care; the remaining 142 were
allocated to receive placebo and usual care). In this group of 294 participants, the mean BDI-II score at
24 weeks was slightly higher in the mirtazapine group (difference 0.26 points, 95% CI –2.41 to 2.94
points) after adjustment for baseline BDI-II score and minimisation and stratification variables. The CI
overlapped zero, suggesting no evidence of a difference between the groups.
At 12 months’ follow-up, 390 participants returned their final follow-up questionnaire and only 231 remained
blinded (110 were allocated to receive mirtazapine and usual care; the remaining 121 were allocated to
receive placebo and usual care). Here, again, the mean BDI-II score was slightly higher at 12 months in the
mirtazapine group (difference 1.48 points, 95% CI –1.57 to 4.53 points) after adjustment for baseline BDI-II
scores and minimisation and stratification variables, although the CI suggests no evidence of a difference
between the groups.
RESULTS
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Chapter 4 Health economic analysis: cost-
effectiveness of mirtazapine added to usual care
compared with placebo added to usual care
Introduction
Aim
The aim of the economic evaluation was to assess the cost-effectiveness of mirtazapine plus usual care
compared with placebo plus usual care in patients with TRD. The economic evaluation was carried out
using data collected as part of the MIR RCT.
The intervention
Mirtazapine is a well-established inexpensive treatment for depression, at £0.04 per tablet (either 15-mg or
30-mg strength),48 with a typical dose being one tablet per day. If it were to show a meaningful improvement
in QoL [here measured in quality-adjusted life-years (QALYs)], there is, ex ante, a high probability that it will
be cost-effective, all other things being equal.
Methods
Form of analysis
The economic evaluation was a within-trial analysis, based on the data collected during the 12-month
trial period. All costs that were incurred in the 12 months following randomisation were included. The
perspective for the primary analysis was that of the NHS and personal social services (PSS). Personal costs
to patients and productivity costs for patients and carers who missed work were included in a secondary
analysis from the societal perspective.
The primary analysis was a cost–utility analysis of the cost per QALY when comparing the two groups.
Results are also presented for a cost-effectiveness analysis for the primary trial outcome of BDI-II score at
12 weeks post randomisation.
Outcomes
The primary trial outcomes were:
1. change in depression symptoms measured as a continuous variable using the BDI-II score at 12 weeks
compared with the baseline score
2. response in depression symptoms, a binary variable defined as a reduction of ≥ 50%.
Secondary trial outcomes of interest for the economic evaluation include:
1. QoL measured using the EQ-5D-5L
2. primary and secondary care resource use.
For the economic evaluation, the primary outcome of interest was the difference in QALYs over
12 months post randomisation compared with baseline. EQ-5D-5L data were captured at four time points
(pre randomisation and 12, 24 and 52 weeks post randomisation) and an area under the curve approach
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was used to estimate total QALYs at 12 months, adjusting for baseline values. The EuroQol-5 Dimensions
(EQ-5D) is recommended by NICE for use in cost–utility analyses.49 Utility scores were derived using the
most recent valuation tariff for the five-level version of the EQ-5D.50 This is based on a representative
sample of the UK population.
Resource-use categories
The analysis was based on the costs associated with caring for all patients from randomisation until
12 months. The following resource use data were included in the analysis.
Direct costs to the health service (NHS)
l The cost of the treatment (mirtazapine).
l Hospital (secondary) care related to depression or mental health including:
¢ inpatient admissions
¢ accident and emergency (A&E) attendances
¢ outpatient appointments.
l Primary and community costs including:
¢ GP or nurse appointments at the surgery, by telephone or at home
¢ counselling or other talking therapies (excluding CBT)
¢ face-to-face or computerised CBT
¢ mental health clinic attendances
¢ prescribed exercise programmes
¢ NHS Direct or 111
¢ NHS walk-in centres.
Direct costs of personal social services
l Mental health nurse home visits.
l Occupational therapy.
l Social worker.
l Day centre use.
l Self-help groups run by social services.
l Home care worker visits.
l Other.
Costs to patients and carers
l Inpatient and outpatient private health care.
l Private counselling.
l Prescription charges.
l Over-the-counter medicines.
l Complementary therapies.
l Private home care.
l Loss of earnings from time off work.
l Other costs.
Productivity costs
l Time off work for patients and carers.
HEALTH ECONOMIC ANALYSIS
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Data collection
Resource use data collection
Resource use data were collected primarily by patient self-report using a bespoke data collection form.
The form was paper based and was incorporated into the assessment forms. Forms were mainly collected
at the relevant face-to-face appointments along with other outcome measures. The form was used to
collect information on public and privately paid-for health and social care, unpaid help received and
employment-related data. Participants were asked about any disability payments received, but not the
specific type of payment or the value of any payments.
Publicly funded health and social care resources
Data were collected in relation to patient use of NHS secondary care (inpatient, outpatient and casualty)
and primary care, paid-for care, home care and informal care. Resource use data were collected at 12 and
24 weeks’ and 12 months’ follow-up. The questionnaires at 12 and 24 weeks asked participants to report
all resource use in the previous 3 months, whereas the 12-month questionnaire asked participants to
report resource use in the previous 6 months. Out of 480 participants, 450 (94%) completed at least one
resource use data questionnaire. Complete cost data were available from 369 participants (77%) and
complete QALY data from 368 participants (77%).
Secondary care resource use was included in the analysis if it related to depression or other mental illness.
By contrast, all primary and community care resources were included – it was not possible from the data
to make the distinction between depression-related service use and other service use. However, when
completing the primary and community care component of the resource use questionnaire, participants
were asked to identify only those activities that were related to their mental health.
General practice system data
Data on participant contacts with GPs, as well as prescription data, were collected from general practice
electronic patient records, with participant consent. This was used as the basis for estimating GP and
prescription resource use. Participants were also asked as part of the patient-reported resource use
questionnaire how many GP visits they had made. To avoid probable double counting, only the GP visits
recorded as part of the electronic health record were used in the analysis. Eight participants withheld their
consent for data to be collected in this way. Four GP practices were unable to provide full participant data.
One provided no data (n = 6 participants), one provided data on prescriptions, but not consultations (n = 5
participants) and two provided data on consultations but not prescriptions (n = 34 participants). Overall,
data on GP contacts and/or prescription data were available for 436 participants from general practice
record systems. Of these, 395 participants had a contact with the general practice surgery or a prescription
for a depression-related medicine during the 12 months of study enrolment.
Private health and social care data
Participants were asked to report if they had used any privately funded health or social care services.
This included both hospital-based care (inpatient, outpatient) and community-based care (counselling,
complementary therapies, over-the-counter medications). Participants were also asked to report any
prescription charges that they had paid, but not whether or not they were exempt from prescription
charges or whether or not they had a pre-payment certificate.
Employment and lost productivity
To estimate the cost to the patient and society of the treatments, data were collected on employment and
income, as well as whether or not participants had missed work or lost income as a result of their mental
health. Participants were asked to report their usual hours worked per week, how many days they had had
off owing to their mental health and the income that they had lost as a result. They were also asked to
report whether or not anyone else had taken time off work to care for them as a result of their mental
health and the lost work time.
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Unit costs
Non-prescription resources
Unit costs have been taken when possible from NHS reference costs51 and the Personal Social Services
Research Unit (PSSRU) annual publications of unit costs of health and social care.52–56 All unit cost sources
are indicated in Table 19. Primary analysis study costs have been estimated from a payer perspective
(NHS and PSS). As described above, additional data were collected on patient costs, unpaid help received
and lost productivity; these are included in a secondary analysis.
Some activities are not associated with a specific unit cost and it has been necessary to categorise these in
a way that allows a unit cost to be assigned. For example, data extracted from general practice electronic
systems provide detailed information on activity for which there is no published unit cost, such as e-mail
consultations or telephone conversations with colleagues about a patient. Unit costs were assigned based
on an assessment of the nearest equivalent activity in terms of time spent for which a unit cost does exist.
For example, a telephone call with a colleague has no published unit cost, whereas a telephone call with
a patient does. The activity is similar and so the same unit cost was applied. Activity has been costed
based on whether it is most like a face-to-face appointment with a GP in the surgery or a GP telephone
consultation.
Prescribed medication
Data from general practice electronic systems were used to estimate the cost of prescriptions for
participants in the study, excluding the cost of study medication. However, the costs of mirtazapine were
included for participants who requested unblinding and switched treatments; these are recorded in the
general practice electronic systems. Only medications used for depression or other mental illnesses were
included. This was defined according to whether or not the medication was listed in the BNF19 in one of
the following categories:
l antidepressants
l antipsychotics (psychoses and related disorders)
l hypnotics and anxiolytics.
Medication unit costs were obtained from the prescription cost analysis data published by the Department
of Health and Social Care and based on August 2016 prices.48 A detailed list of the medicines prescribed
and their unit costs is provided in Appendix 3, Table 43.
The intervention
Participants were prescribed mirtazapine in line with the protocol. The cost of each prescription was based
on the per-tablet cost (see Table 19). Participants could have up to eight prescriptions, with a maximum
intervention cost of £28.56. Participants could stop taking trial medication for a number of reasons,
discussed elsewhere in this report.
Participant direct and indirect costs
Information on personal expenditure by participants was obtained from the patient questionnaires,
including lost earnings, private health and social care payments and prescription charges paid. A full list of
categories and the cost to participants is presented in Table 20. No participants reported use of private
inpatient care, which is not listed in Table 20. Participant costs are not included in the baseline analysis but
are included in the secondary societal perspective analysis.
Productivity costs
Following CoBalT,57 the human capital approach was used to value time absent from work. Median hourly
earnings were obtained from the Office for National Statistics (ONS) 2016 Annual Survey of Hours and
Earnings.61 A mean value across all ages and by sex was applied. Productivity costs are not included in the
baseline analysis but are included in the secondary societal perspective analysis.
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TABLE 19 Resource use and unit costs, all participants
Resource use Unit cost (£) Source
NHS secondary care
General inpatient ward 303.94 CoBalT57
Low-level secure services (per bed-day) 405.67 PSSRU 201556
A&E Mental Health Liaison Services, Adult and Elderly 187.86 2015–16 reference costs51
Psychotherapy, consultant led 158.06 2015–16 reference costs51
Community psychiatric nursing 74.16 CoBalT57
Mental well-being clinic 61.10 CoBalT57
Liaison psychiatry 105.08 2015–16 reference costs51
General practice systems data
GP consultation (in surgery) 33.00 PSSRU 201655
GP consultation (telephone) 26.11 PSSRU 201655
Prescriptions – As per drug costs in 2016 PCA data48
Other GP or community services
Counselling 52.22 PSSRU 201453
CBT (face to face) 97.13 PSSRU 201453
CBT (computer based) 23.37 PSSRU 201354
Mental health clinic 61.10 CoBalT57
Exercise or physical activity scheme 235.00 NICE costing statement58
NHS Direct or 111 9.13 Evaluation report of NHS 111 pilot sites59
NHS walk-in-centre 46.79 Evaluation report of NHS 111 pilot sites59
Home visits
Mental health nurse (advanced nurse) 60.59 PSSRU 201556
Occupational therapist 44.00 PSSRU 201655
Social worker 57.00 PSSRU 201655
GP 141.50 PSSRU 2016;55 PSSRU 201060
Additional help
Home care worker 22.35 CoBalT57
Day centre or social club 22.35 CoBalT57
Self-help group 15.67 CoBalT57
Informal unpaid help
Childcare 7.20 2016 National Minimum Wage, 25 +63
Help in the house (e.g. cooking), band 3 HCA 25.00 PSSRU 201655
Help outside the house (e.g. shopping), band 3 HCA 25.00 PSSRU 201655
Other help, band 3 HCA 25.00 PSSRU 201655
HCA, health-care assistant; PCA, prescription cost analysis.
Notes
PSSRU staff costs include training/qualification costs. GP home visit cost: the 2010 PSSRU60 estimates a home visit to cost
£108, compared with a surgery consultation cost of £32 for an 11.7-minute consultation (£2.74 per minute). The 2016
PSSRU55 estimates a surgery consultation to last 9.2 minutes at a cost of £33 (£3.59 per minute). Given the ratio of home
visit cost-to-surgery cost per minute, a 2016 home visit cost is estimated at £141.50.
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TABLE 20 Primary and community care resource use and costs, complete-case analysis
Resource
Group
Difference
(95% CI),a £
Control Intervention
Participants, n
Mean
cost per
participant
(SE), £ Participants, n
Mean
cost per
participant
(SE), £
GP-extracted resource use
GP consultation
(surgery)
61 135 (10) 69 166 (16) –32 (–69 to 6)
GP consultation
(telephone)
9 55 (15) 10 44 (10) 11 (–27 to 49)
Prescriptionsb 163 44 (12) 135 34 (9) 9 (–21 to 40)
Other GP or community services
Counselling 23 323 (290) 21 414 (537) –90 (–350 to 169)
CBT (face to face) 13 806 (109) 10 524 (195) 282 (–157 to 721)
CBT (computer based) 2 46.74 (23.37) 1 23.37 (–) – (–)
Mental health clinic 5 61.10 (0.00) 4 183 (66) – (–)
Exercise or physical
activity scheme
3 235 (0) 1 235 (–) – (–)
NHS Direct or NHS 111 4 9 (0) 1 9 (–) – (–)
NHS walk-in centre 2 47 (0) 4 58.75 (11.75) – (–)
Any GP or community
service used
35 530 (89) 31 454 (102) 76 (–193 to 345)
Home visits
Mental health nurse
(advanced nurse)
3 61 (0) 6 183 (93) – (–)
Occupational therapist 0 – 1 528 (–) – (–)
Social worker 1 171 (–) 1 684 (–) – (–)
GP 0 – 1 424.5 (–) – (–)
Any home visits 3 118 (57) 4 546 (352) – (–)
Additional help
Home care worker 2 363 (307) 1 11,622 (–) – (–)
Day centre or social
club
0 – 0 – – (–)
Self-help group 1 282 (–) 1 47 (–) – (–)
Any additional help 3 336 (179) 2 5834 (5787) – (–)
Informal unpaid help
Childcare 5 46.08 (19) 4 36.9 (24) – (–)
Help in the house
(e.g. cooking)
30 262 (49) 19 588 (277) –325 (–784 to 132)
Help outside the
house (e.g. shopping)
21 219 (66) 15 425 (272) –207 (–699 to 285)
Other help 14 335 (73) 9 158 (65) 176 (–110 to 463)
Any informal unpaid
help
41 424 (93) 30 638 (301) –214 (–770 to 343)
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Unpaid help
Participants were asked to report whether or not they received any help that was not paid for either by
themselves or by a third party. Such help included help with childcare, help around the house (e.g. with
cooking or cleaning) and help outside the house (e.g. with shopping). The value of such help is hard to
define and there is considerable debate in the literature about the most appropriate methods for valuing
unpaid help. For household help, we followed the approach of the ONS and used a proxy-good method
based on the wage rate of an equivalent paid helper.62 The ONS use the wage of a care assistant to value
non-continuous practical care, which we followed.62 The hourly cost of a care assistant was obtained from
the PSSRU.55 For childcare, we used the national minimum wage for those aged ≥ 25 years.63
Analysis
Resource use by participants in each trial arm is reported as frequencies, with means and medians as
appropriate. SDs and IQRs are also reported as appropriate. Resource use data and unit cost data were
combined to estimate the cost per participant for each cost category.
Missing data
When data were missing, they were assumed to be missing at random and multiple imputation (MI) was
used. MI was conducted in Stata 14. The Stata MI commands were used to generate 50 imputed data sets
using chained equations, which were combined for analysis using Rubin’s rule as specified as part of the
TABLE 20 Primary and community care resource use and costs, complete-case analysis (continued )
Resource
Group
Difference
(95% CI),a £
Control Intervention
Participants, n
Mean
cost per
participant
(SE), £ Participants, n
Mean
cost per
participant
(SE), £
Out-of-pocket costs
Inpatient 0 – 0 – – (–)
Outpatient 1 5000 (–) 0 – – (–)
Counselling 6 590 (311) 8 279 (114) 311 (–337 to 959)
Home care 0 – 1 30 (–) – (–)
Prescription charges 45 45 (6) 42 44 (7) 0.58 (–16 to 17)
Over-the-counter
treatments
19 22 (8) 12 27 (9) –5 (–30 to 20)
Complementary
therapy
10 97 (38) 6 177 (66) –80 (–230 to 70)
Lost income 15 1392 (799) 15 8748 (3799) –7357 (–15,309 to 595)
Other 6 287 (127) 6 458 (334) –172 (–967 to 624)
Any out-of-pocket
costs
48 252 (109) 43 2680 (1422) –2428 (–5110 to 254)
Productivity costs
Patient 35 3550 (1012) 32 5082 (1084) –1532 (–4491 to 1427)
Carer 5 255 (115) 6 332 (158) –78 (–538 to 383)
SE, standard error.
a Differences reported only when n in each arm is ≥ 5.
b Excluding trial treatment prescriptions.
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-mi estimate- command. The imputation model for the analysis included the stratification and minimisation
factors used for randomisation (site, baseline BDI-II score, whether or not a participant was undergoing
talking therapy), age, sex, initial treatment allocation, continuous baseline EQ-5D-5L and BDI-II scores and
a range of cost and quality of life variables.
Missing data were imputed for:
l EQ-5D-5L index scores at baseline and 12, 24 and 52 weeks
l mean patient-reported resource use costs at 12, 24 and 52 weeks
l mean costs of GP consultations and prescriptions.
Uncertainty arising from patient variation
Uncertainty arising from individual patient variability is reported as standard errors (SEs) for the point
estimates of the mean costs and QALYs. Uncertainty in the incremental cost-effectiveness ratio reported
for complete-case analyses is reported as 95% CIs, based on 1000 bootstrap replications. We also report
incremental net monetary benefit (NMB) with CIs for a range of willingness-to-pay (WTP) values and
cost-effectiveness acceptability curves (CEACs).
Discounting
Costs and outcomes were not discounted as the study and analysis was limited to a 12-month period. All
costs were estimated in 2016 prices and have been inflated as necessary using the PSSRU Pay and Prices
inflation index.55
Results
Resource use and costs
General practitioner-collected data
Results from the data collected directly from general practice electronic health records on the number of
GP consultations and prescriptions are presented in Table 20. There was no significant difference in the
cost of GP appointments in the surgery or GP telephone consultations between treatment groups. There
was also no significant difference in the cost of prescribed medication per participant between groups.
On an ITT basis, the mean cost of active treatment was £12.34 (SE £0.081).
Participant-reported resources
In addition, participants were asked to provide self-reported details of resource use. The results for all
self-reported resource use categories are also presented in Table 20. Complete-case results are presented
for the numbers of participants using each resource and the mean cost per participant. No difference in
mean cost between the groups was observed in any resource use category.
Cost–utility
Cost-effectiveness analyses are reported, relating the costs of each strategy to change in:
l QALYs at 12 weeks and 12 months post randomisation
l BDI-II scores at 12 weeks and 12 months post randomisation.
The primary outcome of interest for the economic evaluation was the incremental cost per QALY at
12 months’ follow-up. In keeping with the primary trial outcome, the primary analysis for the economic
evaluation was based on complete cases only. A secondary analysis based on the imputed data is
also reported.
HEALTH ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Primary analyses
12-week cost–utility
No clinically important differences in QALYs or costs were observed between the two groups at 12 weeks’
follow-up (Table 21). At the primary outcome end point of 12 weeks, participants in the active treatment
arm reported QALYs of 0.163 and participants in the control arm reported QALYs of 0.162, a difference of
0.002 QALYs (95% CI –0.002 to 0.005 QALYs). This difference is not meaningful. The active treatment
arm had higher costs (£65) than the control arm (£63). The difference in costs was small (£2, 95% CI
–£27 to £31) and is also not meaningful.
Assuming a WTP threshold of £20,000 per QALY, the expected NMB of the active treatment over placebo
is £144, but with 95% CIs ranging from –£1413 to £1701 (Table 22).
The CEAC (see Figure 5) illustrates the proportion of times that each intervention is cost-effective based
on the bootstrapped samples across a range of WTP estimates. Figure 5 illustrates that, based on the
bootstrapped simulations, at 12 weeks mirtazapine was more likely to have the highest NMB. At a WTP
threshold of £20,000 per QALY, mirtazapine was the more cost-effective option in 77% of the simulations,
rising to 79% at a WTP threshold of £30,000 per QALY.
A CEAC based on the WTP for an additional 1-point improvement in BDI-II score at 12 weeks is presented
in Figure 6. From this, we can see that mirtazapine is likely to have a higher expected NMB depending on
the WTP for a 1-point change in BDI-II score. The shape of this curve is driven by the fact that mirtazapine
provides a small improvement in BDI-II score relative to placebo. In most of the bootstrap simulations,
mirtazapine is both more costly and more effective.
Fifty-two-week cost–utility
At 52 weeks, participants in the treatment arm had an incremental gain of 0.009 QALYs (95% CI –0.016
to 0.035 QALYs) and an incremental cost of £69 (95% CI –£74 to £206) compared with participants in
the placebo arm (see Table 21). The NMB at 52 weeks is positive across the reported levels of WTP for an
additional QALY – at a WTP of £20,000 per QALY, the NMB is £118 (95% CI –£419 to £655) (see Table 22).
Again, consideration of the 95% CI shows a substantial degree of uncertainty around the results.
TABLE 21 Incremental cost-effectiveness ratios, NHS and PSS perspective, complete-case analysis
Primary
analyses
Group
Intervention Control Difference
Costs (SE), £ QALYs (SE) Costs (SE), £ QALYs (SE) Costs (SE), £ QALYs (SE)
QALYsa
12 weeks 67 (11) 0.163 (0.001) 63 (10) 0.162 (0.001) 4 (15) 0.002 (0.002)
52 weeks 261 (52) 0.734 (0.009) 192 (49) 0.724 (0.009) 69 (71) 0.009 (0.013)
BDI-II scoreb
Costs (SE), £
BDI-II score
(points) (SE) Costs (SE), £
BDI-II score
(points) (SE) Costs (SE), £
BDI-II score
(points) (SE)
12 weeks 67 (11) 17.804 (0.748) 63 (10) 19.822 (0.743) 4 (15) –2.128 (1.055)
52 weeks 261 (52) 16.7 0.824 192 (49) 16.8 0.805 69 (71) –0.166 (1.149)
a ITT analysis adjusted for baseline EQ-5D-5L index score, BDI-II score and the stratification and other minimisation
variables, bootstrapped SEs.
b ITT analysis adjusted for baseline BDI-II score and the stratification and other minimisation variables, based on complete
cases, bootstrapped SEs.
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TABLE 22 Incremental NMB of mirtazapine compared with placeboa
Analysis
WTP threshold per QALY (95% CI),a £
£10,000 £20,000 £30,000 £50,000
Complete-case analysis
NHS and PSS perspective
iNMB at
52 weeks
25 (–267 to 137) 118 (–419 to 655) 211 (–582 to 1004) 398 (–914 to 1709)
iNMB at
12 weeks
72 (–706 to 851) 144 (–1413 to 1701) 216 (–2119 to 2552) 360 (–3532 to 4253)
Societal perspective
iNMB at
52 weeks
51,926
(–160,178 to 264,030)
103,852
(–320,356 to 528,060)
155,778
(–480,534 to 792,090)
259,630
(–800,890 to 1,320,149)
iNMB at
12 weeks
2419
(–5475 to 10,313)
4839
(–10,950 to 20,627)
7258
(–16,425 to 30,940)
12,096
(–27,374 to 51,567)
Imputed data analysis
NHS and PSS perspective
iNMB at
52 weeks
15 (–32 to 62) 34 (–48 to 116) 54 (–66 to 174) 92 (–106 to 290)
iNMB at
12 weeks
25 (–270 to 321) 118 (–417 to 654) 212 (–575 to 999) 398 (–898 to 1695)
Societal perspective
iNMB at
52 weeks
–123 (–397 to 152) –103 (–386 to 180) –84 (–381 to 213) –45 (–382 to 292)
iNMB at
12 weeks
–676 (–1443 to 90) –583 (–1478 to 312) –490 (–1560 to 581) –303 (–1798 to 1192)
iNMB, incremental net monetary benefit.
a ITT analysis adjusted for baseline EQ-5D-5L score, baseline BDI-II score and stratification and other minimisation variables.
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FIGURE 5 Cost-effectiveness acceptability curve: probability of highest NMB at 12 weeks across a range of WTP
estimates per QALY.
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The CEAC at 52 weeks (Figure 7) shows similar results to that at 12 weeks. At a WTP of £20,000 per
QALY, active treatment was the more cost-effective option in 69% of the simulations. At a WTP of
£30,000 per QALY, it was more cost-effective in 71% of simulations.
Figure 8 shows the cost-effectiveness planes for the incremental cost per QALY at 12 and 52 weeks.
The overall uncertainty in the results is clear.
Secondary analyses
Societal perspective
In addition to the primary analysis based on the NHS and PSS perspective, we undertook an analysis based
on the wider costs to society. Additional costs included in this analysis were patient out-of-pocket costs
including lost income, as well as productivity losses (as described in Employment and lost productivity).
Across all levels of WTP tested, mirtazapine has a negative NMB when wider societal costs are included in
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FIGURE 6 Cost-effectiveness acceptability curve: probability of highest NMB at 12 weeks across a range of WTP
estimates for a unit change in BDI-II score.
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FIGURE 7 Cost-effectiveness acceptability curve: probability of highest NMB at 52 weeks across a range of WTP
estimates per QALY.
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the analysis. At a WTP of £20,000 per QALY, the societal NMB is –£111 (95% CI –£390 to £169) at
12 weeks and –£370 (95% CI –£1199 to £459) at 52 weeks. As with all other analyses, the CIs for these
estimates suggest a considerable degree of uncertainty in the results.
Imputed data
To assess the impact of missing data on the results, we also undertook analysis using MI. These results are
presented in Table 22. The results also illustrate the wide variability in the NMB estimates caused by the
small observed difference in QALYs at both 12 and 52 weeks. In the NHS and PSS payer perspective
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analysis, for a WTP threshold of £20,000, the expected NMB at 12 weeks is £118 (95% CI –£417 to £654)
in the imputed data set, compared with £144 in the complete-case analysis. At 52 weeks, at a WTP
threshold of £20,000, the NMB is £34 (95% CI –£48 to £116) in the imputed data set, compared with
£118 in the complete-case analysis.
Subgroups
As with the analysis of the primary outcome, we undertook two a priori subgroup analyses to investigate
any differential effects according to baseline depression severity (BDI-II score) and a measure of degree of
treatment resistance based on the duration of symptoms and prior treatment with antidepressants. In both
subgroups, we found no evidence of any effect interaction with regard to the difference between NMB
(at WTP thresholds of £20,000 and £30,000) at 12 or 52 weeks.
Conclusion
The difference in QALYs at both 12 weeks and 1 year is very small and the CIs are wide and include the
null. The difference in NHS and PSS costs at 12 weeks is small and not meaningful. At 52 weeks, the
observed difference in NHS and PSS costs is greater, but the CIs of the difference include the null. There is
no strong evidence that mirtazapine is a cost-effective use of NHS resources.
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Chapter 5 Qualitative findings
Introduction
This chapter describes the methods and findings of the qualitative study embedded within the MIR trial,
aiding our understanding of the acceptability of combining antidepressants in primary care, from the
perspectives of people with depression and GPs.
Background
The MIR trial evaluated whether combining mirtazapine with SSRI or SNRI antidepressants resulted in better
patient outcomes and more efficient NHS care than using SNRI or SSRI therapy alone. The embedded
qualitative study aimed to explore the acceptability of combination treatments for depression to patients
and GPs.
Patients’ health beliefs are central to an agreement about treatment being reached between patient and
GP, requiring a discussion that is inclusive of, and considers the views and beliefs of, both parties.64 Patient
beliefs and attitudes influence adherence to antidepressants.65,66 Previous literature reporting patients’
views on the management of depression suggests that some patients prefer psychological treatments to
medication,67,68 but these preferences vary depending on a number of factors including age, sex and their
own understanding of depression.68,69 Negative views on antidepressants include concerns that they are
addictive68 and older people may be particularly reluctant to take antidepressants.70,71
It cannot be assumed that patients already on antidepressant medications will have a positive attitude to,
or a good understanding of, the treatment or will be willing to take another antidepressant if their depressive
symptoms remain. Evidence suggests that some patients using SSRI antidepressants would prefer to stop
but are afraid to do so72 and that, when considering stopping the use of SSRIs, patients have a number
of concerns about cessation that clinicians should attend to.73,74 In a meta-ethnographic synthesis of
qualitative evidence it was found that patients were heavily engaged in negotiating a ‘medication career’
or ‘moral career’,75 making choices about how to proceed with treatment and sense-making around their
illness. This study also emphasises the vital role that GPs play in facilitating patient decision-making through
discussion to aid understanding and meaning-making around depression and treatment experiences.
The views of patients who decline to take part in research can highlight salient attitudes about interventions.
In their qualitative study exploring the views of people who had declined to participate in a trial of CBT for
TRD, Barnes et al.76 reported that the acceptability of the trial intervention was an important factor in
determining whether or not patients chose to participate in the trial.
O’Cathain et al.77 emphasise that the value of qualitative research to RCTs includes ‘improving the external
validity of trials and facilitating interpretation of trial findings’. This chapter aims to illustrate the value of
the embedded qualitative study in understanding the acceptability of a combination of antidepressants to
patients and GPs and has implications for how the intervention may be received more widely by patients
and GPs in primary care.
Aims
1. To explore patients’ views and experiences of taking either two antidepressant medications or an
antidepressant and a placebo.
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2. To identify patients’ reasons for completing or not completing the study up to 12 weeks, including
stopping the study medication.
3. To explore the views of GPs on prescribing a second antidepressant in this patient group.
Methods
Ethics approval
Ethics approval was given by South East Wales Research Ethics Committee Panel C (reference: 12/WA/0352).
Design
We conducted semistructured interviews with people who were invited to participate in the trial but who
declined, trial participants (who completed the trial and who withdrew) and GPs, to generate in-depth
data on reasons for declining to participate, perspectives of those participating in the trial, reasons for
completion of the trial or stopping the study medication and views and experiences of GPs about
managing people with depression, with a focus on prescribing.
Sampling and recruitment to the qualitative study
People who declined to participate: ‘decliners’
Recruitment was from the pool of potential participants in the MIR trial. All patients invited to participate in
the trial via the record search were sent a postal invitation letter (as described in Chapter 2). Respondents
who declined to participate could give a reason on a form that provided closed questions to indicate their
reason(s) for declining (see Figure 2 and Box 1). There was also a free-text response box for respondents to
give additional details about or alternative reasons for declining. Respondents were also given the option to
indicate their willingness to be contacted to be interviewed about their reasons for declining participation. If
respondents indicated that they were willing to be contacted about their reasons for declining participation,
these data were stored on a Microsoft Access® (Microsoft Corporation, Redmond, WA, USA) database,
which could be accessed by the trial team to be used to invite a sample of willing respondents, categorised
as ‘decliners’, to participate in a semistructured interview.
Purposive sampling from within the decliner population was carried out on the basis of sex, age,
geographical location and reasons for declining to participate, to gain maximum variation within the
sample. People who selected one or more of a, f, g and h from Box 1 were not sampled, as it was thought
that these responses would yield less salient data on reasons for declining in relation to combination of
antidepressants. Free-text responses were also used to direct sampling when respondents had selected
‘other’ as a closed response and when details were given in the free-text box that would indicate their
suitability or unsuitability to be contacted about their reasons for declining. Examples of free-text responses
can be found in Table 23, although this is not exhaustive.
BOX 1 Response options for reasons for declining to participate in the MIR trial
a. I do not want to take part in a research study.
b. I do not want to take mirtazapine.
c. I do not want to take a placebo.
d. I only want to take one antidepressant.
e. I plan to stop taking my current antidepressant.
f. I am not taking antidepressants.
g. I am too busy.
h. I am not depressed.
i. Other.
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Once identified as suitable for contact, the research assistant (Kate Dixon) made telephone contact with the
respondent and gave details about the purpose of the call, the relationship of the qualitative study within
the MIR trial and their rights as a potential participant of the study to confidentiality and to withdraw their
consent at any time. They were then asked if they had further questions and whether or not they would be
willing to participate in a telephone interview. If verbal consent was given, these interviews were usually
conducted at the time of the initial telephone call or arrangements were made to call the respondent at a
more convenient time.
People who participated in the MIR trial: ‘completers’ and those who stopped the
study medication
At 12 weeks (once primary outcome measures were assessed), sampling of trial participants was carried
out, taking sex, age and geographical location into account to gain maximum possible variation within
the available sample. Our aim was to sample participants who had adhered to the trial medication up to
the primary outcome at 12 weeks (hereafter referred to as ‘completers’) and those who had stopped the
study medication before the primary outcome but who had remained in follow-up (hereafter referred to
as ‘withdrawers’).
Participants who had reached the 12-week assessment were advised by the researcher that they may be
contacted by the study team to discuss their experiences of participation in the trial. It was stressed that
their participation in the qualitative study was voluntary. The research assistant received regular reports
from the trial teams on participants who had reached the primary outcome measure and, following review
of the participant records, would attempt to contact participants when the contact notes suggested that
it was appropriate to do so. When there had been any SAEs or AEs or when a participant had declined
further contact after the primary outcome measure (at 12 weeks), these individuals were not invited to
participate in the qualitative study.
Participants were initially contacted by telephone and asked whether or not they would be willing to
take part in an interview to discuss their experiences of being in the MIR trial. If a participant agreed, an
information sheet with further details of the study was sent to the participant and a provisional date for a
face-to-face interview was made (usually 1–2 weeks after the date of the telephone call to allow time for
the information sheet to arrive and the participant to consider the content). The research assistant made
further telephone contact 1–2 days prior to the interview to confirm that the participant was still willing to
be interviewed.
TABLE 23 Examples of free-text responses
Free-text response examples
Deemed suitable
for sampling
Fear of side effects Yes
Don’t want to rock things Yes
Happy with current tablets Yes
I only want to take one antidepressant. I have had mirtazapine previously,
hated it – I put weight on
Yes
I am too busy No
I am on citalopram 20mg per day to help with my bowels not for depression No
I am taking sertraline for OCD not depression No
Job related concerns No
OCD, obsessive compulsive disorder.
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If a participant withdrew from taking the tablets allocated prior to the 12-week assessment, a record of their
status was noted by the research team. The research assistant received reports indicating which participants
had stopped the trial medication but had consented to follow-up assessments and contact with the research
team. Sampling from within the trial medication ‘withdrawer’ population was carried out on the basis of
sex, age and geographical location. Following a review of the participant record and discussion with the
researcher who had visited the participant, when appropriate, the research assistant attempted to contact
the medication ‘withdrawer’ to gain consent for an interview. As with the ‘decliner’ participants, medication
‘withdrawers’ were offered the opportunity to discuss their reasons for withdrawing from the medication.
Participants who had withdrawn from the medication gave verbal consent to discuss their reasons and
interviews were conducted by telephone.
General practitioners
General practitioners were recruited from practices participating in the MIR trial. Sampling of GP practices
was purposive and selection was based on the geographical location of the practice and the sex and
experience of the GPs, to give maximum variation in the available population. Sampling was also
contingent on whether or not the practice had patients who had been randomised to the MIR trial.
General practitioners and practice managers were initially contacted by e-mail, with the information sheet
provided as an attachment, inviting them to discuss their experiences of managing people with depression
and their views of using a combination of antidepressants. If there was no response to the e-mail, telephone
calls were made to the practices. If a GP expressed interest in participating in an interview, the research
assistant arranged a telephone interview at a time that was convenient to the GP.
Consent
Informed consent to participate in the qualitative study was obtained from all participants in the study.
People invited to take part in interviews about their reasons for declining to participate in the MIR trial were
provided with a short questionnaire during the trial recruitment phase on which to indicate consent to be
contacted about their reasons for non-participation. When these people were contacted by telephone, they
were asked to confirm that they had consented to take part in a telephone interview and for their verbal
consent to record the telephone interview. Participants were reminded about their rights as a participant to
confidentiality and to withdraw their consent, at the beginning and the end of the conversation, respectively.
This procedure for gaining consent to conduct and record telephone interviews was also followed when
contacting GPs for telephone interviews for the study.
Patients participating in the trial were sent an information sheet in the post after their 12-week outcome
measure had been taken by a researcher, providing details about participation in the qualitative study.
Those participants who agreed to an interview were asked to sign a written consent form to indicate
their consent to participate and the researcher confirmed this consent verbally before commencing the
interview. The majority of interviews with patient participants were held face-to-face, in their own homes.
Data generation
Data were generated during semistructured interviews conducted either by telephone (with patients who
declined participation in the trial and GPs) or face to face (with trial participants who completed or
withdrew from the trial medication).
Topic guides for the groups of interview participants (decliners, trial participants and GPs) were produced
prior to the commencement of the first interviews (see Appendix 4). These topic guides were amended
and adapted in response to the initial analysis of interviews and after discussion within the research team.
This process was iterative throughout the period of data generation to better explore the concepts and
themes that emerged as being important to the interviewees and required more in-depth examination
during interviews with subsequent participants.
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Data generated from each of these data sets were collected during each interview by the qualitative
research assistant, using a digital audio recorder. These audio files were downloaded to, and stored securely
on, a secure network at the site where the qualitative research team was based (Keele University) and handled
in accordance with the research institute’s SOPs. Audio files were transcribed verbatim by an authorised
transcription company and transcripts were stored securely by the research assistant in accordance with SOPs.
Each interview was checked against the audio recording, cleaned and anonymised prior to analysis.
Analysis
Analysis of the data was conducted both independently and subsequently collectively by three members
of the qualitative research team: the qualitative research assistant, a research fellow (Heather Burroughs)
and the co-investigator with responsibility for managing the qualitative study (Carolyn Chew-Graham).
The researchers were from different professional backgrounds (psychology, health services research and
anthropology, and academic primary care), which increases the trustworthiness of the analysis.78 Transcripts
were read and re-read, themes arising during analysis and data collection were discussed within the team
and the topic guides were modified as data collection and analysis progressed. The qualitative research
team met regularly to discuss and agree coding, revisiting the data from each data set in an iterative
manner to verify coding and themes generated from these codes. This process was repeated until it was
agreed that each data set had reached saturation. Analysis was initially conducted within each data set and
then comparison was carried out across the data sets. NVivo 10 (QSR International, Warrington, UK) was
used to store data and aid analysis.
Patient and public involvement and engagement
The qualitative research team worked with a patient and public involvement and engagement (PPIE) group
to discuss transcripts from the data sets. The aim was for the lay partners to add value to the analysis by
bringing their own perspectives and identifying further areas for the researchers to explore in the interviews.79
Four meetings were held with the PPIE group over the course of data generation.
Additional perspectives provided by patients and the public on the qualitative analysis
The group initially commented on the study patient-facing documents and made valuable suggestions
about how to modify phrases used. The topic guides were discussed in depth and suggestions were made
to rephrase some of the prompts in the topic guides for both ‘completers’ and ‘decliners’.
At a further meeting, the PPIE group looked at two interview transcripts. The group commented on the
narrative in one of the transcripts about the acceptability of medication and talking treatments. The
experience reported by individuals was that antidepressants were offered initially and that there were long
waiting lists for psychological therapies. The group was assured that treatment choice would be explored
in interviews with MIR trial participants. The group suggested that future interviews with GPs and patients
should explore what is being done in primary care while patients are awaiting psychological therapies.
The concern that GPs expressed about continuing two antidepressants was highlighted by the PPIE group
and it was suggested that this should be explored in interviews with trial participants.
The principle of ‘equilibrium’ was introduced to the PPIE group as an important theme arising from the data:
people who felt that they had established an equilibrium may not find participating in a trial acceptable,
whereas people who were at ‘crisis point’ (not being in equilibrium) may be more likely to agree to participate
in a trial (‘worth trying anything’). This perspective was, therefore, developed, in part, in collaboration with
the PPIE group. The group also discussed the uncertainty about how long patients with TRD would need to
take two antidepressants and felt that this should be an important focus of the analysis.
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Results
Details of participants
A total of 60 interviews were conducted: 23 with ‘decliners’ (mean duration 11 minutes and 27 seconds),
23 with ‘completers’ and ‘withdrawers’ from the study medication (mean duration 47 minutes and
35 seconds) and 14 with GPs (mean duration 19 minutes and 31 seconds).
The 23 ‘decliners’ who we interviewed were distributed fairly evenly between the four centres, with seven
from Bristol, six each from Exeter and Keele and four from Hull. Fifteen of the interviewees were female
and eight were male, with an age range of 27–76 years. All were still blinded at the point of interview.
Illustrative data are presented with the sex and age of the participants given as identifiers in the case of
trial participants (‘completers’ and ‘withdrawers’ from the study medication) and ‘decliners’. Data from
GP transcripts are identified with numbers that reflect the chronological order in which the interviews
were conducted.
Decliners
Table 24 lists the reasons that people gave for not wanting to participate in the MIR trial.
The most common reason for declining participation was not wanting to take part in a trial (49%).
Thirty-six per cent of people invited indicated that they did not want to take mirtazapine; it is not known
if this was because of prior experience of being prescribed this antidepressant. Not wanting to take more
than one antidepressant was a reason given by 20% of people for declining to participate in the MIR trial.
Interestingly, 17% of people suggested that they were not taking an antidepressant, even though they
were being prescribed a SSRI or SNRI according to their GP records; 39% of people said that they planned
to stop taking their current antidepressant.
Analysis of the ‘decliner’ data suggested that key themes were ‘the hard work of managing depression’,
uncertainties about antidepressants, including questions over the value of a second antidepressant, and
attainment and maintenance of a hard-won equilibrium.
The hard work of managing depression
Respondents reflected on the history of their depressive symptoms and there were rich descriptions of
endeavours to manage their mental health, including self-management strategies and help-seeking.
TABLE 24 Reasons for declining participation in the MIR trial
Reason Decliners (N= 4702)a n (%)
I do not want to take part in a research study 2298 (49)
I plan to stop taking my current antidepressant 1822 (39)
I do not want to take mirtazapine 1692 (36)
I do not want to take a placebo 1328 (28)
I only want to take one antidepressant 936 (20)
I’m not taking antidepressants 818 (17)
I am too busy 463 (10)
I am not depressed 323 (7)
Other reason(s) 1321 (28)
a Individuals were able to provide more than one reason and, thus, percentages do not add up to 100%.
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Many respondents described delays in recognising the cause of their depression, outlining repeated
investigation for physical problems until a diagnosis of depression was achieved by default:
Erm, what it went back to was – I think it was postnatal depression, it started, and I didn’t realise what it
was. Erm, that was [. . .] so that was 20 years ago and I thought I’d got ME [myalgic encephalomyelitis]
or, or MS [multiple sclerosis] or something, because I, I, physically, couldn’t walk. I wasn’t particularly
unhappy, but I, I was physically fatigued really, really fatigued. And I struggled with that for years, going
for tests, and one thing and another, and it never came to anything, because it was depression.
Female, 55 years
Once recognised as depression, respondents reported that they had tried numerous strategies and lifestyle
changes to manage their own symptoms, including exercise and diet, seeking support from family and
friends, taking steps to ease the pressure on themselves and pursuing psychological and alternative therapies:
Well I’d been on websites to look at the condition . . . to look at what I could do, such as the omega-3,
eating well, exercising, getting as much light as you can . . . all those sort of things.
Male, 57 years
Respondents described a process of ‘trial and error’ in the search for something that works:
I took part in other things as well, like a stress-management course and an online cognitive–
behavioural therapy course which, to be quite honest, I didn’t think they particularly helped me, but I
did them because I was just trying everything to get out of that state.
Female, 44 years
All respondents indicated the work involved in trying to manage their symptoms and find something
that helped:
. . . I’ve been doing a lot of meditation and, sort of, pursuing the mindfulness route [. . .] I think to get
out of depression, you have to probably put in a lot of different things in place to be able to tackle the
things that have got you there, [OK] and exercise and eating well or trying to eat well even though
I didn’t have an appetite.
Female, 37 years
Medication for depression: uncertainties and fear
Some respondents described an initial reluctance to take antidepressants but, having got over this,
suggested that they had come to terms with the need to use drugs to manage their mood. However,
many respondents expressed concerns over the length of time that they would have to take their current
antidepressant and were resistant to taking a second antidepressant:
I felt [. . .] that I didn’t wanna get involved in taking tablets for 6, 9, 12 months. I’m already 6 months
into taking them now [hmm], which is longer than I thought I would be . . . I thought, ‘Oh, I’ll get rid
of it. I’ll be OK. I’ll have a few months or I’ll have a couple of months off. I’ll be back to my normal
self,’ but it hasn’t worked like that. Erm, and whether another antidepressant would help I really
don’t know.
Male, 55 years
Such reluctance was sometimes because of a fear of (additional) side effects:
I didn’t want to start with the side effects what I got from the first one [uh-huh]. I didn’t want to start
with new side effects and things.
Female, 47 years
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. . . also when I read the side effects. I don’t mind the side [effects], you know, like the dry mouth,
I don’t get that with these ones of mine, erm, and I have had pills in the past where I have done, and
it’s not nice, is it? [. . .] And, you know, and I’ve just basically, I suppose, I’ve, you know, I’m OK with
the tablets I’m on, but I don’t want to sort of erm, bring on any more symptoms, basically. [. . .] ’cos
I mean when it, it was bad it was really bad and, and I’d, I’d, I don’t think I wanna go back
there anymore.
Female, 48 years
Some participants, who were taking medication for other conditions, were wary of yet another drug:
I didn’t really wanna be taking another, another pill, really [. . .] again, for me it was, er, the number of
pills I take is a bit of an issue.
Female, 27 years
I think it’s a good thing to have as a study, but like I say, if I was on less tablets I wouldn’t mind sort
of going in for doing it. [Yeah] But as I say, I just dunno how it’ll effect, it might bugger me around
with the other tablets.
Male, 60 years
None of the ‘decliners’ interviewed expressed experience of, or particular concerns about, mirtazapine.
Maintaining equilibrium
The invitation to participate in a trial was described as a difficult decision by many of the ‘decliners’
interviewed. Managing depression was seen as a series of complex decisions, with continued reflection
and self-monitoring required. Respondents indicated that they were declining to take part because they
feared disturbing the sense of balance they had achieved with their current antidepressant medication.
The potential work involved in participation was felt to be a challenge to their current stability:
Because you know when you suddenly drop and you don’t know why? [Hmm] Erm, I’ve had a drop
recently, so that, I don’t know what that was, but I had a drop recently, and I had to, sort of, look
again at what I was doing [yeah]. Erm, so, adding something, changing something, is a bit scary for
me [uh-huh] because I was feeling good, and I like feeling OK.
Female, 53 years
. . . but for me, taking something, erm, potentially taking something that could disrupt the way I am
when I’m, you know, feel I’m on a steady level, I, I didn’t really want to, to take that risk.
Female, 27 years
I’m happy – I’m actually happy with the medication that I’m on [OK]. Erm, I, I’ve, er, I, I tried different
medications to start with, and I really, it really wasn’t successful. I’m in, I’m quite content with the
place that I’m in at the moment.
Female, 27 years
Other respondents, although recognising that something else may be necessary to help them manage their
symptoms, expressed a preference for talking treatments:
. . . I’m on quite a low dose really, 20 mg of, erm, citalopram, and I think it was doing the job it
needed to do [. . .] to get me to point where I could look at some issues.
Female, 39 years
A number of ‘decliner’ participants stated that had they been offered combination treatment at a point of
crisis, when they felt out of balance and unable to cope, they might have agreed to take part in the trial
because of their desperation to overcome their depression. In the following extract, the ‘decliner’
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participant is responding to a question from the researcher about whether or not she would have
considered taking two antidepressants if she had not felt better on one tablet. Her response suggests that
if she had been ‘at rock bottom’, taking two tablets would not have been an issue if it meant getting better:
. . . I needed to do whatever it took to, you know, get well again, quite simply. So I, I would do
whatever it takes. When you – I think when you really hit rock bottom you are prepared to do
whatever it takes and I have absolute faith in my doctor.
Female, 42 years
The participant in the next extract is responding to the same inquiry, about how she would have felt had
she been offered two antidepressants prior to feeling stable on her current antidepressant. She makes
a more extreme comparison, but makes the same point about being willing to accept whatever was
necessary to escape being depressed:
I think, I think if you’d caught me when I was depressed, I would have taken anything to be honest,
I would have done anything to get out of it [. . .] in the first instance I struggled for a few weeks erm,
thinking oh I can get out of this and it’s alright, it’s temporary and then it gets to a point where 2,
3 weeks down the line, I just thought, I can’t deal with this, I’m on a sinking ship, so I think if the
study had been then, and someone had offered me, you know, I don’t know, a shot of heroin a day
to get out of it, I would have done it!
Female, 38 years
The next extract is from a ‘decliner’ who, when asked about taking two antidepressants, sums up the main
themes that arose from analysis of all of the ‘decliner’ transcripts. Taking mirtazapine alongside his current
antidepressant may have been an option if he had had no other options, but now that he was ‘feeling
well’ this was not a risk he wanted to take:
No, I mean it may well be a brilliant, you know I don’t know much about this mirtazapine and erm,
you know, if I was in a more impossible situation, I probably wouldn’t mind trying it out, but erm,
I was so desperate to get out of that state, I don’t want to risk it, so it is simply erm . . . now that I’m
well again, not wanting to risk erm, changing that.
Male, 57 years
Why would another tablet help?
Some respondents expressed scepticism about the ‘chemical imbalance’ story that they felt had been told
to them, to explain why a tablet would help their mood. Why a second antidepressant would help if the
first had not was questioned:
Interviewer: . . . would you have had any concerns about taking two antidepressants?
Respondent: Erm, no, I don’t think so . . . but I should wonder why I suppose I hadn’t had any, er,
sort of beneficial reaction and maybe had to go to the doctors again and say it doesn’t seem to be
working terribly well, what else can we do.
Male, 76 years
The dominance of these themes within the ‘decliner’ data set suggests that, for these people, taking part
in the trial of a combination of antidepressant drugs was too great a risk to their current feelings of
stability. For them, their current antidepressants were helping them maintain a level of functioning, which
they wanted to protect.
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Completers and withdrawers from the study medication
Analysis of data generated from interviews with participants who completed the trial or who withdrew
from medication suggested four main themes, which resonated with the analysis of the ‘decliner’ data:
(1) help-seeking at a point of crisis, (2) hoping for another option, (3) experiences of the trial, emphasising
side effects, which led to (4) a dilemma of whether or not to continue the combination of medication.
Help-seeking at a point of crisis
People who felt that they were approached to participate in the MIR trial when they were at a point of crisis
described seeing the trial as an opportunity to deal with the crisis. Thus, participants detailed the current
impact of their depression on their ability to cope, to the point when they recognised they needed help:
I had a lot of work stress going on as well [uh-huh], er, and it all got on top of me [. . .].
I was massively, er, overeating, erm, oversleeping, permanent low mood, just generally unwell [. . .]
So, er, at, sort of, that point, I went to the doctor and said, ‘Look, this is what’s going on. I need some
help with this’.
Male, 52 years, completer
Another respondent reflected on how his feelings of desperation had led him to accept referral into the
trial by his GP, in the hope that it would offer alleviation of his current condition:
Well I think I was desperate enough to take her advice that it was more likely to be helpful than
anything, than a hindrance, it wasn’t going to do any harm and it might do some good.
Male, 83 years, completer
Hoping for another option
Many of the participants who agreed to take part in the trial described the hope that participation might
provide them with another option to try. Thus, respondents described the protracted sequence of trying
out other antidepressants, increasing the dosage of their medication, which had either been ineffective or
had worked for a limited time and then seemed to stop working, and referrals to talking therapies. The
hope that this trial would be another option for them to regain a sense of well-being was prevalent in
accounts of these participants’ experiences:
I felt that the antidepressants, I’d already been on, you know, I was given 20 mg, and then they were
increased to 40 [uh-huh], and yet I still wasn’t feeling, I wasn’t really feeling, er, 100% [uh-huh]. So I
just felt that that [taking part in the trial] could be a different way of trying to get things, trying to get
me a bit more better, you know.
Male, 54 years, completer
. . . I had these bouts where, maybe, I slipped back, every 6 months, 12 months, maybe even longer
than that. And I found that the symptoms that I was getting were reoccurring more frequently, and
I myself, was wondering, erm, if there was anything different I could try.
Female, 59 years, completer
As with the decliners, participants in the trial were keen to get back to a level of coping and well-being
that they had experienced previously. Participants described that they were no longer feeling a beneficial
effect from their medication and in some cases had sought out another option from their GP. The
participant in the following extract gives an account of approaching her GP to ask them to ‘do something’:
I was taking sertraline erm probably from quite a while, really; about 4 months or so. And I felt they
hadn’t made enough difference. [OK] Erm so I went back to the doctor and I was really worried and
I said, ‘Look, I need some – either to up this medication or change it, do something’.
Female, 49 years, completer
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The opportunity to participate in the MIR trial came at a time when they were seeking an alternative
option to help them manage their depression.
Experiencing the trial: benefits and side effects
Feeling better: improvements in mood
A number of participants who had reached the 12-week assessment in the trial reported that they had
experienced improvements in their mood and general functioning. Participants described themselves as
moving towards the equilibrium that they sought:
Since taking the second tablet, I didn’t feel the need to go back to LIFT [local psychological
intervention group], as well, actually. I didn’t – I felt I didn’t need to talk it through because I felt OK.
Female, 61 years, completer
I’m back to feeling more like myself, looking forward to things, planning things, generally being on
top of stuff. I’m still tired because that’s because we’ve got three small children [laughs]. Bless him.
Erm, but generally, yeah, like, I was picking up and, sort of, the, sort of, the weight is starting to come
off as well, and it’s just, sort of, things are turning around, definitely, I think.
Male, 35 years, completer
I’m quite happy with taking these combinations particularly, particularly this one, because it seems to
be working [. . .] now I wake up and I think, oh it’s quite a nice sunny day I might do such and such
today you know it’s – it’s more positive definitely, er, a more positive outlook [. . .] Er, and one thing
it’s done it has actually increased my appetite it’s definitely done that because I was, er, I was
forgetting to eat basically.
Male, 59 years, completer
This participant was pleased both with his increased positivity and with the increase in appetite and weight
gain, which contrasts with the reports of other completer participants who reported that the side effect of
weight gain had caused them to withdraw from the study medication.
A couple of participants reported withdrawing from the study medication because they felt that they had
regained their equilibrium:
I think the medication that I was on – got me, you know, on an acceptable level, you know. I’m not as
bad as I was [. . .] And then you get to a stage where yeah, things are acceptable. You just accept
things and you just carry on.
Female, 69 years, withdrawer
Side effects: increased appetite and weight
Commonly reported side effects in both completers and withdrawers were increased appetite and weight
gain, which most found problematic:
. . . my sugar, craving for sugar, which I’ve always had, er, a, er, a . . . [Sweet tooth?] Yeah, and I
always called it addiction, erm, and that seemed to lessen with just citalopram, and I lost a lot of
weight last year; I lost over 2 stone. As soon as I started taking these tablets, I was climbing the wall,
erm, immediately, for sugar [uh-huh], and I didn’t seem to have, erm, a stop button to say you’re full.
Female, 61 years, completer
The only problem I have is my weight gain issue. I’ve never been a person that’s been on a diet in my
life. I’m not a person that, erm, has had to worry before about putting weight on and since I’ve been
taking this, these tablets, I’ve put on 2 stone [laughs], which is quite a lot.
Female, 59 years, completer
DOI: 10.3310/hta22630 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 63
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Kessler et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
Had my weight gain not been so severe I would’ve gone on longer taking the drug – and I told her
that. I said to her that I couldn’t warrant having great thoughts and then dying of a cardiac arrest
[laughs] because I’d put on so much weight. I have weight issues anyway, so it was just like the
balance wasn’t right for me by the end of it.
Female, 36 years, completer – withdrew after unblinding
Two antidepressants: whether or not to continue?
Both the completers and those participants who withdrew from the study medication offered a narrative
of balancing improvements in their mood and unpleasant side effects of treatment:
Yeah, I do on one hand. I do feel slower, and like I’m not getting anything done [laughs] which is a
double-edged sword, isn’t it? Because like, I’m feeling obviously a lot better on one hand, and, erm,
you know, is, what is the benefit of me staying on it other than it, it, you know, in case, obviously I’d
take it for as long as I need to, and then I’d come off it and see if I can cope.
Female, 59 years, completer
. . . but I sometimes wonder if it’s worth it. I don’t wanna put all that weight back on.
Female, 61 years, completer
The need to balance the gain in improvement of mood with the side effects is well illustrated in this exchange:
Participant: The only problem is that I gained nearly 3 stone.
Interviewer: OK, er, and, er, you have mentioned that, er, you have put on weight with the
medication, does that mean that you’ve actually stopped taking it?
Participant: Yes I have.
Interviewer: You have, OK.
Participant: Because it’s, er, believe me I’m beginning to notice that I’ve stopped taking it.
Interviewer: Right, OK, in terms of a decline in your positive feelings . . .
Participant: But the amount of weight that I put on was I – I, it, I couldn’t tolerate it [right] it was
making me short of, it was nearly 3 stone.
Interviewer: And that was in the period of time you were on the trial?
Participant: It’s, well, I was alright for the first month [OK] and then it gradually crept up and this last
2 months it literally shot on and since I’ve stopped taking them I’ve actually lost 2 kilos already.
Male, 75 years, completer
General practitioner perspectives
The narratives of GPs about their management of people with depression suggested that it is complex,
individualised and involves a good deal of effort when medication is used. GPs described the ‘hard work’
of managing people with depression, resonating with the patients’ perspectives. Observations about
people presenting at a crisis point linked with the patient data sets.
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The hard work of managing people with depression
Although GPs described managing people with depression as ‘the bread and butter of general practice’,
they reflected on the complexity of the work involved in the assessment of a patient:
I mean all of it is history taking initially, finding out a little bit about the, the, the physical problems,
social problems and obviously their mental health problems. There might be more significant social
connotations. So they might have alcohol-related problems or drug use problems and things like that
so that can make things a bit more challenging.
GP04
. . . you can’t give a global answer to that actually because it’s incredibly tailored individual . . . to
individual patient circumstances and patient beliefs [. . .] so I’m – you know, I just think it’s – it’s just
very individual. I think we all adopt different consultation styles for different patients, don’t we?
GP02
This multifaceted and individual assessment of patients who presented with depressive symptoms or
ongoing depression, described by some GPs as a large component of their workload, was also described as
one that can feel like a ‘battle’ and at times overwhelming:
Erm, so it’s, it’s inevitably a battle [yeah]. Well, not a battle, it’s a challenge to, to relate to the patient
in the way that they understand. That’s what we do for a living, isn’t it? [Hmm] I suppose.
GP12
. . . we have thousands of patients who do seem to have erm, anxiety, stress, depression and mood
problems [. . .] Yeah, within the practice, you know, we are seeing an increasing number of people
who do present with mental health problems, or it feels like that. The reason we employ a specific
nurse to help deal with those problems is a reflection on the fact that we are overwhelmed by it.
GP05
In addition, GPs described the complexity involved in negotiating management with patients:
. . . erm I think it’s – some of it’s about previous response or lack of previous depression, really. [OK]
Erm the, the, I think then that’s looking at the broader context of what the patient’s like, whether it’s
a personality disorder, erm and whether it’s err, circumstantial, you know, whether it’s – there’s,
there’s, it – there’s quite a few things that feed into that, really.
GP10
General practitioners varied in their descriptions of TRD, with some suggesting that it was related to the
patient’s lack of response to medication, while others outlined a more complex definition:
Yeah, well I mean, when I say more challenging I mean more treatment resistant I suppose so [right] if
you’ve got to that point these patients are sort of, if you like, failing to respond to, um, to if you want
to call it first-line treatment and so then, by definition, they’re struggling more so that, they’re sort of,
so they’re more challenging in as much as, um, providing them with effective management I suppose.
GP104
For the GPs, the opportunity to participate in the MIR trial also provided them with another option to offer
to patients with depression.
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Help-seeking in a crisis
General practitioners’ accounts reflected the perspectives of patients – that often help-seeking was at a
point of crisis:
And, and if somebody’s depressed they really – if they’re, you know, if they’re at a watershed and
they’ve actually come to the doctor’s about it [. . .] because it’s often a crisis really when they’ve – or
it’s been a huge step to actually come and do something about it.
GP102
. . . but a lot of the time, when people come and see us, er, it’s normally at the crisis point.
GP08
I think a lot of people by the time they’ve got to us they’re probably quite sort of . . . you know, er,
they’re needing some help really.
GP03
Such help-seeking at crisis point was not just described in new presentations; GPs described how patients
with long-standing mood problems would often re-present at a time of crisis:
Erm, clearly there’s a, quite an imperative to prescribe in some people, people who have been unwell
for years. Some people want medication and don’t have the time or the inclination, or the enthusiasm
to go for counselling, for a long period of time, and wait. They just want something done now, please.
GP114
Two antidepressants: confidence to start and whether or not to continue?
Combination of antidepressants
A number of GP respondents reported that prescribing mirtazapine in combination with SSRIs and SNRIs
was something that they had already tried, although it was far from widespread across the practitioners in
our sample:
. . . the advice we sort of get back [from a psychiatrist] is that you could add mirtazapine type of thing,
so that sort of, as I said, has crept in to our practice a bit, almost by the back door, I think.
GPI03
. . . erm, well MIR, obviously, is asking whether adding mirtazapine in [huh-huh] is, is an option and
that is sometimes done, I – you know. It’s not done very often [huh-huh] but it is occasionally done.
GP102
That’s probably, you know, I wouldn’t say it was high numbers but er, you know, probably two or
three times a year or something like that, you know. Yeah.
GP10
However, most GPs expressed a degree of unfamiliarity with combining antidepressants:
I, you know, we, we manage polypharmacy all the time – if you look at some of our diabetic screens,
and, erm, er, the potential for interactions, er, er, often defeat, even, the computer, and it doesn’t
know quite what to do with them [uh-huh]. So, erm, er, a, a couple of antidepressants isn’t that, er,
so far out of the bounds of possibility that I would worry about it, really.
GP108
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Some GPs described the patients who they have offered this combination to: in order to manage
outstanding symptoms, particularly sleep disturbance, when a patient has been on an antidepressant ‘for
years’ or when a number of antidepressants had already been tried:
Yes I sometimes give people, er, some mirtazapine, er, because we tend to start with the SSRIs,
I sometimes add in mirtazapine especially if they’re having sleep problem.
GP06
I think the time when I would tend to combine might be, er, if somebody’s already been on an
antidepressant for a long time and is getting other symptoms then I might add in a different one [. . .]
we’ve got some people who have been on antidepressants for years so they just might be the ones
where I might prescribe two but not necessarily.
GP106
[Combining is] mainly done in, in people who have had several switches, basically.
GP10
Continuing the combination?
Although some GPs described a level of confidence in prescribing two antidepressants, all expressed
caution about how long such a combination should be continued. Some speculated on how they might try
to reduce one antidepressant in a combination, but none of the GPs interviewed reported experience of
stopping one in the combination:
I dare say we’d reduce one to zero, first of all, and see how it goes, and then reduce the other to zero
[uh-huh]. I don’t think I would stop them both at the same time [yeah]. I don’t know [uh-huh], but I
think I would, I’m sure I would do that, actually. I’d, I’d choose one and say, ‘Well, how are you doing?’
And, ‘We’re gonna have to start reducing these now’ [yeah], and I would suggest that, er, ‘we get you
off one first of all, for a few weeks, and see how you feel, and then withdraw the other one slowly’.
GP12
All GPs expressed concern about patients remaining on two antidepressants, suggesting that patients were
commonly prescribed SSRIs without a plan to withdraw:
It’s all right initiating it, isn’t it, and – but then I think then there becomes a bit more of a long-term
issue about if you – how long do they stay on them both? [huh-huh] Do you – which one do you tail
off first? [huh-huh] And erm, you don’t – you wouldn’t necessary want people stuck on both
antidepressants for time immemorial, which sometimes happens with SSRI, doesn’t it?
GP102
Thus, GPs described a future dilemma if antidepressants were combined.
Discussion
Summary of findings
This embedded qualitative study within the MIR trial explored reasons why people approached to participate
in the MIR trial declined, the experiences of people participating in the MIR trial and the perspectives of GPs
about the role of a combination of two antidepressants for people with TRD.
The narratives of people who declined to participate in the MIR trial, but who were willing to be interviewed
about this decision, and the participants in the trial all described the hard work involved in managing
depression and the importance of a ‘crisis point’ in precipitation of help-seeking. The people who declined
to participate in the MIR trial described feeling that they were at an equilibrium and feared that participating
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in the trial would disturb that hard-won equilibrium. Patients may be ‘resistant to change’, rather than the
depression simply being ‘treatment resistant’.
Experiencing a crisis point seemed to be a motivator to make a change and the offer of trying a second
antidepressant within a trial could act as that motivator. Some ‘decliners’ expressed uncertainties about
the role of medication and feared that a second tablet would not help, or could not see the logic of a
second medication.
The people who participated in the trial (whether they completed the study or withdrew from medication)
described the constant hope that something would help their mood, which was something that the trial
offered. Withdrawal from the study medication was sometimes put down to reported side effects,
particularly weight gain. Of note, at the time of the interview, those people who withdrew did not know
whether they had been taking placebo or mirtazapine. People who withdrew described reaching a point
at which they had to balance improvement in their mood with side effects from the second agent and,
when the balance tipped against side effects, they made the decision to withdraw from the medication.
The narratives of GP respondents reflected the patient data, describing the ‘hard work’ needed to manage
people with depression and how ‘treatment resistance’ is about more than a poor response to an
antidepressant: it is about a complex patient presenting the GP with a challenge in management. GPs
described how patients often present at a crisis point and how the MIR trial offered an option to manage
such patients. Some GPs reported confidence in combining antidepressants, but others did not. All expressed
concern over the dangers of leaving people on two antidepressants, reflecting that, in their experience,
people did remain on a SSRI without review or monitoring and with no attempt to withdraw the drug.
Comparison with previous literature
The most common reason for people declining participation in the MIR trial was not wanting to take part in a
research study, as in Barnes et al.76 But, in contrast to the study by Barnes et al.,76 in which the ‘decliners’
expressed negative feelings about the treatment offered in the trial, in our study ‘decliners’ expressed the view
that they were at an equilibrium, which would be disturbed if they chose to participate in the trial, although
a second antidepressant was not thought to be logical by a number of the ‘decliners’ we interviewed.
Hughes-Morley et al.80 described how individuals declined participation because they judged themselves
ineligible or not in need of the trial therapy. Similarly, our analysis suggests that the ‘decliners’ we
interviewed were not in need of the trial intervention, the second antidepressant.
Trial participants described experiencing a crisis as a motivator to participate in the trial, which resonates
with Schofield et al.,81 who reported that participants described their first course of antidepressants as
typically occurring when they had ‘hit rock bottom’, having exhausted all other possibilities. Schofield et al.81
reported that participants described a period of experimentation in which it was usual to stop and restart
medication, often several times. Ultimately, these recurring cycles lead to participants becoming more
expert about their condition and better able to make an informed decision about medication. This expertise
resonates with our analysis.
Schofield et al.81 also reported that, for older people, there was often an acceptance that their condition,
and medication use, would be long term. This acceptance might resonate with the concept of ‘equilibrium’
that we describe in this study.
In a meta-ethnography, Malpass et al.75 outline the role of the GP in supporting decision-making about
antidepressant use and facilitating concordant relationships with patients regarding antidepressant use.
Not having this discussion at entry into the trial may account for some people declining to participate.
Malpass et al.75 recommend that GPs are aware of the competing demands that patients experience at
a decision-making juncture. We identified the importance of a ‘crisis’ in influencing a decision to try
something new and a sense of equilibrium in resisting change.
QUALITATIVE FINDINGS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Strengths and limitations
Exploring the reasons for non-participation in trials is still unusual; this study describes how interviews to
determine such reasons can be incorporated into a trial recruitment procedure and illuminates the reasons
people declined. It should be noted that people invited to participate in the MIR trial did not necessarily
have TRD – they were people being prescribed one antidepressant in primary care. That 39% of
respondents indicated that they were planning on stopping their antidepressant suggests that a good
proportion of those invited to participate in the MIR trial may not have been depressed. None of the
‘decliners’ interviewed expressed any experience of or concerns about mirtazapine as a particular
antidepressant, even though sampling included those who had given ‘I do not want to take mirtazapine’
as a reason for declining to participate in the MIR trial.
A limitation of the study is that people who responded to the decliner questionnaire, and the invitation to
participate in a telephone interview about their reasons for declining to participate in the MIR trial, were a
self-selected group, which may limit the generalisability of the findings. Perhaps people with stronger
opinions might be more likely to respond. In addition, the telephone interviews were relatively short (mean
duration < 12 minutes).
A strength of this study was involvement of the PPIE group in the analysis,79 although some challenges
arose, including difficulties in recruiting a diverse range of members of the public to carry out the role,
and the research team sometimes experienced difficulties keeping the PPIE members on track.
Implications
Exploring reasons for declining to participate in the MIR trial suggests that some people who are already
taking one antidepressant may be reluctant to take a second. Potential participants were wary of possible
side effects, but were also unconvinced of the logic behind such a combination. They considered that, if
one antidepressant is not working, it was not plausible that a second would be effective. In addition,
people described being in a state of equilibrium and reluctant to make a change, reflecting that this
equilibrium is ‘hard won’ and they are unwilling to risk disturbing this. Understanding a patient’s view on
medication is important for GPs when discussing antidepressants. The key finding of the importance of
achieving an equilibrium is vital for researchers to understand and incorporate into recruitment strategies in
future trials of treatments for depression.
A crisis seems to be the motivator to try something new, including taking a combination of antidepressants,
and this is the point at which people often consult their GP for help. If a patient receives an invitation to
participate in a trial when they are at such a point, they may be more willing to participate. Whether or not
this affected the characteristics of patients recruited to the MIR trial is not known, but we might postulate that
people who felt that their mood was particularly low and who were searching for something to help were the
people recruited into the MIR trial. This does not necessarily mean that people recruited were more depressed,
but their perceptions of their mood might have been that things were particularly difficult at the time that
referral into the MIR trial was offered by their GP or the letter of invitation to participate was received.
Varied levels of confidence were reported by GPs in initiating prescribing of two antidepressants; some GPs
reported that this had ‘crept into’ their practice following advice from a psychiatrist with previous patients.
Other GPs reported that combining antidepressants was not something that they were comfortable with.
All GPs, however, expressed concern over the risks of continued prescribing of two antidepressants,
leaving people on a combination long term, and felt that guidance would be needed to ensure safe
prescribing and withdrawal of one agent.
This qualitative study highlights the concern expressed by all GP respondents that people could then be left
on two antidepressants, given that many already remain on one antidepressant long term and there is a
reluctance from both patient and GP to make changes. This has implications for the education and training
of GPs about the management of TRD, the importance of regular review and how to facilitate continuity
of care for people with depression.
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Chapter 6 Discussion and conclusion
Summary of findings
This study did not find convincing evidence of a clinically important benefit for mirtazapine given in
addition to a SSRI or SNRI antidepressant over placebo in primary care patients with TRD. Patients eligible
for this trial had been adherent to their antidepressant treatment for ≥ 6 weeks and were still suffering
from a major depressive disorder, as defined by the ICD-10.18 Most of them had been on antidepressants
for much longer than 6 weeks. Over 90% of participants had been taking antidepressants for > 6 months
and 72% had been taking antidepressants for > 1 year. One in four participants were severely depressed
and the majority were at least moderately depressed.
In the primary ITT analysis, both the placebo group and the intervention group showed improvements in
the primary outcome at the 12-week follow-up: in the placebo group, BDI-II score improved from a
baseline mean value of 30.6 points to a mean of 19.7 points and, in the intervention group, BDI-II score
improved from a baseline mean value of 31.5 points to a mean of 18 points. We based our sample size
calculation on detecting a between-group difference of 3–4 BDI-II points, which we argued would be
clinically important.41 The adjusted mean difference in BDI-II score between the groups at 12 weeks’
follow-up was –1.83 points (95% CI –3.92 to 0.27 points; p = 0.087) in favour of the intervention group.
Although the lower limit of the 95% CI for this difference (–3.92 points) means that we cannot exclude
the possibility of a clinically meaningful effect, the CI included the null, indicating that the results are also
consistent with no difference between the groups.
Similar evidence of small differences between the treatment groups in favour of the mirtazapine group
was observed for the secondary outcomes at 12 weeks post randomisation, but for most outcomes the
95% CIs surrounding the difference between groups included the null. At 12 weeks’ follow-up, 43.5% of
participants in the treatment group met criteria for response (i.e. BDI-II score improved by ≥ 50% compared
with baseline) compared with 35.9% of those in the placebo group (OR 1.39, 95% CI 0.94 to 2.07). In
the intervention group, 29.4% of participants met criteria for ‘remission’ (i.e. BDI-II score of < 10 points) at
12 weeks, compared with 24.4% of participants in the placebo group (OR 1.29, 95% CI 0.82 to 2.02).
This weak evidence of a small effect is supported by changes in favour of the intervention for which the CIs
did not include the null, that is, in the SF-12 aggregate mental health score (between-group difference 3.91
points, 95% CI 1.63 to 6.20 points) and the GAD-7 score (between-group difference –0.98 points, 95% CI
–1.93 to –0.03 points). Outcomes at later time points showed smaller between-group differences. CACE
and per-protocol analyses for the primary outcome, which are designed to estimate treatment effects in
those who complied with their allocated treatment, showed slightly larger between-group differences than
the ITT analyses, but CIs still crossed zero and per-protocol analyses are known to be biased. Prespecified
subgroup analyses, based on severity and degree of treatment resistance, did not show any evidence of
effect modification.
Participants were offered elective unblinding after the primary outcome at 12 weeks. An additional
sensitivity analysis at 24 and 52 weeks found no between-group differences in BDI-II score in those who
remained blinded throughout the trial. An ‘as-treated’ analysis at 24 weeks comparing those who were
taking mirtazapine and a SSRI or SNRI with those who were taking a SSRI or SNRI only, irrespective of
whether or not they were blinded, found a mean between-group difference of 3.9 points (95% CI –6.45
to –1.37 points) on the BDI-II in favour of the intervention. However, this result is difficult to interpret as it
is not a true randomised blinded comparison.
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There was no evidence of a substantial increase in the burden of AEs in the mirtazapine group compared
with the placebo group using the ASEC AE rating scale (between-group difference 0.26 points, 95% CI
–1.15 to 1.68 points). However, mild AEs were more often reported in the mirtazapine group and were
associated with stopping the medication in 46 participants in this group, compared with only nine
participants in the placebo group. The most common AE reported was ‘drowsiness’. We were not able to
objectively assess and quantify weight gain in the mirtazapine group.
The economic analysis found that the difference in QALYs at both 12 weeks and 1 year was very small,
with wide CIs that crossed zero (between-group difference in QALYs – 12 weeks: 0.02, 95% CI –0.02 to
0.05; 52 weeks: 0.009, 95% CI –0.02 to 0.04). The difference in NHS and PSS costs at 12 weeks was small
and not meaningful. At 52 weeks, the observed difference in NHS and PSS costs was greater (£69, 95% CI
–£72 to £209), but the CI includes the null and this difference was unlikely to be meaningful. In the context
of the results, there was no evidence that mirtazapine was a cost-effective use of NHS resources.
Qualitative findings suggest that, although many GPs are familiar with the strategy of combining two
antidepressants, they are not entirely comfortable with it and have concerns about the burden of AEs for
those who are on two antidepressants long term. Patients in the qualitative study who declined to join the
MIR trial were often concerned about disturbing an ‘equilibrium’ that they had reached with their current
treatment with a single antidepressant, whereas those who entered the study often described their motive
as seeking a resolution to a ‘crisis’.
Strengths and limitations
The CONSORT statement82 and the extensions for pragmatic trials83 were followed both in the conduct and
in the reporting of the trial. Randomisation was carried out by means of a computer-generated code to
ensure concealment of allocation. The main analyses were conducted according to the principle of ITT and
the analysis plan was agreed in advance with the TSC.
Participants, investigators and assessors were all blind to the allocation up to and including the primary
outcome at 12 weeks. Voluntary unblinding of participants after the primary outcome at 12 weeks made
interpretation of longer-term outcomes more difficult. The primary outcome was measured by self-report,
which further reduced the possibility of observer bias. The primary outcome measure was the BDI-II score,27
and the outcomes were consistent with the other self-reported depression symptom measure used in the
study, the PHQ-9.29 All participants had an ICD-10 diagnosis of major depressive disorder using the CIS-R.28
Follow-up rates throughout the trial were good at all sites; the overall follow-up rates were 90% at
12 weeks, 84% at 24 weeks and 81% at 52 weeks. Sensitivity analyses were conducted to assess the
impact of missing data on the analysis of the primary outcome. Whether estimating the missing data
assuming a ‘best’- or ‘worst’-case scenario or using MI, the observed difference in BDI-II scores between
treatment groups at 12 weeks’ follow-up was small. There were some minor baseline imbalances between
the two groups but adjustment for these did not materially affect the trial results.
The criteria for defining TRD that we adopted have been used elsewhere in primary care research21 and were
designed to be inclusive while reflecting NICE treatment guidelines.84 In the last few years, the idea that a
definition of TRD should include at least two unsuccessful courses of treatment has been recommended.17
Our study protocol predates this recommendation and we did not specify that participants should have had
more than one course of antidepressants in the past to be eligible. However, most participants reported
previous episodes of depression and were suffering from moderate to severe depression, in spite of taking
antidepressants for > 6 months. Importantly, there is very little evidence to support the effectiveness of
switching within or between classes of antidepressants as a strategy to manage treatment resistance85 and
hence the population recruited to our trial is closely aligned to the group for whom there is uncertainty
around management in primary care.
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We based our view of the clinically important difference between the intervention group and the placebo
group of 3–4 points on the BDI-II on previous recommendations from NICE.84 Estimating the minimum
clinically important difference (MCID) in depression is difficult and there are no universally accepted
methods for establishing this. Since our protocol was written, an approach towards establishing MCID
using self-rated global ratings of improvement has been developed.41 This approach gives an estimate of a
MCID in depression of a 17.5% reduction in BDI-II score for a non-TRD population, and in CoBalT,21 which
studied a TRD population similar to ours, estimates that a 32% reduction would be required. These
translate to differences in BDI-II score of 3.5 and 5.9 points, respectively. Based on these figures, it seems
unlikely that mirtazapine would provide a clinically important benefit, although there is still considerable
uncertainty around the clinically important difference in treatment outcome for this group of patients.
Adherence to medication was measured using an adapted version of a self-report measure (the Morisky
measure) that had previously been validated against electronic monitoring bottles24 and that has been used
in a trial of similar design in primary care.21
Comparison with existing studies
Earlier small studies of patients who had not failed previous treatment had reported that mirtazapine in
combination with a SSRI gave a greater improvement than monotherapy12 and that it was well tolerated
with either a SSRI or a SNRI (venlafaxine).13 The STAR*D study3 was a large four-stage evaluation of
treatments for major depressive disorder that included assessment of the effectiveness of combinations of
antidepressants for those who do not respond to single-drug treatment. Within the STAR*D study, there
was a comparison of venlafaxine (a SNRI antidepressant) plus mirtazapine with tranylcypromine, a MAOI
antidepressant. Participants included in this part of the STAR*D study can be characterised as having TRD
in that they had not responded to either a single antidepressant or one of a number of augmentation
treatments. There was a modest advantage for the combination of venlafaxine and mirtazapine over the
MAOI. However, there is no placebo group in this comparison and it has been argued that the STAR*D
study casts ‘limited light on the relative efficacy of combinations’.85
The CO-MED (Combining medications to enhance depression outcomes) randomised trial14 compared the
combination of venlafaxine and mirtazapine with escitalopram (a SSRI) and placebo in patients who had
either recurrent depression or chronic depression lasting ≥ 2 years. There was no difference in response
rates between the two groups and the burden of AEs was greater in the combined antidepressant group.
There are some important differences between the CO-MED and MIR trials. Those recruited into the
CO-MED trial were not necessarily taking an antidepressant at baseline and, therefore, do not conform to
our definition of TRD. Those in the combined antidepressant group were treated with venlafaxine and
mirtazapine rather than continuing on their established antidepressant, which in the MIR trial could be
either a SSRI or a SNRI. In effect, the comparison in the CO-MED trial is between escitalopram and the
mirtazapine/venlafaxine combination for a group of patients selected for chronicity and relative severity,
rather than a treatment-resistant group.
Other combinations of antidepressants have also been studied. Two large RCTs examined the effect of
mianserin (an analogue of mirtazapine and a drug that is infrequently used in UK practice) combined with
another antidepressant compared with placebo, with inconclusive results.86,87
We chose 30 mg of mirtazapine as being more typical of clinical practice in the primary care setting
and representing a balance between efficacy and tolerability. We are not aware of clear data about a
mirtazapine dose–response. Although some mirtazapine studies offer the option of increasing mirtazapine
to 45 mg, the picture in combination studies is mixed. Blier et al.13 used a fixed dose of mirtazapine of
30 mg. The CO-MED study14 allowed titration up to 45 mg but the average final dose was only 20 mg.
Carpenter et al.11 used a dose of up to 30 mg but most stayed on 15 mg, whereas the STAR*D10 trial
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aimed to titrate the dose of mirtazapine up to 45 mg and achieved a mean exit dose of 36 mg. Therefore,
the dose used in our study was broadly in line with what has been used in previous augmentation studies,
but, given the equivocal results, it is possible that an option to increase the dose to 45 mg might have
increased efficacy in those not responding to 30 mg.
Lopes Rocha et al.88 performed a systematic review and meta-analysis of studies that assessed the effect
of antidepressant combinations for major depression in patients with incomplete response to an initial
antidepressant. Only five studies with a total of 483 participants satisfied their inclusion criteria. Only one
of these involved the addition of mirtazapine to another antidepressant. This study compared the addition
of mirtazapine to a SSRI with placebo in a group of 26 patients who had not responded to ≥ 4 weeks of
monotherapy.11 Lopes Rocha et al.88 argue that the small number of trials and methodological drawbacks
of those trials preclude definitive conclusions about the effectiveness of combing antidepressants. The
British Association for Psychopharmacology guidelines comment that ‘Clinical experience and open studies
indicate that tolerability and safety are usually good, but there is a lack of controlled data examining the
efficacy of most combinations’.85 A search of the current literature has not found any further studies of
the addition of mirtazapine to another antidepressant in a treatment-resistant group. The MIR trial, thus,
represents a robust contribution to the evidence on the effectiveness of combination therapy in this group.
Comparison with non-pharmacological interventions for treatment-resistant depression
Although this is an extensive field and it is not practical to address it in a comprehensive way in this
context, it is important to mention CoBalT.21 This is a study that compared the addition of CBT to usual
care for TRD, including the continuation of an antidepressant, and much of the design and recruitment
strategy of the MIR trial is based on that of CoBalT. As a result, the populations in these two studies are
more similar than in many TRD studies because of the wide variability in definitions of TRD in the literature,
and a comparison is, therefore, of interest. In CoBalT, CBT was found to be more clinically effective and
cost-effective than usual care and the OR of response in the intervention group was 3.26 (95% CI 2.10 to
5.06) at 24 weeks. However, participants in the usual care group in CoBalT were not blind to treatment
allocation and were not offered any additional treatment, including placebo, and improved less than either
group in the MIR trial. Although it is difficult to make a direct comparison between the two studies, it is
important to note the relatively poor outcomes for TRD patients who are not offered further interventions.
Implications for current practice and suggestions for further research
Half of those who take antidepressants in an adequate dose for an adequate duration remain
depressed.3,22 This represents a substantial burden of illness and an unmet or inadequately met need.
Although many can benefit from CBT, the evidence in TRD is limited to high-intensity CBT rather than
briefer, less expensive therapies. High-intensity CBT is not readily available despite the IAPT programme,89
nor is it always effective in TRD.21 In primary care, where most initial encounters between people with
depression and clinicians take place, antidepressants are still very widely prescribed as a first-line treatment
and the evidence suggests that more patients are taking them for longer.90 Several pharmacological
strategies have been developed to help those who do not respond to this first-line treatment but the
evidence supporting them is not of very high quality. Most of the studies are small, many have not been
replicated and there are multiple definitions of TRD.85 There is, therefore, a lack of clear guidance for
clinicians in an area of unmet need, which is particularly important in primary care because of the size of
the TRD population.22 As highlighted in the introduction to this study, there was reason to believe that the
addition of mirtazapine to a SSRI or SNRI held therapeutic promise. The evidence of benefit from this study
is not strong enough to justify the recommendation of this as a routine strategy in primary care for those
who do not respond to a single antidepressant. However, the evidence does include the possibility of a
clinically meaningful effect and it may be that clinicians and patients would wish to consider this
combination in an informed discussion about risks and benefits.
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There is a need for further research into combination and augmentation treatments for people with TRD
and, in particular, the addition of drugs that can be prescribed safely and appropriately in primary care.
There is modest evidence in support of augmentation of antidepressants with lithium91 and, likewise,
atypical antipsychotics have been found to have some benefit.7 Both strategies have a greater risk of AEs
and, in the case of lithium, an additional administrative and cost burden of ‘near-patient testing’ in
primary care.
There is also a need for research into novel treatments for depression that could be applied in TRD. For
example, theta burst transcranial magnetic stimulation is a promising treatment for those who have not
responded to antidepressants.92 There is also emerging evidence of a possible causal role for cytokines in
depression and that cytokine modulators may have a role as novel drugs for depression in subjects with
chronic inflammation.93
It is important that future studies in this area clearly define TRD and that this definition is appropriate to
primary care. There is a need for evidence to inform the management of patients with TRD in primary care,
where there is a substantial burden of severity and chronicity and where there is the greatest potential for
access to care.
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Appendix 1 MIR trial documents
Adequate doses
A list of commonly used antidepressants with adequate doses for the MIR trial is provided in Table 25.
A full schedule of questionnaires used in the MIR trial is provided in Table 26.
TABLE 25 List of adequate doses for SSRI and SNRI antidepressants19
Antidepressant type and name Minimum adequate daily dose (mg)
SSRIs
Citalopram 20
Escitalopram 10
Fluoxetine 20
Fluvoxamine 100
Paroxetine 20
Sertraline 100
SNRIs
Duloxetine 60
Venlafaxine 75
TABLE 26 Full schedule of questionnaires
Questionnaire
Time point
Postal
screening Baseline
2-week
telephone
call 6 weeks 12 weeks 24 weeks 12 months
Consent form Y
BDI Y Y Y Y Y Y
Biographic and demographic
data, including psychiatric
history, life events, social
support, alcohol use
Y Y
Views on treatment Y
Medication Y Y Y Y Y Y
Morisky questionnaire
(adapted)
Y Y Y Y Y Y
CIS-R Y
PHQ-9 Y Y Y Y
GAD-7 Y Y Y Y
EQ-5D-5L Y Y Y Y
SF-12 Y Y Y Y
continued
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Adverse reactions of mirtazapine as listed in the SMPC (February 2015) are provided in Box 2.
TABLE 26 Full schedule of questionnaires (continued )
Questionnaire
Time point
Postal
screening Baseline
2-week
telephone
call 6 weeks 12 weeks 24 weeks 12 months
Economics Y Y Y
Health events (SAEs) Y Y Y Y
ASEC Y Y Y
2-week check Y
Blinding questions Y
Exit questionnaire Y
Y, yes.
BOX 2 Expected AEs and adverse reactions94
Metabolism and nutrition disorders
l Increase in appetite:b very common (> 1/10 patients).
l Increase in weight:b very common (> 1/10 patients).
l Hypnotraemia: frequency not known.a
Gastrointestinal disorders
l Dry mouth: very common (> 1/10 patients).
l Nausea:c common (1/100 patients to 1/10 patients).
l Diarrhoea:d common (1/100 patients to 1/10 patients).
l Vomiting:d common (1/100 patients to 1/10 patients).
l Constipation:b common (1/100 patients to 1/10 patients).
l Oral hypoaesthesia: uncommon (1/1000 patients to 1/100 patients).
l Pancreatitis: rare (1/10,000 patients to 1/1000 patients).
l Mouth oedema: frequency not known.a
l Increased salivation: frequency not known.a
Nervous system
l Somnolence:b,e very common (> 1/10 patients).
l Sedation:b,e very common (> 1/10 patients).
l Headache:d very common (> 1/10 patients).
l Lethargy:b common (1/100 patients to 1/10 patients).
l Dizziness: common (1/100 patients to 1/10 patients).
l Tremor: common (1/100 patients to 1/10 patients).
l Paraesthesiae:d uncommon (1/1000 patients to 1/100 patients).
l Restless legs: uncommon (1/1000 patients to 1/100 patients).
l Syncope: uncommon (1/1000 patients to 1/100 patients).
l Myoclonus: rare (1/10,000 patients to 1/1000 patients).
l Convulsions: frequency not known.a
l Serotonin syndrome: frequency not known.a
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l Oral paraesthesia: frequency not known.a
l Dysarthria: frequency not known.a
Psychiatric disorders
l Abnormal dreams: common (1/100 patients to 1/10 patients).
l Confusion: common (1/100 patients to 1/10 patients).
l Anxiety:d,f common (1/100 patients to 1/10 patients).
l Insomnia:c,f common (1/100 patients to 1/10 patients).
l Nightmares:d uncommon (1/1000 patients to 1/100 patients).
l Mania: uncommon (1/1000 patients to 1/100 patients).
l Agitation:d uncommon (1/1000 patients to 1/100 patients).
l Hallucinations: uncommon (1/1000 patients to 1/100 patients).
l Psychomotor restlessness (including akathisia and hyperkinesia): uncommon (1/1000 patients to 1/100 patients).
l Aggression: rare (1/10,000 patients to 1/1000 patients).
l Suicidal ideation:g frequency not known.a
l Suicidal behaviour:g frequency not known.a
Musculoskeletal system
l Back pain:b common (1/100 patients to 1/10 patients).
l Arthralgia: common (1/100 patients to 1/10 patients).
l Myalgia: common (1/100 patients to 1/10 patients).
l Rhabdomyolysis: frequency not known.a
Vascular disorders
l Orthostatic hypotension: common (1/100 patients to 1/10 patients).
l Hypotension:d uncommon (1/1000 patients to 1/100 patients).
Blood and lymphatics
l Bone marrow depression: frequency not known.a
l Eosinophilia: frequency not known.a
Hepatobiliary disorders
l Elevations in serum transaminase: rare (1/10,000 patients to 1/1000 patients).
General disorders and administration site conditions
l Peripheral oedema:b common (1/100 patients to 1/10 patients).
l Fatigue: common (1/100 patients to 1/10 patients).
Skin and subcutaneous tissue disorders
l Exanthema:d common (1/100 patients to 1/10 patients).
l Stevens–Johnson syndrome: frequency not known.a
l Dermatitis bullous: frequency not known.a
l Erythema multiforme: frequency not known.a
l Toxic epidermal necrolysis: frequency not known.a
BOX 2 Expected AEs and adverse reactions94 (continued)
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Renal and urinary disorders
l Urinary retention: frequency not known.a
Endocrine disorders
l Inappropriate antidiuretic hormone secretion: frequency not known.a
a The frequency of adverse reactions from spontaneous reporting, when no cases were observed in the
randomised placebo-controlled patient trials, is classified as ‘not known’.
b In clinical trials, these events occurred statistically significantly more frequently during treatment with
mirtazapine than with placebo.
c In clinical trials, these events occurred statistically more frequently during treatment with placebo than with
mirtazapine.
d In clinical trials, these events occurred more frequently during treatment with placebo than with mirtazapine,
but not statistically significantly more frequently.
e Dose reduction generally does not lead to less somnolence/sedation but can jeopardise antidepressant
efficacy.
f On treatment with antidepressants in general, anxiety and insomnia (which may be symptoms of depression)
can develop. Under mirtazapine treatment, development or aggravation of anxiety and insomnia has been
reported.
g Cases of suicidal ideation and suicidal behaviours have been reported during mirtazapine therapy or early
after treatment discontinuation.
Note
Any other symptom, side effect or AE listed in the SMPC or the BNF will not be regarded as unexpected.
BOX 2 Expected AEs and adverse reactions94 (continued)
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TABLE 27 The MIR trial AE reporting
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Appendix 2 Results
TABLE 28 Comparison of age and sex of those identified by GPs as potential participants and those who were
excluded based on the record search
Participants Total, N
Age Female
Number with
available data Mean (SD), years
Number with
available data n (%)
Excluded 7932 7750 53.2 (18.9) 7749 5166 (66.7)
Potential participants 18,966 18,966 49.8 (15.6) 18,962 13,445 (70.9)
TABLE 29 Comparison of age and sex of those accepting the invitation to participate in the trial, those who
declined and those who did not respond
Participants Total, N
Age Female
Number with
available data Mean (SD), years
Number with
available data n (%)
Did not respond 12,134 12,134 47.1 (15.3) 12,131 8459 (69.7)
Declined 4702 4702 56.6 (15.0) 4702 3562 (75.8)
Accepted 2180 2180 50.4 (14.3) 2179 1456 (66.8)
TABLE 30 Comparison of age and sex of those who were sent a postal questionnaire and did not respond, declined
or were not eligible and those who were eligible based on the postal questionnaire
Participants Total, N
Age Female
Number with
available data Mean (SD), years
Number with
available data n (%)
Not responded, not
eligible or declined
1183 1183 49.6 (14.8) 1183 769 (65.0)
Eligible 1116 1116 50.2 (13.8) 1116 773 (69.3)
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TABLE 31 Recruitment statistics by centre
Recruitment statistics
Centre
TotalBristol Exeter Manchester/Keele Hull/York
Number of practices 33 22 31 20 106
Invitations/GP referrals, n 5318 4042 5000 4772 19,132
GP referrals, n 83 46 27 10 166
Total invitations, n 5235 3996 4973 4762 18,966
Number returned 1896 1561 1957 1468 6882
Number (%) accepted 688 (36.3) 518 (33.2) 623 (31.8) 517 (35.2) 2346 (34.1)
Assessment screening questionnaire
completed, n (%)
573 (83.2) 425 (82.0) 523 (83.9) 422 (81.6) 1943 (82.8)
Eligible for baseline assessment, n (%) 345 (60.2) 251 (59.1) 287 (54.9) 233 (55.2) 1116 (57.4)
Baseline assessments, n 285 198 130 138 751
Randomisations
Number 177 122 82 99 480
Percentage of baseline assessments 62 62 63 72 64
TABLE 32 Withdrawal from the trial medication
Withdrawal and reasons
Randomised to, n (%)
Total (N= 480), n (%)
Usual care+mirtazapine
(N= 241)
Usual care+ placebo
(N= 239)
Any withdrawal from the trial
medication
6 (2.5) 12 (5.0) 18 (3.8)
Reason
Health 1 (0.4) 2 (0.8) 3 (0.6)
Lack of willingness to participate 3 (1.2) 8 (3.3) 11 (2.3)
Other 1 (0.4) 2 (0.8) 3 (0.6)
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TABLE 34 Protocol deviations
Protocol deviations
Randomised to, n (%)
Total (N= 480), n (%)
Usual care+mirtazapine
(N= 241)
Usual care+ placebo
(N= 239)
Any protocol deviation 10 (4.1) 10 (4.2) 20 (4.2)
Medicine handling 1 (0.4) 3 (1.3) 4 (0.8)
Unblinding error 1 (0.4) 0 (0) 1 (0.2)
Delivery of medication 5 (2.1) 5 (2.1) 10 (2.1)
Ran out of medication and
GP prescribed mirtazapine
0 (0) 1 (0.4) 1 (0.2)
SAE reporting 2 (0.8) 0 (0) 2 (0.4)
Prescribed mirtazapine 1 (0.4) 1 (0.4) 2 (0.4)
TABLE 33 Details of individual withdrawals from the trial medication
Allocated treatment
group
Days between
randomisation and
withdrawal from
the trial medication
(estimated when
dates not provided)
Withdrawal
decision
made by Reason
Completed
further
follow-up
Usual care+ placebo 91 Subject Lack of willingness to participate No
Usual care+ placebo 40 Subject Lack of willingness to participate No
Usual care+ placebo 102 Subject Other No
Usual care+mirtazapine 40 Study team Lack of willingness to participate No
Usual care+ placebo 40 Subject Lack of willingness to participate No
Usual care+mirtazapine 176 Subject Health No
Usual care+ placebo 52 Subject Lack of willingness to participate No
Usual care+ placebo 41 Subject Lack of willingness to participate No
Usual care+ placebo 471a Subject Lack of willingness to participate No
Usual care+mirtazapine 168 Subject Lack of willingness to participate No
Usual care+ placebo 245 Subject Lack of willingness to participate No
Usual care+ placebo 175 Subject Other No
Usual care+mirtazapine 229 GP Other No
Usual care+mirtazapine 29 Subject Lack of willingness to participate No
Usual care+mirtazapine 78 Subject Other No
Usual care+ placebo 60 Subject Lack of willingness to participate No
Usual care+ placebo 178 Subject Health No
Usual care+ placebo 298 Subject Health No
a Patient withdrew from the study when contacted regarding the exit questionnaire after the 12-month follow-up. They
claimed that they thought that they had withdrawn from the study earlier.
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TABLE 35 Details of individual protocol deviations
Allocated treatment
group Centre Further details (exact nature dependent on type of deviation)
Usual care + placebo Bristol Medication handling error; one participant received the medication of
another placebo participant
Usual care + mirtazapine Exeter Unblinding error
Usual care + placebo Exeter Unable to collect trial medication from GP
Usual care + placebo and
usual care+mirtazapine
Exeter Medication handling error at GP surgery; a participant allocated to receive
placebo received medication of a mirtazapine participant and vice versa
Usual care +mirtazapine Hull Data protection breach
Usual care +mirtazapine Keele Delayed SAE report
Usual care +mirtazapine Keele GP prescribed mirtazapine – protocol breach
Usual care + placebo Keele GP prescribed mirtazapine
Usual care +mirtazapine Hull Participant ran out of medication
Usual care +mirtazapine Hull Participant ran out of medication
Usual care + placebo Hull Delay/difficulty contacting patient regarding medication collection
Usual care + placebo Hull Participant ran out of medication; emergency unblinding
Usual care +mirtazapine Hull Script requested but not issued. Participant almost ran out of medication
Usual care + placebo Hull Participant ran out of medication; GP prescribed mirtazapine
Usual care + placebo Keele Participant ran out of medication
Usual care +mirtazapine Hull Participant ran out of medication
Usual care + placebo Hull Participant ran out of medication
Usual care + placebo Hull Participant ran out of medication/no contact
Usual care +mirtazapine Hull Participant ran out of medication
TABLE 36 Antidepressant medication use at baseline
Antidepressant
medication
Dose (mg),
median (range)
Allocated treatment group, n (%)
Total (N= 480),
n (%)
Mirtazapine+
usual care (N= 241)
Placebo+ usual care
(N= 239)
Citalopram/Cipramil (SSRI) 30 (20–60) 98 (40.7) 102 (42.7) 200 (41.7)
Duloxetine/Cymbalta/
Yentreve (SNRI)
60 (60–60) 1 (0.4) 1 (0.4) 2 (0.4)
Escitalopram/Cipralax (SSRI) 20 (10–20) 5 (2.1) 3 (1.3) 8 (1.7)
Fluoxetine/Prozac (SSRI) 40 (20–60) 56 (23.2) 62 (25.9) 118 (24.6)
Paroxetine/Seroxat (SSRI) 30 (20–50) 12 (5.0) 6 (2.5) 18 (3.8)
Sertraline/Lustral (SSRI) 100 (100–300) 44 (18.3) 42 (17.6) 86 (17.9)
Venlafaxine/Efexor (SNRI) 150 (75–300) 25 (10.4) 23 (9.6) 48 (10.0)
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TABLE 37 Summary of baseline variables related to missing BDI-II data at 24 weeks
Variable
Data, n (%)
Present (N= 402) Missing (N= 78)
Stratification variable
Centre
Bristol 152 (37.8) 25 (32.1)
Exeter 104 (25.9) 18 (23.1)
Manchester/Keele 65 (16.2) 17 (21.8)
Hull/York 81 (20.1) 18 (23.1)
Minimisation variables
Female 275 (68.4) 57 (73.1)
Baseline BDI-II score (points)
14–25 140 (34.8) 16 (20.5)
26–34 129 (32.1) 27 (34.6)
≥ 35 133 (33.1) 35 (44.9)
Currently receiving psychological services 45 (11.2) 17 (21.8)
Sociodemographic variables
Age (years), mean (SD) 51.2 (12.9) 44.6 (13.1)
Ethnic group
White 391 (97.3) 77 (98.7)
Mixed 7 (1.7) 1 (1.3)
Asian/British Asian 2 (0.5) 0 (0.0)
Other 2 (0.5) 0 (0.0)
Marital status
Married/cohabiting 237 (59.0) 40 (51.3)
Single 84 (20.9) 16 (20.5)
Separated 14 (3.5) 4 (5.1)
Divorced 43 (10.7) 16 (20.5)
Widowed 24 (6.0) 2 (2.6)
Employment status
Employed 199 (49.5) 45 (57.7)
Unemployed 203 (50.5) 33 (42.3)
Educational attainment
Degree or equivalent 82 (20.4) 13 (16.7)
HNC, HND, SVQ (Level 4 or 5) or RSA Higher Diploma 34 (8.5) 11 (14.1)
A level, Higher or equivalent [GNVQ/NVQ Advanced,
GSVQ/SVQ (Level 3) or RSA Advanced Diploma]
76 (18.9) 14 (17.9)
GSCE, Standard Grade, O level or equivalent 130 (32.3) 20 (25.6)
No formal qualification 80 (19.9) 20 (25.6)
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TABLE 37 Summary of baseline variables related to missing BDI-II data at 24 weeks (continued )
Variable
Data, n (%)
Present (N= 402) Missing (N= 78)
Housing
Home owner 229 (57.0) 34 (43.6)
Tenant 146 (36.3) 38 (48.7)
Living with relative or friend 26 (6.5) 6 (7.7)
Other 1 (0.2) 0 (0.0)
Financial well-being
Comfortable/OK 199 (49.5) 25 (32.1)
Just about getting by or worse 203 (50.5) 53 (67.9)
Alcohol consumption (units), median (IQR) 2.0 (1.0–4.0) 2.5 (1.0–5.0)
Number of life events in the previous 6 months, mean (SD) 1.0 (1.0) 1.2 (1.2)
Social support score, mean (SD) 12.6 (4.0) 11.6 (4.6)
Providing care for someone who is disabled 56 (13.9) 11 (14.1)
How many children aged < 5 years live with you?
None 364 (90.5) 68 (87.2)
1 or 2 35 (8.7) 10 (12.8)
≥ 3 3 (0.7) 0 (0.0)
Treatment preference
Do you have a preference for either group?
Prefer to receive mirtazapine 239 (59.5) 50 (64.1)
Prefer to receive the placebo 2 (0.5) 0 (0.0)
Do not mind either way 161 (40.0) 28 (35.9)
If you were to be allocated to the other group, how disappointed would you be?
Very 32 (13.3) 9 (18.0)
Moderately 77 (32.0) 16 (32.0)
A little bit 79 (32.8) 10 (20.0)
Not really 53 (22.0) 15 (30.0)
Measures of depression
Suffered from depression in the past 331 (82.3) 65 (83.3)
Family history of depression 211 (63.7) 52 (80.0)
Previous referral to a psychiatrist for depression 105 (31.7) 26 (40.0)
Number of prior episodes of depression
None 8 (2.4) 0 (0.0)
1 18 (5.4) 4 (6.2)
2–4 139 (42.0) 22 (33.8)
≥ 5 166 (50.2) 39 (60.0)
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TABLE 37 Summary of baseline variables related to missing BDI-II data at 24 weeks (continued )
Variable
Data, n (%)
Present (N= 402) Missing (N= 78)
Duration of current course of antidepressants
< 6 months 39 (9.7) 7 (9.0)
≥ 6 months 363 (90.3) 71 (91.0)
ICD-10 primary diagnosis
Mild 70 (17.4) 12 (15.4)
Moderate 235 (58.5) 47 (60.3)
Severe 97 (24.1) 19 (24.4)
Secondary psychiatric diagnosis according to the CIS-R
No diagnosis identified 6 (1.5) 1 (1.3)
Mixed anxiety and depressive disorder (mild) 48 (11.9) 9 (11.5)
Generalised anxiety disorder (mild) 5 (1.2) 0 (0.0)
Mixed anxiety and depressive disorder 96 (23.9) 18 (23.1)
Specific (isolated) phobia 18 (4.5) 7 (9.0)
Social phobia 17 (4.2) 5 (6.4)
Agoraphobia 18 (4.5) 3 (3.8)
Generalised anxiety disorder 157 (39.1) 27 (34.6)
Panic disorder 37 (9.2) 8 (10.3)
BDI-II score (points), mean (SD) 30.5 (9.8) 34.0 (10.2)
GAD-7 score (points), mean (SD) 10.7 (4.8) 12.2 (4.8)
PHQ-9 score (points), mean (SD) 16.2 (5.5) 17.4 (5.3)
EQ-5D-5L score (points), mean (SD) 0.7 (0.2) 0.7 (0.2)
SF-12 aggregate physical functioning score (points), mean (SD) 29.3 (9.6) 25.6 (10.1)
SF-12 aggregate mental functioning score (points), mean (SD) 45.2 (13.8) 49.3 (12.2)
CIS-R score, mean (SD) 27.5 (8.3) 28.8 (8.3)
Suicidal ideation (CIS-R thoughts/plans)
No suicidal thoughts 173 (43.0) 27 (34.6)
Patient feels life is not worth living 86 (21.4) 17 (21.8)
Suicidal thoughts 143 (35.6) 34 (43.6)
A level, Advanced level; GCSE, General Certificate of Secondary Education; GNVQ, General National Vocational Qualification;
GSVQ, General Scottish Vocational Qualification; HNC, Higher National Certificate; HND, Higher National Diploma;
NVQ, National Vocational Qualification; RSA, The Royal Society of Arts; SVQ, Scottish Vocational Qualification.
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TABLE 38 Summary of baseline variables related to missing BDI-II data at 12 months
Variable
Data, n (%)
Present (N= 388) Missing (N= 92)
Stratification variable
Centre
Bristol 152 (39.2) 25 (27.2)
Exeter 95 (24.5) 27 (29.3)
Manchester/Keele 66 (17.0) 16 (17.4)
Hull/York 75 (19.3) 24 (26.1)
Minimisation variables
Female 266 (68.6) 66 (71.7)
Baseline BDI-II score (points)
14–25 138 (35.6) 18 (19.6)
26–34 124 (32.0) 32 (34.8)
≥ 35 126 (32.5) 42 (45.7)
Currently receiving psychological services 42 (10.8) 20 (21.7)
Sociodemographic variables
Age (years), mean (SD) 51.7 (12.5) 43.8 (14.0)
Ethnic group
White 381 (98.2) 87 (94.6)
Mixed 4 (1.0) 4 (4.3)
Asian/British Asian 1 (0.3) 1 (1.1)
Other 2 (0.5) 0 (0.0)
Marital status
Married/cohabiting 234 (60.3) 43 (46.7)
Single 77 (19.8) 23 (25.0)
Separated 10 (2.6) 8 (8.7)
Divorced 44 (11.3) 15 (16.3)
Widowed 23 (5.9) 3 (3.3)
Employment status
Employed 196 (50.5) 48 (52.2)
Unemployed 192 (49.5) 44 (47.8)
Educational attainment
Degree or equivalent 77 (19.8) 18 (19.6)
HNC, HND, SVQ (Level 4 or 5) or RSA Higher Diploma 33 (8.5) 12 (13.0)
A level, Higher or equivalent [GNVQ/NVQ Advanced,
GSVQ/SVQ (Level 3) or RSA Advanced Diploma]
70 (18.0) 20 (21.7)
GSCE, Standard Grade, O level or equivalent 126 (32.5) 24 (26.1)
No formal qualification 82 (21.1) 18 (19.6)
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TABLE 38 Summary of baseline variables related to missing BDI-II data at 12 months (continued )
Variable
Data, n (%)
Present (N= 388) Missing (N= 92)
Housing
Home owner 229 (59.0) 34 (37.0)
Tenant 136 (35.1) 48 (52.2)
Living with relative or friend 22 (5.7) 10 (10.9)
Other 1 (0.3) 0 (0.0)
Financial well-being
Comfortable/OK 196 (50.5) 28 (30.4)
Just about getting by or worse 192 (49.5) 64 (69.6)
Alcohol consumption, median (IQR) 2.0 (1.0–4.0) 3.0 (1.0–5.0)
Number of life events in the past 6 months, mean (SD) 1.0 (1.0) 1.3 (1.2)
Social support score, mean (SD) 12.6 (4.0) 11.8 (4.5)
Providing care for someone who is disabled 54 (13.9) 13 (14.1)
How many children aged < 5 years live with you?
None 353 (91.0) 79 (85.9)
1 or 2 32 (8.2) 13 (14.1)
≥ 3 3 (0.8) 0 (0.0)
Treatment preference
Do you have a preference for either group?
Prefer to receive mirtazapine 231 (59.5) 58 (63.0)
Prefer to receive the placebo 2 (0.5) 0 (0.0)
Do not mind either way 155 (39.9) 34 (37.0)
If you were to be allocated to the other group, how disappointed would you be?
Very 26 (11.2) 15 (25.9)
Moderately 75 (32.2) 18 (31.0)
A little bit 79 (33.9) 10 (17.2)
Not really 53 (22.7) 15 (25.9)
Measures of depression
Suffered from depression in the past 318 (82.0) 78 (84.8)
Family history of depression 207 (65.1) 56 (71.8)
Previous referral to a psychiatrist for depression 97 (30.5) 34 (43.6)
Number of prior episodes of depression
None 6 (1.9) 2 (2.6)
1 19 (6.0) 3 (3.8)
2–4 137 (43.1) 24 (30.8)
≥ 5 156 (49.1) 49 (62.8)
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TABLE 38 Summary of baseline variables related to missing BDI-II data at 12 months (continued )
Variable
Data, n (%)
Present (N= 388) Missing (N= 92)
Duration of current course of antidepressants
< 6 months 36 (9.3) 10 (10.9)
≥ 6 months 352 (90.7) 82 (89.1)
ICD-10 primary diagnosis
Mild 69 (17.8) 13 (14.1)
Moderate 229 (59.0) 53 (57.6)
Severe 90 (23.2) 26 (28.3)
Secondary psychiatric diagnosis according to the CIS-R
No diagnosis identified 6 (1.5) 1 (1.1)
Mixed anxiety and depressive disorder (mild) 46 (11.9) 11 (12.0)
Generalised anxiety disorder (mild) 4 (1.0) 1 (1.1)
Mixed anxiety and depressive disorder 95 (24.5) 19 (20.7)
Specific (isolated) phobia 19 (4.9) 6 (6.5)
Social phobia 16 (4.1) 6 (6.5)
Agoraphobia 18 (4.6) 3 (3.3)
Generalised anxiety disorder 152 (39.2) 32 (34.8)
Panic disorder 32 (8.2) 13 (14.1)
BDI-II score (points), mean (SD) 30.3 (9.7) 34.4 (10.2)
GAD-7 score (points), mean (SD) 10.7 (4.7) 12.2 (4.8)
PHQ-9 score (points), mean (SD) 16.1 (5.5) 17.6 (5.2)
EQ-5D-5L score (points), mean (SD) 0.7 (0.2) 0.6 (0.2)
SF-12 aggregate physical functioning score (points), mean (SD) 29.5 (9.5) 25.3 (10.2)
SF-12 aggregate mental functioning score (points), mean (SD) 45.2 (13.8) 48.5 (12.6)
CIS-R score, mean (SD) 27.2 (8.1) 29.7 (8.8)
Suicidal ideation (CIS-R thoughts/plans)
No suicidal thoughts 164 (42.3) 36 (39.1)
Patient feels life is not worth living 91 (23.5) 12 (13.0)
Suicidal thoughts 133 (34.3) 44 (47.8)
A level, Advanced level; GCSE, General Certificate of Secondary Education; GNVQ, General National Vocational Qualification;
GSVQ, General Scottish Vocational Qualification; HNC, Higher National Certificate; HND, Higher National Diploma;
NVQ, National Vocational Qualification; RSA, The Royal Society of Arts; SVQ, Scottish Vocational Qualification.
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TABLE 39 Adverse events by 12 weeks
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Randomised to usual care +mirtazapine (N = 241)
Allergy 2 2 2 2 0 0 0 2 0 1 1 0
Anticholinergic 16 16 3 14 2 0 1 5 10 13 3 0
Central nervous
system (drowsy)
41 41 19 36 5 0 0 11 30 41 0 0
Central nervous
system (headache)
4 4 1 4 0 0 2 1 1 3 1 0
Central nervous
system (other)
4 4 1 3 1 0 0 3 1 4 0 0
Central nervous
system (TIA)
1 1 0 0 0 1 1 0 0 0 0 1
Central nervous
system (unpleasant
dreams)
11 11 2 9 2 0 0 4 7 9 2 0
CVS 4 4 1 3 1 0 4 0 0 0 3 1
Dental 1 1 0 0 1 0 1 0 0 0 0 1
Discontinuation
syndrome when
stopped
1 1 0 1 0 0 0 1 0 1 0 0
Endocrine – new
diabetes
1 1 1 1 0 0 1 0 0 0 1 0
ENT 1 1 0 1 0 0 1 0 0 0 1 0
Epistaxis 2 2 0 2 0 0 2 0 0 0 2 0
Eyes 2 2 1 2 0 0 2 0 0 0 2 0
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TABLE 39 Adverse events by 12 weeks (continued )
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
GI (nausea) 2 2 0 2 0 0 0 1 1 2 0 0
GI (other) 5 5 1 4 1 0 2 3 0 2 3 0
GUS 1 1 0 1 0 0 1 0 0 0 1 0
Gynaecological 1 1 0 0 1 0 1 0 0 0 0 1
Haematological 1 1 0 1 0 0 1 0 0 0 1 0
Infective 2 2 0 1 1 0 2 0 0 0 2 0
Metabolic – increase
in appetite
2 2 0 1 1 0 0 0 2 2 0 0
Metabolic – weight
increased
24 24 7 20 4 0 0 2 22 24 0 0
Musculoskeletal
(other)
7 7 3 7 0 0 5 2 0 2 5 0
Musculoskeletal –
restless legs/cramps
3 3 0 3 0 0 1 2 0 3 0 0
Musculoskeletal
trauma
5 6 1 3 3 0 5 0 1 1 5 0
Oedema 9 9 3 7 2 0 6 2 1 2 7 0
Pancreatitis 1 1 1 0 0 1 0 1 0 1 0 0
Psychiatric 8 8 4 5 2 1 3 4 1 5 2 1
Respiratory 2 2 0 0 2 0 2 0 0 0 1 1
Skin and
subcutaneous
tissue disorder
3 3 2 3 0 0 2 1 0 2 1 0
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Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Randomised to usual care + placebo (N = 239)
Anticholinergic 4 4 0 3 1 0 1 0 3 3 1 0
Central nervous
system (drowsy)
5 5 1 5 0 0 0 1 4 5 0 0
Central nervous
system (headache)
4 4 0 3 1 0 0 3 1 4 0 0
Central nervous
system (other)
2 2 0 2 0 0 1 1 0 1 1 0
Central nervous
system (unpleasant
dreams)
9 9 1 7 2 0 0 6 3 8 1 0
Dental 2 2 1 2 0 0 2 0 0 0 2 0
Endocrine disorders 2 2 1 1 1 0 0 2 0 2 0 0
ENT 1 1 0 1 0 0 1 0 0 0 1 0
GI (nausea) 3 3 0 3 0 0 1 1 1 2 1 0
GI (other) 6 6 0 5 1 0 3 2 1 3 3 0
Gynaecological 1 1 0 0 1 0 1 0 0 0 1 0
Haematological 3 3 1 3 0 0 3 0 0 0 3 0
Hepatobiliary
disorder
1 1 0 1 0 0 1 0 0 0 1 0
Infective 5 5 1 5 0 0 5 0 0 0 4 1
Metabolic – increase
in appetite
1 1 0 1 0 0 0 0 1 1 0 0
Metabolic – weight
increased
7 7 0 5 2 0 1 1 5 6 1 0
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TABLE 39 Adverse events by 12 weeks (continued )
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Musculoskeletal
(other)
8 8 0 7 1 0 7 1 0 1 7 0
Musculoskeletal –
restless legs/cramps
3 3 0 3 0 0 2 1 0 1 2 0
Musculoskeletal
trauma
6 6 2 3 3 0 6 0 0 0 4 2
Non-cardiological
chest pains
1 1 0 0 1 0 1 0 0 0 1 0
Oedema 1 1 0 1 0 0 0 1 0 1 0 0
Psychiatric 5 5 0 4 1 0 0 4 1 5 0 0
Psychosexual 1 1 0 1 0 0 1 0 0 1 0 0
Renal and urinary
disorders
1 1 0 0 1 0 1 0 0 0 1 0
Respiratory 3 3 2 3 0 0 3 0 0 0 3 0
Skin and
subcutaneous tissue
disorders
4 4 1 3 1 0 3 0 1 1 3 0
Sleep disturbance 1 1 0 1 0 0 1 0 0 0 1 0
Sweating 1 1 0 1 0 0 1 0 0 0 1 0
CVS, cardiovascular system; ENT, ear, nose and throat; GI, gastrointestinal; GUS, genitourinary system; N/A, not applicable.
Note
SAEs are a subset of AEs.
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TABLE 40 Serious adverse events by 12 weeks
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Randomised to usual care +mirtazapine (N = 241)
Central nervous
system (TIA)
1 1 0 0 0 1 1 0 0 0 0 1
CVS 1 1 0 0 1 0 1 0 0 0 0 1
Dental 1 1 0 0 1 0 1 0 0 0 0 1
Gynaecological 1 1 0 0 1 0 1 0 0 0 0 1
Pancreatitis 1 1 1 0 0 1 0 1 0 1 0 0
Psychiatric 2 2 2 0 1 1 1 1 0 1 0 1
Respiratory 1 1 0 0 1 0 1 0 0 0 0 1
Randomised to usual care + placebo (N = 239)
Infective 1 1 1 1 0 0 1 0 0 0 0 1
Musculoskeletal
trauma
2 2 1 0 2 0 2 0 0 0 0 2
CVS, cardiovascular system; N/A, not applicable.
Note
SAEs are a subset of AEs.
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TABLE 41 Adverse events from 12 weeks
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Randomised to usual care +mirtazapine (N = 241)
Anticholinergic 1 1 1 1 0 0 1 0 0 1 0 0
Central nervous
system (drowsy)
3 3 1 3 0 0 0 3 0 3 0 0
Central nervous
system (other)
1 1 0 1 0 0 1 0 0 0 1 0
Central nervous
system (TIA)
1 1 0 1 0 0 1 0 0 0 0 1
Central nervous
system (unpleasant
dreams)
1 1 0 1 0 0 0 0 1 1 0 0
CVS 1 1 0 1 0 0 1 0 0 0 1 0
Death because of
drug overdose
(heroin)
1 1 1 0 0 1 1 0 0 0 0 1
Dental 2 2 1 2 0 0 2 0 0 0 2 0
Endocrine – new
diabetes
2 2 1 1 1 0 0 2 0 0 2 0
ENT 3 3 1 1 2 0 3 0 0 0 2 1
Eyes 2 2 1 2 0 0 2 0 0 0 2 0
GI (other) 3 3 3 2 1 0 3 0 0 0 2 1
GUS 1 1 1 0 1 0 1 0 0 0 0 1
Gynaecological 1 1 1 1 0 0 1 0 0 0 0 1
Haematological 2 2 0 1 0 1 2 0 0 0 1 1
Hepatobiliary disorder 1 1 0 1 0 0 1 0 0 0 0 1
Infective 6 6 4 3 2 1 6 0 0 0 3 3
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Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Metabolic – weight
increased
2 2 1 1 1 0 1 0 1 1 0 1
Musculoskeletal
(other)
8 9 6 7 2 0 8 1 0 1 5 3
Musculoskeletal –
restless legs/cramps
1 1 0 1 0 0 0 1 0 1 0 0
Musculoskeletal
trauma
8 8 1 7 1 0 8 0 0 0 7 1
Oedema 3 3 1 3 0 0 2 0 1 1 2 0
Psychiatric 3 3 0 2 1 0 2 1 0 2 1 0
Respiratory 2 2 1 1 1 0 2 0 0 0 1 1
Skin and
subcutaneous tissue
disorders
3 4 1 3 1 0 4 0 0 0 2 2
Randomised to usual care + placebo (N = 239)
Vitamin B12 deficiency 1 1 0 1 0 0 1 0 0 0 1 0
Central nervous
system (headache)
1 1 0 1 0 0 1 0 0 0 1 0
Central nervous
system (other)
2 3 1 1 2 0 3 0 0 0 0 3
Central nervous
system (unpleasant
dreams)
2 2 0 2 0 0 0 2 0 2 0 0
Central nervous
system epilepsy
1 1 1 0 1 0 1 0 0 0 0 1
CFS/ME 1 1 0 1 0 0 1 0 0 0 1 0
CVS 3 3 1 2 1 0 3 0 0 0 2 1
DVT 1 1 0 0 1 0 1 0 0 0 1 0
continued
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TABLE 41 Adverse events from 12 weeks (continued )
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Endocrine disorders 2 2 1 1 1 0 1 1 0 0 2 0
Endocrine – new
diabetes
2 2 1 1 1 0 0 1 1 2 0 0
ENT 1 1 0 1 0 0 1 0 0 0 0 1
Epistaxis 1 1 0 1 0 0 1 0 0 0 1 0
GI (other) 4 5 4 3 2 0 5 0 0 0 2 3
Gynaecological 4 4 0 3 1 0 4 0 0 0 2 2
Hepatobiliary
disorder
2 2 0 1 1 0 2 0 0 0 1 1
Infective 8 8 1 7 1 0 8 0 0 0 8 0
Metabolic – weight
increased
2 2 1 2 0 0 1 0 1 2 0 0
Musculoskeletal
(other)
5 5 2 5 0 0 5 0 0 0 5 0
Musculoskeletal –
restless legs/cramps
1 1 0 1 0 0 0 0 1 1 0 0
Musculoskeletal
trauma
10 10 3 6 4 0 10 0 0 0 7 3
Oedema 1 1 0 1 0 0 0 1 0 0 1 0
Psychiatric 2 2 1 2 0 0 1 1 0 1 1 0
Renal and urinary
disorders
2 2 0 2 0 0 2 0 0 0 2 0
Respiratory 2 2 1 1 1 0 2 0 0 0 1 1
CFS, chronic fatigue syndrome; CVS, cardiovascular system; DVT, deep-vein thrombosis; ENT, ear, nose and throat; GI, gastrointestinal; GUS, genitourinary system; N/A, not applicable.
Note
SAEs are a subset of AEs.
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TABLE 42 Serious adverse events from 12 weeks
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Randomised to usual care +mirtazapine (N = 241)
Central nervous
system (TIA)
1 1 0 1 0 0 1 0 0 0 0 1
Death because of
drug overdose
(heroin)
1 1 1 0 0 1 1 0 0 0 0 1
ENT 1 1 1 0 1 0 1 0 0 0 0 1
GI (other) 1 1 1 0 1 0 1 0 0 0 0 1
GUS 1 1 1 0 1 0 1 0 0 0 0 1
Gynaecological 1 1 1 1 0 0 1 0 0 0 0 1
Haematological 1 1 0 0 0 1 1 0 0 0 0 1
Hepatobiliary
disorder
1 1 0 1 0 0 1 0 0 0 0 1
Infective 3 3 2 0 2 1 3 0 0 0 0 3
Metabolic – weight
increased
1 1 1 0 1 0 1 0 0 0 0 1
Musculoskeletal
(other)
3 3 3 1 2 0 3 0 0 0 0 3
Musculoskeletal
trauma
1 1 0 0 1 0 1 0 0 0 0 1
Psychiatric 1 1 0 0 1 0 0 1 0 1 0 0
Respiratory 1 1 1 0 1 0 1 0 0 0 0 1
Skin and
subcutaneous tissue
disorders
1 2 0 1 1 0 2 0 0 0 0 2
continued
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TABLE 42 Serious adverse events from 12 weeks (continued )
Category
Number of
participants
Number
of events
Number of
participants
who stopped
treatment
Intensity (n) Relatedness (n) Expectedness (n)
Mild Moderate Severe
Not
related/
unlikely
Possibly
related
Probably/
definitely
related Expected Unexpected N/A
Randomised to usual care + placebo (N = 239)
Central nervous
system (other)
2 3 1 1 2 0 3 0 0 0 0 3
Central nervous
system epilepsy
1 1 1 0 1 0 1 0 0 0 0 1
CVS 1 1 1 0 1 0 1 0 0 0 0 1
ENT 1 1 0 1 0 0 1 0 0 0 0 1
GI (other) 2 3 3 1 2 0 3 0 0 0 0 3
Gynaecological 2 2 0 1 1 0 2 0 0 0 0 2
Hepatobiliary
disorder
1 1 0 0 1 0 1 0 0 0 0 1
Musculoskeletal
trauma
3 3 1 1 2 0 3 0 0 0 0 3
Respiratory 1 1 1 0 1 0 1 0 0 0 0 1
CVS, cardiovascular system; ENT, ear, nose and throat; GI, gastrointestinal; GUS, genitourinary system; N/A, not applicable.
Note
SAEs are a subset of AEs.
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Appendix 3 Health economic documents
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Patient reported resource use data collection form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 month economic questionnaire 
 
MIR 
 
Mirtazapine for treatment-resistant depression in 
primary care 
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Thank you for answering this questionnaire. As you know, MIR is comparing two treatments (mirtazapine and 
placebo) for depression to see how it affects your well-being. As part of this we are interested in seeing whether the 
treatment you receive affects the health services you use, and the care and extra support you receive. 
 
We would like to know a bit about how much extra help you have had, how often you have used services and the 
cost of this to you and others.  
 
We understand that some of the questions can seem quite personal so we would like to remind you that you don’t 
have to answer anything that you don’t want to.  We always compare the two treatment groups anonymously as a 
whole rather than looking at an individual patient’s data. 
 
Thanks. 
Patient Study ID ________________ 
Date of birth ____/____/19____ 
Gender                male / female 
Today’s date ____/____/20____ 
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1. NHS hospital care 
1(a) During the past 6 months, have you been admitted to hospital for an overnight stay for 
any reason? 
Yes 1 
Please give more 
details below 
No 0 
Please go 
to 1(b) 
i) How many separate stays in hospital have you had? ……………………   stays 
For each separate stay in hospital, how many nights did you stay, what was the main reason for your stay and what 
treatment did you receive? 
Stay
Number of 
nights 
Reason for stay 
(e.g. psychotic episode, hysterectomy) 
Did you have 
surgery? 
Name of hospital
1   Yes 1     No 0  
2 Yes 1     No 0  
3   Yes 1     No 0  
4   Yes 1     No 0  
5   Yes 1     No 0  
6   Yes 1     No 0  
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1(b) During the past 6 months, have you been to A&E (Casualty) for any reason? 
Yes 1 
Please give more 
details below 
No 0 
Please go 
to 1(c) 
i) How many separate visits to A&E have you made? 
 
……………………   visits 
For each separate visit, what was the main reason you attended A&E? 
Visit Reason attended A&E 
(e.g. psychotic episode, broken limb) 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
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1(c) During the past 6 months, have you attended an NHS hospital outpatient clinic for 
any reason?  
Yes 1 
Please give more 
details below 
No 0 
Please go to 
2(a) 
i) How many different clinics have you been to? 
 
……………………   clinics 
For each separate location you attended, what was the name of the clinic, how many visits did you make, and what was 
the reason for attending? 
Clinic Name of clinic 
(e.g. Psychiatry, Dermatology) 
Number 
of visits 
Reason attended clinic 
(e.g. diabetes, depression) 
1 
   
2 
   
3 
   
4 
   
5 
   
6 
   
7 
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2.  Paid-for healthcare 
 
 
2(a) During the past 6 months, have you had any over-the-counter medication, prescription 
charges or other paid-for or private healthcare because of your mental health?  
Yes 1 
Please give more 
details below 
No 0 
Please go to 
3(a) 
Type of healthcare  
Approximately how much have 
you spent on this healthcare? 
i) Hospital inpatient Yes 1     No 
0 
£         :             
ii) Hospital outpatient Yes 1     No 
0 £         :             
iii) Counselling Yes 1     No 
0 
£         :             
iv) Home care 
Yes 1     No 
0 £         :             
v) Prescription charges 
Yes 1     No 
0 £         :             
vi) Over-the-counter treatments or remedies 
Yes 1     No 
0 £         :             
vii) Complementary therapy (e.g. acupuncture, hypnotherapy) 
Yes 1     No 
0 £         :             
viii) Other paid-for healthcare (please specify) 
 
.......................................................................... 
Yes 1     No 
0 £         :            
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3.  GP or community-based NHS care (i.e. care outside of a hospital) 
 
3(a) During the past 6 months, have you received any community services provided free by 
the NHS or charities because of your mental health? 
Yes 1 
Please give more 
details below 
No 0 
Please go to 
4(a) 
 
 Number of visits, 
sessions or calls 
Where were these 
visits/sessions 
held?  
(e.g. Brislington, home) 
i) GP visits at surgery Yes 1     No 0 
 
ii) Counselling (or talking therapy) Yes 1     No 0  
iii) Face to face cognitive behavioural therapy (CBT) Yes 1     No 0  
iv) Computer-based cognitive behavioural therapy 
(CBT) Yes 1     No 0  
v) Mental health clinic Yes 1     No 0  
vi) Exercise or physical activity scheme or “Exercise 
on prescription” 
Yes 1     No 0   
vii) NHS Direct or “Call 111” Yes 1     No 0   
viii) NHS walk-in centres Yes 1     No 0   
ix) Other (please specify) 
 
           
....................................................................... 
Yes 1     No 0   
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4.  Home visits 
 
 
4(a) During the past 6 months, have you had any home visits from NHS healthcare workers 
because of your mental health? 
Yes 1 
Please give 
more details 
below 
No 0 
Please go
to 5(a) 
Type of home visit  Number of visits 
i) Have you had any home visits from a mental health nurse (CPN)? Yes 1     No 0 
 
ii) Have you had any home visits from an occupational therapist? Yes 1     No 0 
 
iii) Have you had any home visits from a social worker? Yes 1     No 0 
 
iv) Have you had any home visits from a GP? Yes 1     No 0 
 
v) Have you had any other home visits from healthcare professionals? 
(please specify) 
 
............................................................................................... 
Yes 1     No 0 
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5.  Additional help 
 
 
5(a) During the past 6 months, have you received additional help from a home help or home 
care worker or attended any groups because of your mental health? 
Yes 1 
Please give more 
details below 
No 0 
Please go to 
6(a) 
Type of additional help  Approximately how much have you 
spent on using this help? 
i) Have you received additional help from a home help 
or home care worker? 
Yes 1     No 
0 
£       :            [zero if nothing] 
ii) Have you been to a day centre/drop-in/social club? 
Yes 1     No 
0 
£       :            [zero if nothing] 
iii) Have you been to a self-help group? 
Yes 1     No 
0 
£       :            [zero if nothing] 
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6.  Informal unpaid help 
 
  
6(a) During the past 6 months, have friends or relatives given you any extra help because of 
your mental health? 
Yes 1 
Please give more 
details below 
No 0 
Please go 
to 7(a) 
Type of help  
Approximately how many hours of 
ADDITIONAL help have they given 
per week?  
(i.e. help that has only been given because of 
your mental health) 
i) Extra childcare Yes 1     No 0  
ii) Extra help around the house (e.g. cooking, cleaning) Yes 1     No 0  
iii) Extra help outside the house (e.g. shopping, transport) Yes 1     No 0  
iv) Any other extra help (please specify) 
 
......................................................................... 
Yes 1     No 0  
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7.  Employment and benefits    
 
 
7(a) During the past 6 months, have you done any paid work as an employee, on a 
government-sponsored training scheme, as a self-employed/freelance or in your 
own/family business? 
Yes 1 
Please give more 
details below 
No 0 
Please go to 
7(b) 
i) How many hours have you worked per week? 
……………………   hours 
7(b) During the past 6 months, have you had any time off work because of your mental 
health? 
Yes 1 
Please give more 
details below 
No 0 
Please go to 
7(c) 
i) Approximately how many days have you had off work in the past 6 months 
(including work time lost because of reduced working hours)? ……………………   days 
ii) How much income (if any) have you lost in total? £       :            [zero if nothing] 
7(c) During the past 6 months, has someone else has had time off work to care for you 
because of your mental health? 
Yes 1 
Please give more 
details below 
No 0 
Please go to 
7(d) 
i) Approximately how many days has he/she taken off work in the past 6 months?  
……………………   days 
7(d) During the past 6 months, have you received any disability payments? (e.g. Disability Living 
Allowance, Employment Support Allowance or Incapacity Benefit) 
 
Yes 1 
 
 
No 0 
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Please add anything else that you think might help us: 
 
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………………………………………………… 
Many thanks for completing this questionnaire. 
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All unit costs were derived from the August 2016 Prescription Cost Analysis.48
TABLE 43 Prescribed medication and unit costs
Drug name Cost per quantity (£)
Amitriptyline 10-mg tablets 0.03
Amitriptyline 25-mg tablets 0.03
Amitriptyline 50-mg tablets 0.12
Amitriptyline hydrochloride 10-mg tablets 0.03
Chlordiazepoxide 10-mg capsules 0.50
Cipralex 20-mg tablets (Lundbeck Ltd) 0.90
Cipramil 20-mg tablets (Lundbeck Ltd) 0.32
Citalopram 10-mg tablets 0.03
Citalopram 20-mg tablets 0.03
Citalopram 20-mg tablets (price for 28 tablets) 0.83
Citalopram 40-mg tablets 0.03
Citalopram hydrobromide 10-mg tablets 0.03
Citalopram hydrobromide 20-mg tablets 0.03
Citalopram hydrobromide 40-mg tablets 0.03
Colestyramine 4-g oral powder sachets 0.40
Diazepam 2-mg tablets 0.03
Diazepam 5-mg tablets 0.03
Dosulepin 75-mg tablets 0.05
Duloxetine 20-mg gastro-resistant capsules 0.20
Duloxetine 30-mg gastro-resistant capsules 0.17
Duloxetine 60-mg gastro-resistant capsules 0.16
Escitalopram 10-mg tablets 0.04
Escitalopram 20-mg tablets 0.05
Escitalopram 5-mg tablets 0.04
Fluoxetine 20-mg capsules 0.03
Fluoxetine 20-mg capsules 0.03
Fluoxetine 20-mg capsules (price for 30 capsules) 0.93
Fluoxetine 60-mg capsules 0.34
Fluoxetine hydrochloride capsules 20 mg 0.03
Haloperidol 5 mg/1 ml solution for injection ampoules 3.47
Lofepramine 70-mg tablets 0.22
Lofepramine 70-mg tablets (Actavis UK Ltd) 0.22
Lorazepam 1-mg tablets 0.08
Mirtazapine 15-mg tablets 0.04
Mirtazapine 30-mg tablets 0.04
Mirtazapine 15-mg orodispersible tablets 0.04
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TABLE 43 Prescribed medication and unit costs (continued )
Drug name Cost per quantity (£)
Mirtazapine 15-mg tablets 0.04
Mirtazapine 30-mg tablets 0.04
Mirtazapine 45-mg tablets 0.05
Nitrazepam 5-mg tablets 0.04
Nortriptyline 10-mg tablets 0.48
Oxactin 20-mg capsules (Discovery Pharmaceuticals Ltd) 0.03
Oxycodone 5 mg/5 ml sugar-free oral solution 0.04
Paroxetine 10-mg tablets 0.60
Paroxetine 10 mg/5 ml sugar-free oral suspension 0.06
Paroxetine 20-mg tablets 0.05
Paroxetine 30-mg tablets 0.06
Paroxetine hydrochloride 20-mg tablets 0.05
Priadel 200-mg modified-release tablets (Sanofi) 0.03
Priadel 400-mg modified-release tablets (Sanofi) 0.04
Promethazine hydrochloride 25-mg tablets 0.49
Quetiapine 150-mg modified-release tablets 0.04
Quetiapine 50-mg modified-release tablets 0.04
Reboxetine 4-mg tablets 0.32
Sertraline 100-mg tablets 0.05
Sertraline 100-mg tablets (price for 28 tablets) 1.49
Sertraline 50-mg tablets 0.04
Sertraline hydrochloride 100-mg tablets 0.05
Sertraline hydrochloride 50-mg tablets 0.04
Sodium alginate and potassium bicarbonate oral suspension,
sugar free, peppermint 500 mg+ 100mg/5 ml
5.11
Sodium picosulfate sugar-free 5 mg/5 ml oral solution 2.37
Temazepam 10-mg tablets 0.10
Temazepam 20-mg tablets 0.10
Tonpular XL 75-mg capsules (Wockhardt UK Ltd) 0.25
Trazodone 50-mg capsules 0.36
Venaxx Xl M/R 75-mg capsules 0.37
Venaxx XL 75-mg capsules (AMCo) 0.37
Venlablue XL 150-mg capsules (Bluefish Pharmaceuticals AB) 0.36
Venlablue XL 75-mg capsules (Bluefish Pharmaceuticals AB) 0.25
Venlafaxine 75-mg tablets 0.04
Venlafaxine 150-mg modified-release capsules 1.31
Venlafaxine 150-mg modified-release tablets 1.31
Venlafaxine 225-mg modified-release tablets 0.04
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TABLE 43 Prescribed medication and unit costs (continued )
Drug name Cost per quantity (£)
Venlafaxine 37.5-mg tablets 0.04
Venlafaxine 75-mg modified-release capsules 0.04
Venlafaxine 75-mg modified-release tablets 0.04
Venlafaxine 75-mg tablets 0.04
Venlalic XL 150-mg tablets (DB Ashbourne Ltd) 0.62
Venlalic XL 225-mg tablets (DB Ashbourne Ltd) 1.12
Venlalic XL 75-mg tablets (DB Ashbourne Ltd) 0.37
Vensir XL 150-mg capsules (Morningside Healthcare Ltd) 0.14
Vensir XL 75-mg capsules (Morningside Healthcare Ltd) 0.09
Zolpidem 10-mg tablets 0.04
Zolpidem 5-mg tablets 0.04
Zopiclone 7.5-mg tablets 0.04
Zopiclone 3.75-mg tablets 0.04
Adapted from Prescription Cost Analysis, England – 2016.48 Copyright © 2017 Health and Social Care Information Centre.
Contains public sector information licensed under the Open Government Licence v3.0.
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Appendix 4 Qualitative topic guides
Topic Guide for Decliners –  
Exploring perspectives of people who declined to participate in the MIR trial 
 
Prior to interview 
Remind the individual they can decline to answer a question or withdraw from the 
interview without giving a reason 
Give opportunity to ask questions 
Secure consent to audio-record the interview 
 
Thank you for agreeing to be interviewed about your reasons for declining to take part in the 
MIR study.  Everything you say will be treated as strictly confidential.  The information you 
provide will be useful in helping us understand people’s concerns about the study.  
 
The aim of this interview is to discuss your view of being asked to participate in a study, and 
about your experiences of depression. 
1. Could you start by telling me how you heard about this study? How was the study 
explained to you? Could you explain what you thought the study was about? Could you 
explain why you thought the study was not for you? 
a. Explore the processes of being in a study (randomisation, effect on usual care, 
time, hassle) 
b. Explore views on antidepressants (particularly taking two) 
2. Could you tell me about being depressed? 
3. What sorts of treatments have you had in the past (before you were invited to participate 
in this study? 
4. How did you feel about taking anti-depressants before being invited to take part in this 
study? Could I ask if you have ever taken anti-depressants? Do you think they have 
worked for you? Have you any concerns about taking anti-depressants – if so, explore 
what?  
5. Have you had other treatments for depression (such as ‘talking treatments’)? 
6. Do you have anything else you want to say about the study? 
 
Thank individual for taking part and reiterate about confidentiality 
Qualitative topic guide for decliners v1.0   7 November 2012 
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Topic Guide for patients –  
Exploring perspectives of participation in the MIR trial 
 
The aim of this interview is to examine your experiences of participation in the MIR trial. 
1. Could you start by telling me how you came to participate in this study? What did you 
think was going to happen? How did that compare with what happened? 
 
2. Could you tell me about being depressed? 
 
3. What sorts of treatments have you had in the past (before starting on this research study)? 
 
4. How did you feel about taking anti-depressants before starting on this study? 
 
5. Have you had other treatments for depression (such as ‘talking treatments’)? 
 
6. How did you feel about taking a second tablet for depression? Do you feel you improved 
with the second tablet?  
a. If so, how? 
b. If not, in what way? 
 
7. How was taking the second tablet explained to you? 
 
8. How comfortable do you think your GP was with supporting you when you were taking 
two tablets for depression? 
 
9. For people who ‘dropped out’: Could you explain why you stopped taking the second 
tablet? (explore fears, side-effects, pressure from others, confidence in GP, confidence in 
study etc) 
 
CCG 06/10/2012    
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